<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Lisdexamfetamine</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Lisdexamfetamine">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Lisdexamfetamine</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Lisdexamfetamine</b>, sold under the brand name <b>Vyvanse</b> among <a href="#Names">others</a>, is a medication that is a derivative of <a href="Amphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amphetamine" title="Amphetamine">amphetamine</a>. It is mainly used to treat attention deficit hyperactivity disorder (ADHD) in people over the age of five as well as moderate-to-severe binge eating disorder in adults.<span class="mw-ref" id="cite_ref-AHFS2019_1-1"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> Lisdexamfetamine is taken by mouth.<span class="mw-ref" id="cite_ref-AHFS2019_1-2"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-DailyMed2019_6-0"><a href="#cite_note-DailyMed2019-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> In the United Kingdom it is usually less preferred than <a href="Methylphenidate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methylphenidate" title="Methylphenidate">methylphenidate</a>.<span class="mw-ref" id="cite_ref-BNF76_7-0"><a href="#cite_note-BNF76-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span> Its effects generally begin within 2 hours and last for up to 12 hours.<span class="mw-ref" id="cite_ref-AHFS2019_1-3"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></p>


<div role="note" class="hatnote navigation-not-searchable">Not to be confused with <a href="Levoamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Levoamphetamine" title="Levoamphetamine">Levoamphetamine</a>.</div>
<p></p>
<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Lisdexamfetamine</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Lisdexamfetamine_structure.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Lisdexamfetamine_structure.svg.png" data-file-width="512" data-file-height="159" data-file-type="drawing" height="62" width="200"></figure-inline></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Lisdexamfetamine_ball-and-stick_model.png" tppabs="https://ptable.com/wiki/compounds/I/m/Lisdexamfetamine_ball-and-stick_model.png" data-file-width="2537" data-file-height="1099" data-file-type="bitmap" height="87" width="200"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Tyvense, Elvanse, Vyvanse, others</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td>(2<i>S</i>)-2,6-Diamino-<i>N</i>-[(2<i>S</i>)-1-phenylpropan-2-yl]hexanamide<br><i>N</i>-[(2<i>S</i>)-1-Phenyl-2-propanyl]-<small>L</small>-lysinamide</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/lisdexamfetamine-dimesylate.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/lisdexamfetamine-dimesylate.html'" tppabs="https://www.drugs.com/monograph/lisdexamfetamine-dimesylate.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a607047.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a607047.html'" tppabs="https://medlineplus.gov/druginfo/meds/a607047.html" class="external text external">a607047</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span>DailyMed:<span>&nbsp;</span><span><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lisdexamfetamine  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lisdexamfetamine'" tppabs="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lisdexamfetamine" class="external text external">Lisdexamfetamine</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span><span>FDA:<span>&nbsp;</span><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Lisdexamfetamine&SearchType=BasicSearch  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Lisdexamfetamine&SearchType=BasicSearch'" tppabs="https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Lisdexamfetamine&SearchType=BasicSearch" class="external text external">Lisdexamfetamine</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>B3<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>C (Risk not ruled out)<span> </span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Dependence<br>liability</th><td>High<span class="mw-ref" id="cite_ref-AHFS2019_1-0"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-Stahl's_Essential_Psychopharmacology_-_Lisdexamfetamine_2-0"><a href="#cite_note-Stahl's_Essential_Psychopharmacology_-_Lisdexamfetamine-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Addiction<br>liability</th><td>Moderate</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>By mouth (capsules)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>N06BA12<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=N06BA12  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=N06BA12'" tppabs="https://www.whocc.no/atc_ddd_index/?code=N06BA12" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>S8 (Controlled drug)<span> </span></li>
<li><small><abbr class="country-name">BR</abbr>:</small><span> </span>Class A3 (Psychoactive drugs)<span> </span></li>
<li><small><abbr class="country-name">CA</abbr></small>:<span> </span>Schedule II<span> </span></li>
<li><small><abbr class="country-name">DE</abbr></small>:<span> </span>Anlage III (Special prescription form required)<span> </span></li>
<li><small><abbr class="country-name">UK</abbr>:</small><span> </span>Class B<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>Schedule II<span> </span></li>
<li>In<span>&nbsp;</span>general: ℞<span>&nbsp;</span>(Prescription only)</li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>96.4%<span class="mw-ref" id="cite_ref-3"><a href="#cite_note-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Hydrolysis by enzymes in red blood cells initially.<br>Subsequent metabolism follows <a href="Amphetamine.htm#Pharmacokinetics" tppabs="https://ptable.com/wiki/compounds/A/Amphetamine#Pharmacokinetics" title="Amphetamine">Amphetamine#Pharmacokinetics</a>.</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Onset of action</th><td>2<span>&nbsp;</span>h<span class="mw-ref" id="cite_ref-Millichap:_onset,_peak,_and_duration_4-0"><a href="#cite_note-Millichap:_onset,_peak,_and_duration-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-XR_onset-duration_5-0"><a href="#cite_note-XR_onset-duration-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>≤1<span>&nbsp;</span>h (prodrug molecule)<br>9–11<span>&nbsp;</span>h (dextroamphetamine)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Duration of action</th><td>10–12<span>&nbsp;</span>h<span class="mw-ref" id="cite_ref-Stahl's_Essential_Psychopharmacology_-_Lisdexamfetamine_2-1"><a href="#cite_note-Stahl's_Essential_Psychopharmacology_-_Lisdexamfetamine-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-Millichap:_onset,_peak,_and_duration_4-1"><a href="#cite_note-Millichap:_onset,_peak,_and_duration-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-XR_onset-duration_5-1"><a href="#cite_note-XR_onset-duration-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>Renal: ~2%</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">(2<i>S</i>)-2,6-Diamino-<i>N</i>-[(1<i>S</i>)-1-methyl-2-phenylethyl]hexanamide</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=608137-32-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=608137-32-2'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=608137-32-2" class="external text external">608137-32-2</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span>[IUPHAR]</sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/11597698  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/11597698'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/11597698" class="external text external">11597698</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7213  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7213'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7213" class="external text external">7213</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB01255  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB01255'" tppabs="https://www.drugbank.ca/drugs/DB01255" class="external text external">DB01255</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.9772458.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.9772458.html'" tppabs="http://www.chemspider.com/Chemical-Structure.9772458.html" class="external text external">9772458</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=H645GUL8KJ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=H645GUL8KJ'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=H645GUL8KJ" class="external text external">H645GUL8KJ</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201222  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201222'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201222" class="external text external">ChEMBL1201222</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID00209652  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID00209652'" tppabs="https://comptox.epa.gov/dashboard/DTXSID00209652" class="external text external">DTXSID00209652</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>15</sub><span>H</span><sub>25</sub><span>N</span><sub>3</sub><span>O</span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">263.385</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC%28N%5BC%40H%5D%28Cc1ccccc1%29C%29%5BC%40%40H%5D%28N%29CCCCN  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC%28N%5BC%40H%5D%28Cc1ccccc1%29C%29%5BC%40%40H%5D%28N%29CCCCN'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC%28N%5BC%40H%5D%28Cc1ccccc1%29C%29%5BC%40%40H%5D%28N%29CCCCN" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">O=C(N[C@H](Cc1ccccc1)C)[C@@H](N)CCCCN</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:VOBHXZCDAVEXEY-JSGCOSHPSA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=418022579&page2=Lisdexamfetamine  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=418022579&page2=Lisdexamfetamine'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=418022579&page2=Lisdexamfetamine" class="external text external">(verify)</a></span></span></td></tr></tbody></table>

<p>Common side effects of lisdexamfetamine include loss of appetite, anxiety, diarrhea, trouble sleeping, irritability, and nausea.<span class="mw-ref" id="cite_ref-AHFS2019_1-4"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> Rare but serious side effects include mania, sudden cardiac death in those with underlying heart problems, and psychosis.<span class="mw-ref" id="cite_ref-AHFS2019_1-5"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> It has a high potential for abuse per the <a href="Drug_Enforcement_Administration.htm" tppabs="https://ptable.com/wiki/compounds/A/Drug_Enforcement_Administration" title="Drug Enforcement Administration">DEA</a>.<span class="mw-ref" id="cite_ref-AHFS2019_1-6"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-DailyMed2019_6-1"><a href="#cite_note-DailyMed2019-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> Serotonin syndrome may occur if used with certain other medications.<span class="mw-ref" id="cite_ref-AHFS2019_1-7"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> Its use during pregnancy may result in harm to the baby and use during breastfeeding is not recommended by the manufacturer.<span class="mw-ref" id="cite_ref-BNF76_7-1"><a href="#cite_note-BNF76-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-AHFS2019_1-8"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-DailyMed2019_6-2"><a href="#cite_note-DailyMed2019-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> Lisdexamfetamine is a central nervous system (CNS) stimulant that works after being converted by the body into <a href="Dextroamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dextroamphetamine" title="Dextroamphetamine">dextroamphetamine</a>.<span class="mw-ref" id="cite_ref-AHFS2019_1-9"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span class="mw-ref" id="cite_ref-Amp2013_8-0"><a href="#cite_note-Amp2013-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> Chemically, lisdexamfetamine is composed of the amino acid <a href="Lysine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lysine" title="Lysine"><small>L</small>-lysine</a>, attached to dextroamphetamine.<span class="mw-ref" id="cite_ref-pmid17407369_9-0"><a href="#cite_note-pmid17407369-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>


<p>Lisdexamfetamine was approved for medical use in the United States in 2007.<span class="mw-ref" id="cite_ref-AHFS2019_1-10"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> A month's supply in the United Kingdom costs the British National Health Service about £<span>58</span> <span>as of 2019</span><span>.</span><span class="mw-ref" id="cite_ref-BNF76_7-2"><a href="#cite_note-BNF76-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span> In the United States, the wholesale cost of this amount is about US$<span>264</span>.<span class="mw-ref" id="cite_ref-NADAC2019_10-0"><a href="#cite_note-NADAC2019-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> In 2017, it was the 91st most commonly prescribed medication in the United States, with more than eight million prescriptions.<span class="mw-ref" id="cite_ref-11"><a href="#cite_note-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-12"><a href="#cite_note-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> It is a Schedule II controlled substance in the United Kingdom and a Schedule II controlled substance in the United States.<span class="mw-ref" id="cite_ref-BNF76_7-3"><a href="#cite_note-BNF76-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-DEA2017_13-0"><a href="#cite_note-DEA2017-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>
<style data-mw-deduplicate="TemplateStyles:r886046785">.mw-parser-output .toclimit-2 .toclevel-1 ul,.mw-parser-output .toclimit-3 .toclevel-2 ul,.mw-parser-output .toclimit-4 .toclevel-3 ul,.mw-parser-output .toclimit-5 .toclevel-4 ul,.mw-parser-output .toclimit-6 .toclevel-5 ul,.mw-parser-output .toclimit-7 .toclevel-6 ul{display:none}</style><div class="toclimit-3"><meta property="mw:PageProp/toc"></div>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Uses">Uses</h2></summary>
    



    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Medical">Medical</h3></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:222px"><img src="../I/m/30mg_Vyvanse_capsules.JPG" tppabs="https://ptable.com/wiki/compounds/I/m/30mg_Vyvanse_capsules.JPG" data-file-width="2914" data-file-height="2253" data-file-type="bitmap" height="170" width="220"><div class="thumbcaption" style="text-align: left">30mg Vyvanse capsules</div></div></div>

<p>Lisdexamfetamine is used primarily as a treatment for attention deficit hyperactivity disorder (ADHD) and binge eating disorder;<span class="mw-ref" id="cite_ref-USVyvanselabel_14-0"><a href="#cite_note-USVyvanselabel-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> it has similar <span class="nowrap">off-label</span> uses as those of other pharmaceutical amphetamines.<span class="mw-ref" id="cite_ref-Stahl's_Essential_Psychopharmacology_-_Lisdexamfetamine_2-2"><a href="#cite_note-Stahl's_Essential_Psychopharmacology_-_Lisdexamfetamine-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Individuals over the age of 65 were not commonly tested in clinical trials of lisdexamfetamine for ADHD.<span class="mw-ref" id="cite_ref-USVyvanselabel_14-1"><a href="#cite_note-USVyvanselabel-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span>
Long-term amphetamine exposure at sufficiently high doses in some animal species is known to produce abnormal dopamine system development or nerve damage,<span class="mw-ref" id="cite_ref-pmid22392347_15-0"><a href="#cite_note-pmid22392347-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span><span class="mw-ref" id="cite_ref-AbuseAndAbnormalities_16-0"><a href="#cite_note-AbuseAndAbnormalities-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> but, in humans with ADHD, pharmaceutical amphetamines, at therapeutic dosages, appear to improve brain development and nerve growth.<span class="mw-ref" id="cite_ref-Neuroplasticity_1_17-0"><a href="#cite_note-Neuroplasticity_1-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span><span class="mw-ref" id="cite_ref-Neuroplasticity_2_18-0"><a href="#cite_note-Neuroplasticity_2-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span><span class="mw-ref" id="cite_ref-Neuroplasticity_3_19-0"><a href="#cite_note-Neuroplasticity_3-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span> Reviews of magnetic resonance imaging (MRI) studies suggest that long-term treatment with amphetamine decreases abnormalities in brain structure and function found in subjects with ADHD, and improves function in several parts of the brain, such as the right caudate nucleus of the basal ganglia.<span class="mw-ref" id="cite_ref-Neuroplasticity_1_17-1"><a href="#cite_note-Neuroplasticity_1-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span><span class="mw-ref" id="cite_ref-Neuroplasticity_2_18-1"><a href="#cite_note-Neuroplasticity_2-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span><span class="mw-ref" id="cite_ref-Neuroplasticity_3_19-1"><a href="#cite_note-Neuroplasticity_3-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span></p><span>

</span><p>Reviews of clinical stimulant research have established the safety and effectiveness of long-term continuous amphetamine use for the treatment of ADHD.<span class="mw-ref" id="cite_ref-Long-Term_Outcomes_Medications_20-0"><a href="#cite_note-Long-Term_Outcomes_Medications-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-Millichap_21-0"><a href="#cite_note-Millichap-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span><span class="mw-ref" id="cite_ref-Long-term_2015_22-0"><a href="#cite_note-Long-term_2015-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> Randomized controlled trials of continuous stimulant therapy for the treatment of ADHD spanning 2<span>&nbsp;</span>years have demonstrated treatment effectiveness and safety.<span class="mw-ref" id="cite_ref-Long-Term_Outcomes_Medications_20-1"><a href="#cite_note-Long-Term_Outcomes_Medications-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-Millichap_21-1"><a href="#cite_note-Millichap-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span> Two reviews have indicated that long-term continuous stimulant therapy for ADHD is effective for reducing the core symptoms of ADHD (i.e., hyperactivity, inattention, and impulsivity), enhancing quality of life and academic achievement, and producing improvements in a large number of functional outcomes<span class="mw-ref" id="cite_ref-23"><a href="#cite_note-23" style="counter-reset: mw-Ref 1;" data-mw-group="note"><span class="mw-reflink-text">[note 1]</span></a></span> across 9<span>&nbsp;</span>categories of outcomes related to academics, antisocial behavior, driving, non-medicinal drug use, obesity, occupation, self-esteem, service use (i.e., academic, occupational, health, financial, and legal services), and social function.<span class="mw-ref" id="cite_ref-Long-Term_Outcomes_Medications_20-2"><a href="#cite_note-Long-Term_Outcomes_Medications-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-Long-term_2015_22-4"><a href="#cite_note-Long-term_2015-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> One review highlighted a nine-month randomized controlled trial of amphetamine treatment for ADHD in children that found an average increase of 4.5<span>&nbsp;</span><a href="Intelligence_quotient.htm" tppabs="https://ptable.com/wiki/compounds/A/Intelligence_quotient" title="Intelligence quotient">IQ</a> points, continued increases in attention, and continued decreases in disruptive behaviors and hyperactivity.<span class="mw-ref" id="cite_ref-Millichap_21-2"><a href="#cite_note-Millichap-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span> Another review indicated that, based upon the longest follow-up studies conducted to date, lifetime stimulant therapy that begins during childhood is continuously effective for controlling ADHD symptoms and reduces the risk of developing a substance use disorder as an adult.<span class="mw-ref" id="cite_ref-Long-Term_Outcomes_Medications_20-3"><a href="#cite_note-Long-Term_Outcomes_Medications-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span></p><span>

</span><p>Current models of ADHD suggest that it is associated with functional impairments in some of the brain's neurotransmitter systems;<span class="mw-ref" id="cite_ref-Malenka_2009_03_24-0"><a href="#cite_note-Malenka_2009_03-24" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span> these functional impairments involve impaired <a href="Dopamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dopamine" title="Dopamine">dopamine</a> neurotransmission in the mesocorticolimbic projection and norepinephrine neurotransmission in the noradrenergic projections from the locus coeruleus to the prefrontal cortex.<span class="mw-ref" id="cite_ref-Malenka_2009_03_24-1"><a href="#cite_note-Malenka_2009_03-24" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span> Psychostimulants like <a href="Methylphenidate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methylphenidate" title="Methylphenidate">methylphenidate</a> and amphetamine are effective in treating ADHD because they increase neurotransmitter activity in these systems.<span class="mw-ref" id="cite_ref-Malenka_2009_25-0"><a href="#cite_note-Malenka_2009-25" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span><span class="mw-ref" id="cite_ref-Malenka_2009_03_24-2"><a href="#cite_note-Malenka_2009_03-24" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span><span class="mw-ref" id="cite_ref-cognition_enhancers_26-0"><a href="#cite_note-cognition_enhancers-26" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span> Approximately 80% of those who use these stimulants see improvements in ADHD symptoms.<span class="mw-ref" id="cite_ref-Long-term_36_27-0"><a href="#cite_note-Long-term_36-27" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span> Children with ADHD who use stimulant medications generally have better relationships with peers and family members, perform better in school, are less distractible and impulsive, and have longer attention spans.<span class="mw-ref" id="cite_ref-Millichap_3_28-0"><a href="#cite_note-Millichap_3-28" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span><span class="mw-ref" id="cite_ref-ADHD_29-0"><a href="#cite_note-ADHD-29" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span> The Cochrane reviews<span class="mw-ref" id="cite_ref-31"><a href="#cite_note-31" style="counter-reset: mw-Ref 2;" data-mw-group="note"><span class="mw-reflink-text">[note 2]</span></a></span> on the treatment of ADHD in children, adolescents, and adults with pharmaceutical amphetamines stated that short-term studies have demonstrated that these drugs decrease the severity of symptoms, but they have higher discontinuation rates than non-stimulant medications due to their adverse side effects.<span class="mw-ref" id="cite_ref-Cochrane_Amphetamines_ADHD_32-0"><a href="#cite_note-Cochrane_Amphetamines_ADHD-32" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span><span class="mw-ref" id="cite_ref-pmid26844979_33-0"><a href="#cite_note-pmid26844979-33" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span> A Cochrane review on the treatment of ADHD in children with tic disorders such as Tourette syndrome indicated that stimulants in general do not make tics worse, but high doses of dextroamphetamine could exacerbate tics in some individuals.<span class="mw-ref" id="cite_ref-pmid29944175_34-0"><a href="#cite_note-pmid29944175-34" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Enhancing_performance">Enhancing performance</h3></summary>
    


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Cognitive_performance">Cognitive performance</h4></summary>
    <span>
</span><p>In 2015, a systematic review and a meta-analysis of high quality clinical trials found that, when used at low (therapeutic) doses, amphetamine produces modest yet unambiguous improvements in cognition, including working memory, long-term episodic memory, inhibitory control, and some aspects of attention, in normal healthy adults;<span class="mw-ref" id="cite_ref-Unambiguous_PFC_D1_A2_35-0"><a href="#cite_note-Unambiguous_PFC_D1_A2-35" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span><span class="mw-ref" id="cite_ref-Cognitive_and_motivational_effects_36-0"><a href="#cite_note-Cognitive_and_motivational_effects-36" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span> these cognition-enhancing effects of amphetamine are known to be partially mediated through the indirect activation of both dopamine receptor D<sub>1</sub> and adrenoceptor α<sub>2</sub> in the prefrontal cortex.<span class="mw-ref" id="cite_ref-Malenka_2009_25-1"><a href="#cite_note-Malenka_2009-25" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span><span class="mw-ref" id="cite_ref-Unambiguous_PFC_D1_A2_35-1"><a href="#cite_note-Unambiguous_PFC_D1_A2-35" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span> A systematic review from 2014 found that low doses of amphetamine also improve memory consolidation, in turn leading to improved recall of information.<span class="mw-ref" id="cite_ref-Cognition_enhancement_2014_systematic_review_37-0"><a href="#cite_note-Cognition_enhancement_2014_systematic_review-37" style="counter-reset: mw-Ref 35;"><span class="mw-reflink-text">[35]</span></a></span> Therapeutic doses of amphetamine also enhance cortical network efficiency, an effect which mediates improvements in working memory in all individuals.<span class="mw-ref" id="cite_ref-Malenka_2009_25-2"><a href="#cite_note-Malenka_2009-25" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span><span class="mw-ref" id="cite_ref-pmid11337538_38-0"><a href="#cite_note-pmid11337538-38" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span> Amphetamine and other ADHD stimulants also improve task saliency (motivation to perform a task) and increase arousal (wakefulness), in turn promoting goal-directed behavior.<span class="mw-ref" id="cite_ref-Malenka_2009_25-3"><a href="#cite_note-Malenka_2009-25" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span><span class="mw-ref" id="cite_ref-Malenka_NAcc_39-0"><a href="#cite_note-Malenka_NAcc-39" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span><span class="mw-ref" id="cite_ref-Continuum_40-0"><a href="#cite_note-Continuum-40" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span> Stimulants such as amphetamine can improve performance on difficult and boring tasks and are used by some students as a study and test-taking aid.<span class="mw-ref" id="cite_ref-Malenka_2009_25-4"><a href="#cite_note-Malenka_2009-25" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span><span class="mw-ref" id="cite_ref-Continuum_40-1"><a href="#cite_note-Continuum-40" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span><span class="mw-ref" id="cite_ref-Test_taking_aid_41-0"><a href="#cite_note-Test_taking_aid-41" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span> Based upon studies of self-reported illicit stimulant use, <span class="nowrap">5–35%</span> of college students use diverted ADHD stimulants, which are primarily used for enhancement of academic performance rather than as recreational drugs.<span class="mw-ref" id="cite_ref-pmid16999660_42-0"><a href="#cite_note-pmid16999660-42" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span><span class="mw-ref" id="cite_ref-Diversion_prevalence_1_43-0"><a href="#cite_note-Diversion_prevalence_1-43" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span><span class="mw-ref" id="cite_ref-Diversion_prevalence_2_44-0"><a href="#cite_note-Diversion_prevalence_2-44" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span> However, high amphetamine doses that are above the therapeutic range can interfere with working memory and other aspects of cognitive control.<span class="mw-ref" id="cite_ref-Malenka_2009_25-5"><a href="#cite_note-Malenka_2009-25" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span><span class="mw-ref" id="cite_ref-Continuum_40-2"><a href="#cite_note-Continuum-40" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span></p><span>

</span>
</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Physical_performance">Physical performance</h4></summary>
    <span>
</span><p>Amphetamine is used by some athletes for its psychological and athletic performance-enhancing effects, such as increased endurance and alertness;<span class="mw-ref" id="cite_ref-Ergogenics_45-0"><a href="#cite_note-Ergogenics-45" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span><span class="mw-ref" id="cite_ref-Westfall_46-0"><a href="#cite_note-Westfall-46" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> however, non-medical amphetamine use is prohibited at sporting events that are regulated by collegiate, national, and international anti-doping agencies.<span class="mw-ref" id="cite_ref-NCAA_47-0"><a href="#cite_note-NCAA-47" style="counter-reset: mw-Ref 45;"><span class="mw-reflink-text">[45]</span></a></span><span class="mw-ref" id="cite_ref-WADA_&amp;_AD_regulation_48-0"><a href="#cite_note-WADA_&amp;_AD_regulation-48" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></span> In healthy people at oral therapeutic doses, amphetamine has been shown to increase muscle strength, acceleration, athletic performance in anaerobic conditions, and endurance (i.e., it delays the onset of fatigue), while improving reaction time.<span class="mw-ref" id="cite_ref-Ergogenics_45-1"><a href="#cite_note-Ergogenics-45" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span><span class="mw-ref" id="cite_ref-Ergogenics2_49-0"><a href="#cite_note-Ergogenics2-49" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></span><span class="mw-ref" id="cite_ref-Roelands_2013_50-0"><a href="#cite_note-Roelands_2013-50" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span> Amphetamine improves endurance and reaction time primarily through reuptake inhibition and release of dopamine in the central nervous system.<span class="mw-ref" id="cite_ref-Ergogenics2_49-1"><a href="#cite_note-Ergogenics2-49" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></span><span class="mw-ref" id="cite_ref-Roelands_2013_50-1"><a href="#cite_note-Roelands_2013-50" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span><span class="mw-ref" id="cite_ref-Amph-DA_reaction_time_51-0"><a href="#cite_note-Amph-DA_reaction_time-51" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></span> Amphetamine and other dopaminergic drugs also increase power output at fixed levels of perceived exertion by overriding a "safety switch", allowing the core temperature limit to increase in order to access a reserve capacity that is normally off-limits.<span class="mw-ref" id="cite_ref-Roelands_2013_50-2"><a href="#cite_note-Roelands_2013-50" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span><span class="mw-ref" id="cite_ref-Central_mechanisms_affecting_exertion_52-0"><a href="#cite_note-Central_mechanisms_affecting_exertion-52" style="counter-reset: mw-Ref 50;"><span class="mw-reflink-text">[50]</span></a></span><span class="mw-ref" id="cite_ref-Monoamine+drug_effects_on_exercise_-_fatigue_and_heat_53-0"><a href="#cite_note-Monoamine+drug_effects_on_exercise_-_fatigue_and_heat-53" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span> At therapeutic doses, the adverse effects of amphetamine do not impede athletic performance;<span class="mw-ref" id="cite_ref-Ergogenics_45-2"><a href="#cite_note-Ergogenics-45" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span><span class="mw-ref" id="cite_ref-Ergogenics2_49-2"><a href="#cite_note-Ergogenics2-49" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></span> however, at much higher doses, amphetamine can induce effects that severely impair performance, such as rapid muscle breakdown and elevated body temperature.<span class="mw-ref" id="cite_ref-FDA_54-0"><a href="#cite_note-FDA-54" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-Ergogenics2_49-3"><a href="#cite_note-Ergogenics2-49" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Contraindications">Contraindications</h2></summary>
    
<p>Pharmaceutical lisdexamfetamine dimesylate is contraindicated in patients with hypersensitivity to amphetamine products or any of the formulation's inactive ingredients.<span class="mw-ref" id="cite_ref-USVyvanselabel_14-2"><a href="#cite_note-USVyvanselabel-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> It is also contraindicated in patients who have used a monoamine oxidase inhibitor (MAOI) within the last 14<span>&nbsp;</span>days.<span class="mw-ref" id="cite_ref-USVyvanselabel_14-3"><a href="#cite_note-USVyvanselabel-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-International_55-0"><a href="#cite_note-International-55" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span> Amphetamine products are contraindicated by the United States Food and Drug Administration (USFDA) in people with a history of drug abuse, heart disease, or severe agitation or anxiety, or in those currently experiencing arteriosclerosis, glaucoma,  hyperthyroidism, or severe hypertension.<span class="mw-ref" id="cite_ref-FDA_Contra_Warnings_56-0"><a href="#cite_note-FDA_Contra_Warnings-56" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span> The USFDA advises anyone with bipolar disorder, depression, elevated blood pressure, liver or kidney problems, mania, psychosis, Raynaud's phenomenon, seizures, thyroid problems, tics, or Tourette syndrome to monitor their symptoms while taking amphetamine.<span class="mw-ref" id="cite_ref-FDA_Contra_Warnings_56-1"><a href="#cite_note-FDA_Contra_Warnings-56" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span>  Amphetamine is classified in US pregnancy category C.<span class="mw-ref" id="cite_ref-FDA_Contra_Warnings_56-2"><a href="#cite_note-FDA_Contra_Warnings-56" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span> This means that detriments to the fetus have been observed in animal studies and adequate human studies have not been conducted; amphetamine may still be prescribed to pregnant women if the potential benefits outweigh the risks.<span class="mw-ref" id="cite_ref-57"><a href="#cite_note-57" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span>  Amphetamine has also been shown to pass into breast milk, so the USFDA advises mothers to avoid breastfeeding when using it.<span class="mw-ref" id="cite_ref-FDA_Contra_Warnings_56-3"><a href="#cite_note-FDA_Contra_Warnings-56" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span> Due to the potential for stunted growth, the USFDA advises monitoring the height and weight of children and adolescents prescribed amphetamines.<span class="mw-ref" id="cite_ref-FDA_Contra_Warnings_56-4"><a href="#cite_note-FDA_Contra_Warnings-56" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span> Prescribing information approved by the Australian Therapeutic Goods Administration further contraindicates anorexia.<span class="mw-ref" id="cite_ref-58"><a href="#cite_note-58" style="counter-reset: mw-Ref 56;"><span class="mw-reflink-text">[56]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Adverse_effects">Adverse effects</h2></summary>
    

<p>Products containing lisdexamfetamine have a comparable drug safety profile to those containing amphetamine.<span class="mw-ref" id="cite_ref-pmid17407369_9-1"><a href="#cite_note-pmid17407369-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>

    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Physical">Physical</h3></summary>
    <span>
</span><p>Cardiovascular side effects can include hypertension or hypotension from a vasovagal response, Raynaud's phenomenon (reduced blood flow to the hands and feet), and tachycardia (increased heart rate).<span class="mw-ref" id="cite_ref-FDA_54-1"><a href="#cite_note-FDA-54" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-Westfall_46-1"><a href="#cite_note-Westfall-46" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span><span class="mw-ref" id="cite_ref-pmid18295156_59-0"><a href="#cite_note-pmid18295156-59" style="counter-reset: mw-Ref 57;"><span class="mw-reflink-text">[57]</span></a></span> Sexual side effects in males may include erectile dysfunction, frequent erections, or prolonged erections.<span class="mw-ref" id="cite_ref-FDA_54-2"><a href="#cite_note-FDA-54" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span> Gastrointestinal side effects may include abdominal pain, constipation, diarrhea, and nausea.<span class="mw-ref" id="cite_ref-Stahl's_Essential_Psychopharmacology_60-0"><a href="#cite_note-Stahl's_Essential_Psychopharmacology-60" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></span><span class="mw-ref" id="cite_ref-FDA_54-3"><a href="#cite_note-FDA-54" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-Dyanavel_61-0"><a href="#cite_note-Dyanavel-61" style="counter-reset: mw-Ref 59;"><span class="mw-reflink-text">[59]</span></a></span> Other potential physical side effects include appetite loss, blurred vision, dry mouth, excessive grinding of the teeth, nosebleed, profuse sweating, rhinitis medicamentosa (drug-induced nasal congestion), reduced seizure threshold, tics (a type of movement disorder), and weight loss.<span class="mw-ref" id="cite_ref-63"><a href="#cite_note-63" style="counter-reset: mw-Ref 1;" data-mw-group="sources"><span class="mw-reflink-text">[sources 1]</span></a></span> Dangerous physical side effects are rare at typical pharmaceutical doses.<span class="mw-ref" id="cite_ref-Westfall_46-3"><a href="#cite_note-Westfall-46" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span></p><span>

</span><p>Amphetamine stimulates the medullary respiratory centers, producing faster and deeper breaths.<span class="mw-ref" id="cite_ref-Westfall_46-4"><a href="#cite_note-Westfall-46" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> In a normal person at therapeutic doses, this effect is usually not noticeable, but when respiration is already compromised, it may be evident.<span class="mw-ref" id="cite_ref-Westfall_46-5"><a href="#cite_note-Westfall-46" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> Amphetamine also induces contraction in the urinary bladder sphincter, the muscle which controls urination, which can result in difficulty urinating.<span class="mw-ref" id="cite_ref-Westfall_46-6"><a href="#cite_note-Westfall-46" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> This effect can be useful in treating bed wetting and loss of bladder control.<span class="mw-ref" id="cite_ref-Westfall_46-7"><a href="#cite_note-Westfall-46" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> The effects of amphetamine on the gastrointestinal tract are unpredictable.<span class="mw-ref" id="cite_ref-Westfall_46-8"><a href="#cite_note-Westfall-46" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> If intestinal activity is high, amphetamine may reduce gastrointestinal motility (the rate at which content moves through the digestive system);<span class="mw-ref" id="cite_ref-Westfall_46-9"><a href="#cite_note-Westfall-46" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> however, amphetamine may increase motility when the smooth muscle of the tract is relaxed.<span class="mw-ref" id="cite_ref-Westfall_46-10"><a href="#cite_note-Westfall-46" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> Amphetamine also has a slight analgesic effect and can enhance the pain relieving effects of opioids.<span class="mw-ref" id="cite_ref-Stahl's_Essential_Psychopharmacology_60-2"><a href="#cite_note-Stahl's_Essential_Psychopharmacology-60" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></span><span class="mw-ref" id="cite_ref-Westfall_46-11"><a href="#cite_note-Westfall-46" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span></p><span>

</span><p>USFDA-commissioned studies from 2011 indicate that in children, young adults, and adults there is no association between serious adverse cardiovascular events (sudden death, heart attack, and stroke) and the medical use of amphetamine or other ADHD stimulants.<span class="mw-ref" id="cite_ref-68"><a href="#cite_note-68" style="counter-reset: mw-Ref 2;" data-mw-group="sources"><span class="mw-reflink-text">[sources 2]</span></a></span> However, amphetamine pharmaceuticals are contraindicated in individuals with cardiovascular disease.<span class="mw-ref" id="cite_ref-69"><a href="#cite_note-69" style="counter-reset: mw-Ref 3;" data-mw-group="sources"><span class="mw-reflink-text">[sources 3]</span></a></span></p><span>

</span>
</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Psychological">Psychological</h3></summary>
    <span>
</span><p>At normal therapeutic doses, the most common psychological side effects of amphetamine include increased alertness, apprehension, concentration, initiative, self-confidence and sociability, mood swings (elated mood followed by mildly depressed mood), insomnia or wakefulness, and decreased sense of fatigue.<span class="mw-ref" id="cite_ref-FDA_54-6"><a href="#cite_note-FDA-54" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-Westfall_46-12"><a href="#cite_note-Westfall-46" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> Less common side effects include anxiety, change in libido, grandiosity, irritability, repetitive or obsessive behaviors, and restlessness;<span class="mw-ref" id="cite_ref-72"><a href="#cite_note-72" style="counter-reset: mw-Ref 4;" data-mw-group="sources"><span class="mw-reflink-text">[sources 4]</span></a></span> these effects depend on the user's personality and current mental state.<span class="mw-ref" id="cite_ref-Westfall_46-14"><a href="#cite_note-Westfall-46" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> Amphetamine psychosis (e.g., delusions and paranoia) can occur in heavy users.<span class="mw-ref" id="cite_ref-FDA_54-8"><a href="#cite_note-FDA-54" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-Cochrane_73-0"><a href="#cite_note-Cochrane-73" style="counter-reset: mw-Ref 67;"><span class="mw-reflink-text">[67]</span></a></span><span class="mw-ref" id="cite_ref-Amphetamine-induced_psychosis_74-0"><a href="#cite_note-Amphetamine-induced_psychosis-74" style="counter-reset: mw-Ref 68;"><span class="mw-reflink-text">[68]</span></a></span> Although very rare, this psychosis can also occur at therapeutic doses during long-term therapy.<span class="mw-ref" id="cite_ref-FDA_54-9"><a href="#cite_note-FDA-54" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-Amphetamine-induced_psychosis_74-1"><a href="#cite_note-Amphetamine-induced_psychosis-74" style="counter-reset: mw-Ref 68;"><span class="mw-reflink-text">[68]</span></a></span><span class="mw-ref" id="cite_ref-Stimulant_Misuse_75-0"><a href="#cite_note-Stimulant_Misuse-75" style="counter-reset: mw-Ref 69;"><span class="mw-reflink-text">[69]</span></a></span> According to the USFDA, "there is no systematic evidence" that stimulants produce aggressive behavior or hostility.<span class="mw-ref" id="cite_ref-FDA_54-10"><a href="#cite_note-FDA-54" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span></p><span>

</span><p>Amphetamine has also been shown to produce a conditioned place preference in humans taking therapeutic doses,<span class="mw-ref" id="cite_ref-Cochrane_Amphetamines_ADHD_32-1"><a href="#cite_note-Cochrane_Amphetamines_ADHD-32" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span><span class="mw-ref" id="cite_ref-Human_CPP_76-0"><a href="#cite_note-Human_CPP-76" style="counter-reset: mw-Ref 70;"><span class="mw-reflink-text">[70]</span></a></span> meaning that individuals acquire a preference for spending time in places where they have previously used amphetamine.<span class="mw-ref" id="cite_ref-Human_CPP_76-1"><a href="#cite_note-Human_CPP-76" style="counter-reset: mw-Ref 70;"><span class="mw-reflink-text">[70]</span></a></span><span class="mw-ref" id="cite_ref-Addiction_glossary_77-0"><a href="#cite_note-Addiction_glossary-77" style="counter-reset: mw-Ref 71;"><span class="mw-reflink-text">[71]</span></a></span></p><span>

</span>
</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Reinforcement_disorders">Reinforcement disorders</h3></summary>
    <span>

</span>
</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Addiction">Addiction</h4></summary>
    <span>
</span><table class="infobox mw-collapsible mw-collapsed" style="width:22em;width:610px; ; border-collapse:collapse;"><tbody><tr><th colspan="2" style="text-align:center;font-size:125%;font-weight:bold;font-size:100%; background:#FFCC66; -moz-box-shadow: inset 3px 3px 0 #fafafa, inset -3px -3px 0 #fafafa; -webkit-box-shadow: inset 3px 3px 0 #fafafa, inset -3px -3px 0 #fafafa; box-shadow: inset 3px 3px 0 #fafafa, inset -3px -3px 0 #fafafa;; padding:5px;">Addiction and dependence glossary<span class="mw-ref" id="cite_ref-Addiction_glossary_77-1"><a href="#cite_note-Addiction_glossary-77" style="counter-reset: mw-Ref 71;"><span class="mw-reflink-text">[71]</span></a></span><span class="mw-ref" id="cite_ref-Cellular_basis_78-0"><a href="#cite_note-Cellular_basis-78" style="counter-reset: mw-Ref 72;"><span class="mw-reflink-text">[72]</span></a></span><span class="mw-ref" id="cite_ref-Nestler_Labs_Glossary_79-0"><a href="#cite_note-Nestler_Labs_Glossary-79" style="counter-reset: mw-Ref 73;"><span class="mw-reflink-text">[73]</span></a></span><span class="mw-ref" id="cite_ref-Brain_disease_80-0"><a href="#cite_note-Brain_disease-80" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span></th></tr><tr><td colspan="2" style="text-align:center;text-align:left; padding-left:0;">
<ul><li><b>addiction</b> – a biopsychosocial disorder characterized by compulsively seeking to achieve a desired effect, such as intoxication, despite harm and adverse consequences to self and others</li>
<li><b>addictive behavior</b> – a behavior that is both rewarding and reinforcing</li>
<li><b>addictive drug</b> – a drug that is both rewarding and reinforcing</li>
<li><b>dependence</b> – an adaptive state associated with a withdrawal syndrome upon cessation of repeated exposure to a stimulus (e.g., drug intake)</li>
<li><b>drug sensitization</b> or <b>reverse tolerance</b> – the escalating effect of a drug resulting from repeated administration at a given dose</li>
<li><b>drug withdrawal</b> – symptoms that occur upon cessation of repeated drug use</li>
<li><b>physical dependence</b> – dependence that involves persistent physical–<a href="javascript:if(confirm('https://en.wiktionary.org/wiki/somatic  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wiktionary.org/wiki/somatic'" tppabs="https://en.wiktionary.org/wiki/somatic" title="wikt:somatic" class="external">somatic</a> withdrawal symptoms (e.g., fatigue and delirium tremens)</li>
<li><b>psychological dependence</b> – dependence that involves emotional–motivational withdrawal symptoms (e.g., dysphoria and anhedonia)</li>
<li><b>reinforcing stimuli</b> – stimuli that increase the probability of repeating behaviors paired with them</li>
<li><b>rewarding stimuli</b> – stimuli that the brain interprets as intrinsically positive and desirable or as something to approach</li>
<li><b>sensitization</b> – an amplified response to a stimulus resulting from repeated exposure to it</li>
<li><b>substance use disorder</b> – a condition in which the use of substances leads to clinically and functionally significant impairment or distress</li>
<li><b>tolerance</b> – the diminishing effect of a drug resulting from repeated administration at a given dose</li></ul>
</td></tr><tr><td colspan="2" style="text-align:center;text-align:right; padding-top:0; padding-right:5px;"></td></tr></tbody></table><span>
</span><table class="infobox mw-collapsible mw-collapsed" style="width:22em;width:610px; ; border-collapse:collapse;"><tbody><tr><th colspan="2" style="text-align:center;font-size:125%;font-weight:bold;font-size:100%; background:#FFCC66; -moz-box-shadow: inset 3px 3px 0 #fafafa, inset -3px -3px 0 #fafafa; -webkit-box-shadow: inset 3px 3px 0 #fafafa, inset -3px -3px 0 #fafafa; box-shadow: inset 3px 3px 0 #fafafa, inset -3px -3px 0 #fafafa;; padding:5px;">Transcription factor glossary</th></tr><tr><td colspan="2" style="text-align:center;text-align:left; padding-left:0;">
<ul><li><b>gene expression</b> – the process by which information from a gene is used in the synthesis of a functional gene product such as a protein</li>
<li><b>transcription</b> – the process of making messenger RNA (mRNA) from a DNA template by RNA polymerase</li>
<li><b>transcription factor</b> – a protein that binds to DNA and regulates gene expression by promoting or suppressing transcription</li>
<li><b>transcriptional regulation</b> – <i>controlling</i> the rate of gene transcription for example by helping or hindering RNA polymerase binding to DNA</li>
<li><b>upregulation</b>, <b>activation</b>, or <b>promotion</b> – <i>increase</i> the rate of gene transcription</li>
<li><b>downregulation</b>, <b>repression</b>, or <b>suppression</b> – <i>decrease</i> the rate of gene transcription</li>
<li><b>coactivator</b> – a protein that works with transcription factors to <i>increase</i> the rate of gene transcription</li>
<li><b>corepressor</b> – a protein that works with transcription factors to <i>decrease</i> the rate of gene transcription</li>
<li><b>response element</b> – a specific sequence of DNA that a transcription factor binds to</li></ul>
</td></tr><tr><td colspan="2" style="text-align:center;text-align:right; padding-top:0; padding-right:5px;"></td></tr></tbody></table><span>

</span><table role="presentation" cellpadding="0" style="border-spacing:0; clear:right; float:right;">
<tbody><tr>
<td><div class="thumb tright">
<div class="thumbinner" style="width:602px; ">
<div style="clear: both; font-weight: bold; font-size: 106.4%; text-align: center; background-color: #F0F8FF;margin-bottom:3px;">Signaling cascade in the nucleus accumbens that results in amphetamine addiction<br></div>
<div style="position:relative; width:600px; height:620px; overflow:hidden; border:solid #ccc 1px; background-color:white;">
<div style="left:0px; top:0px; width:600px; position:absolute"> <figure-inline><img src="../I/m/ΔFosB.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/%CE%94FosB.svg.png" data-file-width="935" data-file-height="965" data-file-type="drawing" height="619" width="600"></figure-inline>
</div> 
<div style="text-align:center; font-size:14px; line-height:110%;">
<div style="background-color:transparent; color:black"><div id="annotation_475x5" style="position:absolute; left:475px; top:5px;   font-size:12px;   line-height:14px; "><span style="background-color:transparent; "><b>Note: colored text contains article links.</b></span></div>

<div id="annotation_320x325" style="position:absolute; left:320px; top:325px;      line-height:110% "><span style="background-color:transparent; ">Nuclear pore</span></div>
<div id="annotation_350x362" style="position:absolute; left:350px; top:362px;      line-height:110% "><span style="background-color:transparent; ">Nuclear membrane</span></div>
<div id="annotation_475x425" style="position:absolute; left:475px; top:425px;      line-height:110% "><span style="background-color:transparent; ">Plasma membrane</span></div>

<div id="annotation_65x48" style="position:absolute; left:65px; top:48px;      line-height:110% "><span style="background-color:transparent; ">Ca<sub>v</sub>1.2</span></div>
<div id="annotation_43x98" style="position:absolute; left:43px; top:98px;      line-height:110% "><span style="background-color:transparent; ">NMDAR</span></div>
<div id="annotation_33x185" style="position:absolute; left:33px; top:185px;      line-height:110% "><span style="background-color:transparent; ">AMPAR</span></div>
<div id="annotation_41x238" style="position:absolute; left:41px; top:238px;      line-height:110% "><span style="background-color:transparent; ">DRD1</span></div>
<div id="annotation_42x285" style="position:absolute; left:42px; top:285px;      line-height:110% "><span style="background-color:transparent; ">DRD5</span></div>
<div id="annotation_47x331" style="position:absolute; left:47px; top:331px;      line-height:110% "><span style="background-color:transparent; ">DRD2</span></div>
<div id="annotation_56x366" style="position:absolute; left:56px; top:366px;      line-height:110% "><span style="background-color:transparent; ">DRD3</span></div>
<div id="annotation_84x385" style="position:absolute; left:84px; top:385px;      line-height:110% "><span style="background-color:transparent; ">DRD4</span></div>

<div id="annotation_172x256" style="position:absolute; left:172px; top:256px;      line-height:110% "><span style="background-color:transparent; ">G<sub>s</sub></span></div>
<div id="annotation_173x325" style="position:absolute; left:173px; top:325px;      line-height:110% "><span style="background-color:transparent; ">G<sub>i/o</sub></span></div>
<div id="annotation_234x288" style="position:absolute; left:234px; top:288px;      line-height:110% "><span style="background-color:transparent; ">AC</span></div>
<div id="annotation_18x595" style="position:absolute; left:18px; top:595px;   font-size:9.5px;   line-height:11.5px; "><span style="background-color:transparent; "><a href="Cyclic_adenosine_monophosphate.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclic_adenosine_monophosphate" title="Cyclic adenosine monophosphate"><b>cAMP</b></a></span></div>
<div id="annotation_269x340" style="position:absolute; left:269px; top:340px;   font-size:10px;   line-height:12px; "><span style="background-color:transparent; "><a href="Cyclic_adenosine_monophosphate.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclic_adenosine_monophosphate" title="Cyclic adenosine monophosphate"><b>cAMP</b></a></span></div>
<div id="annotation_312x288" style="position:absolute; left:312px; top:288px;      line-height:110% "><span style="background-color:transparent; ">PKA</span></div>

<div id="annotation_228x110.5" style="position:absolute; left:228px; top:110.5px;      line-height:110% "><span style="background-color:transparent; ">CaM</span></div>
<div id="annotation_329x99" style="position:absolute; left:329px; top:99px;      line-height:110% "><span style="background-color:transparent; ">CaMKII</span></div>
<div id="annotation_301x215" style="position:absolute; left:301px; top:215px;      line-height:110% "><span style="background-color:transparent; ">DARPP-32</span></div>
<div id="annotation_328x161.5" style="position:absolute; left:328px; top:161.5px;      line-height:110% "><span style="background-color:transparent; ">PP1</span></div>
<div id="annotation_247.5x159" style="position:absolute; left:247.5px; top:159px;      line-height:110% "><span style="background-color:transparent; ">PP2B</span></div>

<div id="annotation_458x163" style="position:absolute; left:458px; top:163px;      line-height:110% "><span style="background-color:transparent; "><span style="color:MediumVioletRed">CREB</span></span></div>
<div id="annotation_440x222" style="position:absolute; left:440px; top:222px;      line-height:110% "><span style="background-color:transparent; "><b><span style="color:MediumVioletRed">ΔFosB</span></b></span></div>
<div id="annotation_447x241" style="position:absolute; left:447px; top:241px;      line-height:110% "><span style="background-color:transparent; "><b><span style="color:MediumVioletRed">JunD</span></b></span></div>
<div id="annotation_542x233.5" style="position:absolute; left:542px; top:233.5px;      line-height:110% "><span style="background-color:transparent; "><span style="color:MediumVioletRed"><span class="nowrap">c-Fos</span></span></span></div>
<div id="annotation_442x274.5" style="position:absolute; left:442px; top:274.5px;      line-height:110% "><span style="background-color:transparent; ">SIRT1</span></div>
<div id="annotation_468.5x299" style="position:absolute; left:468.5px; top:299px;      line-height:110% "><span style="background-color:transparent; ">HDAC1</span></div>

<div id="annotation_495x35" style="position:absolute; left:495px; top:35px;      line-height:110% "><span style="background-color:transparent; "><span class="mw-ref" id="cite_ref-81"><a href="#cite_note-81" style="counter-reset: mw-Ref 1;" data-mw-group="Color legend"><span class="mw-reflink-text">[Color legend 1]</span></a></span></span></div></div>
</div>
</div>
<div class="thumbcaption" style="clear:left"><div style="float:left;margin-right:0.5em"><figure-inline><span><img src="../I/m/Interactive_icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Interactive_icon.svg.png" data-file-width="133" data-file-height="200" data-file-type="drawing" height="27" width="18"></span></figure-inline></div>This diagram depicts the signaling events in the brain's reward center that are induced by chronic high-dose exposure to psychostimulants that increase the concentration of synaptic dopamine, like <a href="Amphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amphetamine" title="Amphetamine">amphetamine</a>, <a href="Methamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Methamphetamine" title="Methamphetamine">methamphetamine</a>, and <a href="Phenethylamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenethylamine" title="Phenethylamine">phenethylamine</a>. Following presynaptic <a href="Dopamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dopamine" title="Dopamine">dopamine</a> and glutamate co-release by such psychostimulants,<span class="mw-ref" id="cite_ref-Nestler-Renthal_Figure_2_82-0"><a href="#cite_note-Nestler-Renthal_Figure_2-82" style="counter-reset: mw-Ref 75;"><span class="mw-reflink-text">[75]</span></a></span><span class="mw-ref" id="cite_ref-Glutamate-dopamine_cotransmission_review_83-0"><a href="#cite_note-Glutamate-dopamine_cotransmission_review-83" style="counter-reset: mw-Ref 76;"><span class="mw-reflink-text">[76]</span></a></span> postsynaptic receptors for these neurotransmitters trigger internal signaling events through a cAMP-dependent pathway and a calcium-dependent pathway that ultimately result in increased <abbr>CREB</abbr> phosphorylation.<span class="mw-ref" id="cite_ref-Nestler-Renthal_Figure_2_82-1"><a href="#cite_note-Nestler-Renthal_Figure_2-82" style="counter-reset: mw-Ref 75;"><span class="mw-reflink-text">[75]</span></a></span><span class="mw-ref" id="cite_ref-Amphetamine_KEGG_ΔFosB_84-0"><a href="#cite_note-Amphetamine_KEGG_ΔFosB-84" style="counter-reset: mw-Ref 77;"><span class="mw-reflink-text">[77]</span></a></span><span class="mw-ref" id="cite_ref-Meth_cAMP/calcium-dependent_cascade_85-0"><a href="#cite_note-Meth_cAMP/calcium-dependent_cascade-85" style="counter-reset: mw-Ref 78;"><span class="mw-reflink-text">[78]</span></a></span>  Phosphorylated CREB increases levels of ΔFosB, which in turn represses the <span class="nowrap">c-Fos</span> gene with the help of corepressors;<span class="mw-ref" id="cite_ref-Nestler-Renthal_Figure_2_82-2"><a href="#cite_note-Nestler-Renthal_Figure_2-82" style="counter-reset: mw-Ref 75;"><span class="mw-reflink-text">[75]</span></a></span><span class="mw-ref" id="cite_ref-Nestler1_86-0"><a href="#cite_note-Nestler1-86" style="counter-reset: mw-Ref 79;"><span class="mw-reflink-text">[79]</span></a></span><span class="mw-ref" id="cite_ref-Nestler2_87-0"><a href="#cite_note-Nestler2-87" style="counter-reset: mw-Ref 80;"><span class="mw-reflink-text">[80]</span></a></span> <span class="nowrap">c-Fos</span> repression acts as a molecular switch that enables the accumulation of ΔFosB in the neuron.<span class="mw-ref" id="cite_ref-c-Fos_repression_88-0"><a href="#cite_note-c-Fos_repression-88" style="counter-reset: mw-Ref 81;"><span class="mw-reflink-text">[81]</span></a></span> A highly stable (phosphorylated) form of ΔFosB, one that persists in neurons for <span class="nowrap">1–2</span><span>&nbsp;</span>months, slowly accumulates following repeated high-dose exposure to stimulants through this process.<span class="mw-ref" id="cite_ref-Nestler1_86-1"><a href="#cite_note-Nestler1-86" style="counter-reset: mw-Ref 79;"><span class="mw-reflink-text">[79]</span></a></span><span class="mw-ref" id="cite_ref-Nestler2_87-1"><a href="#cite_note-Nestler2-87" style="counter-reset: mw-Ref 80;"><span class="mw-reflink-text">[80]</span></a></span> ΔFosB functions as "one of the master control proteins" that produces addiction-related structural changes in the brain, and upon sufficient accumulation, with the help of its downstream targets (e.g., nuclear factor kappa B), it induces an addictive state.<span class="mw-ref" id="cite_ref-Nestler1_86-2"><a href="#cite_note-Nestler1-86" style="counter-reset: mw-Ref 79;"><span class="mw-reflink-text">[79]</span></a></span><span class="mw-ref" id="cite_ref-Nestler2_87-2"><a href="#cite_note-Nestler2-87" style="counter-reset: mw-Ref 80;"><span class="mw-reflink-text">[80]</span></a></span></div>
</div>
</div></td></tr>
</tbody></table><span>
</span><p>Addiction is a serious risk with heavy recreational amphetamine use, but is unlikely to occur from long-term medical use at therapeutic doses;<span class="mw-ref" id="cite_ref-Long-Term_Outcomes_Medications_20-4"><a href="#cite_note-Long-Term_Outcomes_Medications-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-NHMH_3e-Addiction_doses_89-0"><a href="#cite_note-NHMH_3e-Addiction_doses-89" style="counter-reset: mw-Ref 82;"><span class="mw-reflink-text">[82]</span></a></span><span class="mw-ref" id="cite_ref-Addiction_risk_90-0"><a href="#cite_note-Addiction_risk-90" style="counter-reset: mw-Ref 83;"><span class="mw-reflink-text">[83]</span></a></span> in fact, lifetime stimulant therapy for ADHD that begins during childhood reduces the risk of developing substance use disorders as an adult.<span class="mw-ref" id="cite_ref-Long-Term_Outcomes_Medications_20-5"><a href="#cite_note-Long-Term_Outcomes_Medications-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> Compared to other amphetamine pharmaceuticals, lisdexamfetamine may have a lower liability for abuse as a recreational drug.<span class="mw-ref" id="cite_ref-LDX_abuse_91-0"><a href="#cite_note-LDX_abuse-91" style="counter-reset: mw-Ref 84;"><span class="mw-reflink-text">[84]</span></a></span> Pathological overactivation of the mesolimbic pathway, a dopamine pathway that connects the ventral tegmental area to the nucleus accumbens, plays a central role in amphetamine addiction.<span class="mw-ref" id="cite_ref-Amphetamine_KEGG_–_ΔFosB_92-0"><a href="#cite_note-Amphetamine_KEGG_–_ΔFosB-92" style="counter-reset: mw-Ref 85;"><span class="mw-reflink-text">[85]</span></a></span><span class="mw-ref" id="cite_ref-Magnesium_93-0"><a href="#cite_note-Magnesium-93" style="counter-reset: mw-Ref 86;"><span class="mw-reflink-text">[86]</span></a></span> Individuals who frequently self-administer high doses of amphetamine have a high risk of developing an amphetamine addiction, since chronic use at high doses gradually increase the level of accumbal ΔFosB, a "molecular switch" and "master control protein" for addiction.<span class="mw-ref" id="cite_ref-Cellular_basis_78-1"><a href="#cite_note-Cellular_basis-78" style="counter-reset: mw-Ref 72;"><span class="mw-reflink-text">[72]</span></a></span><span class="mw-ref" id="cite_ref-What_the_ΔFosB?_94-0"><a href="#cite_note-What_the_ΔFosB?-94" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></span><span class="mw-ref" id="cite_ref-Nestler_95-0"><a href="#cite_note-Nestler-95" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span> Once nucleus accumbens ΔFosB is sufficiently overexpressed, it begins to increase the severity of addictive behavior (i.e., compulsive drug-seeking) with further increases in its expression.<span class="mw-ref" id="cite_ref-What_the_ΔFosB?_94-1"><a href="#cite_note-What_the_ΔFosB?-94" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></span><span class="mw-ref" id="cite_ref-Natural_and_drug_addictions_96-0"><a href="#cite_note-Natural_and_drug_addictions-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span> While there are currently no effective drugs for treating amphetamine addiction, regularly engaging in sustained aerobic exercise appears to reduce the risk of developing such an addiction.<span class="mw-ref" id="cite_ref-Running_vs_addiction_97-0"><a href="#cite_note-Running_vs_addiction-97" style="counter-reset: mw-Ref 90;"><span class="mw-reflink-text">[90]</span></a></span><span class="mw-ref" id="cite_ref-Exercise,_addiction_prevention,_and_ΔFosB_98-0"><a href="#cite_note-Exercise,_addiction_prevention,_and_ΔFosB-98" style="counter-reset: mw-Ref 91;"><span class="mw-reflink-text">[91]</span></a></span> Sustained aerobic exercise on a regular basis also appears to be an effective treatment for amphetamine addiction;<span class="mw-ref" id="cite_ref-Exercise_therapy_99-0"><a href="#cite_note-Exercise_therapy-99" style="counter-reset: mw-Ref 5;" data-mw-group="sources"><span class="mw-reflink-text">[sources 5]</span></a></span> exercise therapy improves <a href="javascript:if(confirm('https://en.wiktionary.org/wiki/clinical  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wiktionary.org/wiki/clinical'" tppabs="https://en.wiktionary.org/wiki/clinical" title="wikt:clinical" class="external">clinical</a> treatment outcomes and may be used as an adjunct therapy with behavioral therapies for addiction.<span class="mw-ref" id="cite_ref-Running_vs_addiction_97-1"><a href="#cite_note-Running_vs_addiction-97" style="counter-reset: mw-Ref 90;"><span class="mw-reflink-text">[90]</span></a></span><span class="mw-ref" id="cite_ref-Exercise_Rev_3_100-0"><a href="#cite_note-Exercise_Rev_3-100" style="counter-reset: mw-Ref 92;"><span class="mw-reflink-text">[92]</span></a></span></p><span>

</span>
</details>
<details data-level="5" open="">
    <summary class="section-heading"><h5 id="Biomolecular_mechanisms">Biomolecular mechanisms</h5></summary>
    <span>
</span><p>Chronic use of amphetamine at excessive doses causes alterations in gene expression in the mesocorticolimbic projection, which arise through transcriptional and epigenetic mechanisms.<span class="mw-ref" id="cite_ref-Nestler_95-1"><a href="#cite_note-Nestler-95" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span><span class="mw-ref" id="cite_ref-Nestler,_Hyman,_and_Malenka_2_101-0"><a href="#cite_note-Nestler,_Hyman,_and_Malenka_2-101" style="counter-reset: mw-Ref 93;"><span class="mw-reflink-text">[93]</span></a></span><span class="mw-ref" id="cite_ref-Addiction_genetics_102-0"><a href="#cite_note-Addiction_genetics-102" style="counter-reset: mw-Ref 94;"><span class="mw-reflink-text">[94]</span></a></span> The most important transcription factors<span class="mw-ref" id="cite_ref-104"><a href="#cite_note-104" style="counter-reset: mw-Ref 3;" data-mw-group="note"><span class="mw-reflink-text">[note 3]</span></a></span> that produce these alterations are <i>Delta FBJ murine osteosarcoma viral oncogene homolog B</i> (ΔFosB), <i><a href="Cyclic_adenosine_monophosphate.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyclic_adenosine_monophosphate" title="Cyclic adenosine monophosphate">cAMP</a> response element binding protein</i> (CREB), and <i>nuclear factor-kappa B</i> (NF-κB).<span class="mw-ref" id="cite_ref-Nestler_95-2"><a href="#cite_note-Nestler-95" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span> ΔFosB is the most significant biomolecular mechanism in addiction because ΔFosB overexpression (i.e., an abnormally high level of gene expression which produces a pronounced gene-related phenotype) in the D1-type medium spiny neurons in the nucleus accumbens is necessary and sufficient<span class="mw-ref" id="cite_ref-105"><a href="#cite_note-105" style="counter-reset: mw-Ref 4;" data-mw-group="note"><span class="mw-reflink-text">[note 4]</span></a></span> for many of the neural adaptations and regulates multiple behavioral effects (e.g., reward sensitization and escalating drug self-administration) involved in addiction.<span class="mw-ref" id="cite_ref-Cellular_basis_78-2"><a href="#cite_note-Cellular_basis-78" style="counter-reset: mw-Ref 72;"><span class="mw-reflink-text">[72]</span></a></span><span class="mw-ref" id="cite_ref-What_the_ΔFosB?_94-2"><a href="#cite_note-What_the_ΔFosB?-94" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></span><span class="mw-ref" id="cite_ref-Nestler_95-3"><a href="#cite_note-Nestler-95" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span> Once ΔFosB is sufficiently overexpressed, it induces an addictive state that becomes increasingly more severe with further increases in ΔFosB expression.<span class="mw-ref" id="cite_ref-Cellular_basis_78-3"><a href="#cite_note-Cellular_basis-78" style="counter-reset: mw-Ref 72;"><span class="mw-reflink-text">[72]</span></a></span><span class="mw-ref" id="cite_ref-What_the_ΔFosB?_94-3"><a href="#cite_note-What_the_ΔFosB?-94" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></span> It has been implicated in addictions to alcohol, cannabinoids, <a href="Cocaine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cocaine" title="Cocaine">cocaine</a>, <a href="Methylphenidate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methylphenidate" title="Methylphenidate">methylphenidate</a>, <a href="Nicotine.htm" tppabs="https://ptable.com/wiki/compounds/A/Nicotine" title="Nicotine">nicotine</a>, opioids, <a href="Phencyclidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phencyclidine" title="Phencyclidine">phencyclidine</a>, <a href="Propofol.htm" tppabs="https://ptable.com/wiki/compounds/A/Propofol" title="Propofol">propofol</a>, and substituted amphetamines, among others.<span class="mw-ref" id="cite_ref-108"><a href="#cite_note-108" style="counter-reset: mw-Ref 6;" data-mw-group="sources"><span class="mw-reflink-text">[sources 6]</span></a></span></p><span>

</span><p>ΔJunD, a transcription factor, and G9a, a histone methyltransferase enzyme, both oppose the function of ΔFosB and inhibit increases in its expression.<span class="mw-ref" id="cite_ref-Cellular_basis_78-4"><a href="#cite_note-Cellular_basis-78" style="counter-reset: mw-Ref 72;"><span class="mw-reflink-text">[72]</span></a></span><span class="mw-ref" id="cite_ref-Nestler_95-5"><a href="#cite_note-Nestler-95" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span><span class="mw-ref" id="cite_ref-Nestler_2014_epigenetics_109-0"><a href="#cite_note-Nestler_2014_epigenetics-109" style="counter-reset: mw-Ref 98;"><span class="mw-reflink-text">[98]</span></a></span> Sufficiently overexpressing ΔJunD in the nucleus accumbens with viral vectors can completely block many of the neural and behavioral alterations seen in chronic drug abuse (i.e., the alterations mediated by ΔFosB).<span class="mw-ref" id="cite_ref-Nestler_95-6"><a href="#cite_note-Nestler-95" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span> Similarly, accumbal G9a hyperexpression results in markedly increased histone 3 <a href="Lysine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lysine" title="Lysine">lysine</a> residue 9 dimethylation (H3K9me2) and blocks the induction of ΔFosB-mediated neural and behavioral plasticity by chronic drug use,<span class="mw-ref" id="cite_ref-113"><a href="#cite_note-113" style="counter-reset: mw-Ref 7;" data-mw-group="sources"><span class="mw-reflink-text">[sources 7]</span></a></span> which occurs via H3K9me2-mediated repression of transcription factors for ΔFosB and H3K9me2-mediated repression of various ΔFosB transcriptional targets (e.g., CDK5).<span class="mw-ref" id="cite_ref-Nestler_95-8"><a href="#cite_note-Nestler-95" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span><span class="mw-ref" id="cite_ref-Nestler_2014_epigenetics_109-1"><a href="#cite_note-Nestler_2014_epigenetics-109" style="counter-reset: mw-Ref 98;"><span class="mw-reflink-text">[98]</span></a></span><span class="mw-ref" id="cite_ref-G9a_reverses_ΔFosB_plasticity_110-1"><a href="#cite_note-G9a_reverses_ΔFosB_plasticity-110" style="counter-reset: mw-Ref 99;"><span class="mw-reflink-text">[99]</span></a></span> ΔFosB also plays an important role in regulating behavioral responses to natural rewards, such as palatable food, sex, and exercise.<span class="mw-ref" id="cite_ref-Natural_and_drug_addictions_96-2"><a href="#cite_note-Natural_and_drug_addictions-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span><span class="mw-ref" id="cite_ref-Nestler_95-9"><a href="#cite_note-Nestler-95" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span><span class="mw-ref" id="cite_ref-ΔFosB_reward_114-0"><a href="#cite_note-ΔFosB_reward-114" style="counter-reset: mw-Ref 102;"><span class="mw-reflink-text">[102]</span></a></span> Since both natural rewards and addictive drugs induce the expression of ΔFosB (i.e., they cause the brain to produce more of it), chronic acquisition of these rewards can result in a similar pathological state of addiction.<span class="mw-ref" id="cite_ref-Natural_and_drug_addictions_96-3"><a href="#cite_note-Natural_and_drug_addictions-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span><span class="mw-ref" id="cite_ref-Nestler_95-10"><a href="#cite_note-Nestler-95" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span> Consequently, ΔFosB is the most significant factor involved in both amphetamine addiction and amphetamine-induced sexual addictions, which are compulsive sexual behaviors that result from excessive sexual activity and amphetamine use.<span class="mw-ref" id="cite_ref-Natural_and_drug_addictions_96-4"><a href="#cite_note-Natural_and_drug_addictions-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span><span class="mw-ref" id="cite_ref-Amph-Sex_X-sensitization_through_D1_signaling_115-0"><a href="#cite_note-Amph-Sex_X-sensitization_through_D1_signaling-115" style="counter-reset: mw-Ref 103;"><span class="mw-reflink-text">[103]</span></a></span><span class="mw-ref" id="cite_ref-Amph-Sex_X-sensitization_through_NMDA_signaling_116-0"><a href="#cite_note-Amph-Sex_X-sensitization_through_NMDA_signaling-116" style="counter-reset: mw-Ref 104;"><span class="mw-reflink-text">[104]</span></a></span> These sexual addictions are associated with a dopamine dysregulation syndrome which occurs in some patients taking dopaminergic drugs.<span class="mw-ref" id="cite_ref-Natural_and_drug_addictions_96-5"><a href="#cite_note-Natural_and_drug_addictions-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span><span class="mw-ref" id="cite_ref-ΔFosB_reward_114-1"><a href="#cite_note-ΔFosB_reward-114" style="counter-reset: mw-Ref 102;"><span class="mw-reflink-text">[102]</span></a></span></p><span>

</span><p>The effects of amphetamine on gene regulation are both dose- and route-dependent.<span class="mw-ref" id="cite_ref-Addiction_genetics_102-1"><a href="#cite_note-Addiction_genetics-102" style="counter-reset: mw-Ref 94;"><span class="mw-reflink-text">[94]</span></a></span> Most of the research on gene regulation and addiction is based upon animal studies with intravenous amphetamine administration at very high doses.<span class="mw-ref" id="cite_ref-Addiction_genetics_102-2"><a href="#cite_note-Addiction_genetics-102" style="counter-reset: mw-Ref 94;"><span class="mw-reflink-text">[94]</span></a></span> The few studies that have used equivalent (weight-adjusted) human therapeutic doses and oral administration show that these changes, if they occur, are relatively minor.<span class="mw-ref" id="cite_ref-Addiction_genetics_102-3"><a href="#cite_note-Addiction_genetics-102" style="counter-reset: mw-Ref 94;"><span class="mw-reflink-text">[94]</span></a></span> This suggests that medical use of amphetamine does not significantly affect gene regulation.<span class="mw-ref" id="cite_ref-Addiction_genetics_102-4"><a href="#cite_note-Addiction_genetics-102" style="counter-reset: mw-Ref 94;"><span class="mw-reflink-text">[94]</span></a></span></p><span>

</span>
</details>
<details data-level="5" open="">
    <summary class="section-heading"><h5 id="Pharmacological_treatments">Pharmacological treatments</h5></summary>
    <span>
</span><span>
</span><p>As of December 2019, there is no effective pharmacotherapy for amphetamine addiction.<span class="mw-ref" id="cite_ref-NHMH_3e-Physical_dependence_+_psychostimulant_addiction_treatment_117-0"><a href="#cite_note-NHMH_3e-Physical_dependence_+_psychostimulant_addiction_treatment-117" style="counter-reset: mw-Ref 105;"><span class="mw-reflink-text">[105]</span></a></span><span class="mw-ref" id="cite_ref-SystRev-Meta_analysis_amphetamine_addiction_pharmacotherapy_118-0"><a href="#cite_note-SystRev-Meta_analysis_amphetamine_addiction_pharmacotherapy-118" style="counter-reset: mw-Ref 106;"><span class="mw-reflink-text">[106]</span></a></span><span class="mw-ref" id="cite_ref-pmid24716825_119-0"><a href="#cite_note-pmid24716825-119" style="counter-reset: mw-Ref 107;"><span class="mw-reflink-text">[107]</span></a></span> Reviews from 2015 and 2016 indicated that TAAR1-selective agonists have significant therapeutic potential as a treatment for psychostimulant addictions;<span class="mw-ref" id="cite_ref-Miller+Grandy_2016_120-0"><a href="#cite_note-Miller+Grandy_2016-120" style="counter-reset: mw-Ref 108;"><span class="mw-reflink-text">[108]</span></a></span><span class="mw-ref" id="cite_ref-TAAR1_addiction_2015_121-0"><a href="#cite_note-TAAR1_addiction_2015-121" style="counter-reset: mw-Ref 109;"><span class="mw-reflink-text">[109]</span></a></span> however, as of February 2016, the only compounds which are known to function as TAAR1-selective agonists are experimental drugs.<span class="mw-ref" id="cite_ref-Miller+Grandy_2016_120-1"><a href="#cite_note-Miller+Grandy_2016-120" style="counter-reset: mw-Ref 108;"><span class="mw-reflink-text">[108]</span></a></span><span class="mw-ref" id="cite_ref-TAAR1_addiction_2015_121-1"><a href="#cite_note-TAAR1_addiction_2015-121" style="counter-reset: mw-Ref 109;"><span class="mw-reflink-text">[109]</span></a></span> Amphetamine addiction is largely mediated through increased activation of dopamine receptors and <span class="nowrap"><a href="javascript:if(confirm('https://en.wiktionary.org/wiki/colocalize  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wiktionary.org/wiki/colocalize'" tppabs="https://en.wiktionary.org/wiki/colocalize" title="wikt:colocalize" class="external">co-localized</a></span> NMDA receptors<span class="mw-ref" id="cite_ref-123"><a href="#cite_note-123" style="counter-reset: mw-Ref 5;" data-mw-group="note"><span class="mw-reflink-text">[note 5]</span></a></span> in the nucleus accumbens;<span class="mw-ref" id="cite_ref-Magnesium_93-1"><a href="#cite_note-Magnesium-93" style="counter-reset: mw-Ref 86;"><span class="mw-reflink-text">[86]</span></a></span> <a href="Magnesium.htm" tppabs="https://ptable.com/wiki/compounds/A/Magnesium" title="Magnesium">magnesium ions</a> inhibit NMDA receptors by blocking the receptor calcium channel.<span class="mw-ref" id="cite_ref-Magnesium_93-2"><a href="#cite_note-Magnesium-93" style="counter-reset: mw-Ref 86;"><span class="mw-reflink-text">[86]</span></a></span><span class="mw-ref" id="cite_ref-NHM-NMDA_122-1"><a href="#cite_note-NHM-NMDA-122" style="counter-reset: mw-Ref 110;"><span class="mw-reflink-text">[110]</span></a></span> One review suggested that, based upon animal testing, pathological (addiction-inducing) psychostimulant use significantly reduces the level of intracellular magnesium throughout the brain.<span class="mw-ref" id="cite_ref-Magnesium_93-3"><a href="#cite_note-Magnesium-93" style="counter-reset: mw-Ref 86;"><span class="mw-reflink-text">[86]</span></a></span> Supplemental magnesium<span class="mw-ref" id="cite_ref-124"><a href="#cite_note-124" style="counter-reset: mw-Ref 6;" data-mw-group="note"><span class="mw-reflink-text">[note 6]</span></a></span> treatment has been shown to reduce amphetamine self-administration (i.e., doses given to oneself) in humans, but it is not an effective monotherapy for amphetamine addiction.<span class="mw-ref" id="cite_ref-Magnesium_93-5"><a href="#cite_note-Magnesium-93" style="counter-reset: mw-Ref 86;"><span class="mw-reflink-text">[86]</span></a></span></p><span>

</span><p>A systematic review and meta-analysis from 2019 assessed the efficacy of 17 different pharmacotherapies used in RCTs for amphetamine and methamphetamine addiction;<span class="mw-ref" id="cite_ref-SystRev-Meta_analysis_amphetamine_addiction_pharmacotherapy_118-1"><a href="#cite_note-SystRev-Meta_analysis_amphetamine_addiction_pharmacotherapy-118" style="counter-reset: mw-Ref 106;"><span class="mw-reflink-text">[106]</span></a></span> it found only low-strength evidence that methylphenidate might reduce amphetamine or methamphetamine self-administration.<span class="mw-ref" id="cite_ref-SystRev-Meta_analysis_amphetamine_addiction_pharmacotherapy_118-2"><a href="#cite_note-SystRev-Meta_analysis_amphetamine_addiction_pharmacotherapy-118" style="counter-reset: mw-Ref 106;"><span class="mw-reflink-text">[106]</span></a></span> There was low- to moderate-strength evidence of no benefit for most of the other medications used in RCTs, which included antidepressants (bupropion, <a href="Mirtazapine.htm" tppabs="https://ptable.com/wiki/compounds/A/Mirtazapine" title="Mirtazapine">mirtazapine</a>, <a href="Sertraline.htm" tppabs="https://ptable.com/wiki/compounds/A/Sertraline" title="Sertraline">sertraline</a>), antipsychotics (<a href="Aripiprazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Aripiprazole" title="Aripiprazole">aripiprazole</a>), anticonvulsants (<a href="Topiramate.htm" tppabs="https://ptable.com/wiki/compounds/A/Topiramate" title="Topiramate">topiramate</a>, <a href="Baclofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Baclofen" title="Baclofen">baclofen</a>, <a href="Gabapentin.htm" tppabs="https://ptable.com/wiki/compounds/A/Gabapentin" title="Gabapentin">gabapentin</a>), <a href="Naltrexone.htm" tppabs="https://ptable.com/wiki/compounds/A/Naltrexone" title="Naltrexone">naltrexone</a>, <a href="Varenicline.htm" tppabs="https://ptable.com/wiki/compounds/A/Varenicline" title="Varenicline">varenicline</a>, <a href="Citicoline.htm" tppabs="https://ptable.com/wiki/compounds/A/Citicoline" title="Citicoline">citicoline</a>, <a href="Ondansetron.htm" tppabs="https://ptable.com/wiki/compounds/A/Ondansetron" title="Ondansetron">ondansetron</a>, prometa, <a href="Riluzole.htm" tppabs="https://ptable.com/wiki/compounds/A/Riluzole" title="Riluzole">riluzole</a>, <a href="Atomoxetine.htm" tppabs="https://ptable.com/wiki/compounds/A/Atomoxetine" title="Atomoxetine">atomoxetine</a>, dextroamphetamine, and <a href="Modafinil.htm" tppabs="https://ptable.com/wiki/compounds/A/Modafinil" title="Modafinil">modafinil</a>.<span class="mw-ref" id="cite_ref-SystRev-Meta_analysis_amphetamine_addiction_pharmacotherapy_118-3"><a href="#cite_note-SystRev-Meta_analysis_amphetamine_addiction_pharmacotherapy-118" style="counter-reset: mw-Ref 106;"><span class="mw-reflink-text">[106]</span></a></span></p><span>

</span>
</details>
<details data-level="5" open="">
    <summary class="section-heading"><h5 id="Behavioral_treatments">Behavioral treatments</h5></summary>
    <span>
</span><p>A 2018 systematic review and network meta-analysis of 50 trials involving 12 different psychosocial interventions for amphetamine, methamphetamine, or cocaine addiction found that combination therapy with both contingency management and community reinforcement approach had the highest efficacy (i.e., abstinence rate) and acceptability (i.e., lowest dropout rate).<span class="mw-ref" id="cite_ref-Psychosocial_interventions_network_meta-analysis_125-0"><a href="#cite_note-Psychosocial_interventions_network_meta-analysis-125" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span> Other treatment modalities examined in the analysis included monotherapy with contingency management or community reinforcement approach, cognitive behavioral therapy, 12-step programs, non-contingent reward-based therapies, psychodynamic therapy, and other combination therapies involving these.<span class="mw-ref" id="cite_ref-Psychosocial_interventions_network_meta-analysis_125-1"><a href="#cite_note-Psychosocial_interventions_network_meta-analysis-125" style="counter-reset: mw-Ref 111;"><span class="mw-reflink-text">[111]</span></a></span></p><span>

</span><p>Additionally, research on the neurobiological effects of physical exercise suggests that daily aerobic exercise, especially endurance exercise (e.g., marathon running), prevents the development of drug addiction and is an effective adjunct therapy (i.e., a supplemental treatment) for amphetamine addiction.<span class="mw-ref" id="cite_ref-Exercise_therapy_99-1"><a href="#cite_note-Exercise_therapy-99" style="counter-reset: mw-Ref 5;" data-mw-group="sources"><span class="mw-reflink-text">[sources 5]</span></a></span> Exercise leads to better treatment outcomes when used as an adjunct treatment, particularly for psychostimulant addictions.<span class="mw-ref" id="cite_ref-Running_vs_addiction_97-3"><a href="#cite_note-Running_vs_addiction-97" style="counter-reset: mw-Ref 90;"><span class="mw-reflink-text">[90]</span></a></span><span class="mw-ref" id="cite_ref-Exercise_Rev_3_100-2"><a href="#cite_note-Exercise_Rev_3-100" style="counter-reset: mw-Ref 92;"><span class="mw-reflink-text">[92]</span></a></span><span class="mw-ref" id="cite_ref-Addiction_review_2016_126-1"><a href="#cite_note-Addiction_review_2016-126" style="counter-reset: mw-Ref 112;"><span class="mw-reflink-text">[112]</span></a></span> In particular, aerobic exercise decreases psychostimulant self-administration, reduces the reinstatement (i.e., relapse) of drug-seeking, and induces increased dopamine receptor D<sub>2</sub> (DRD2) density in the striatum.<span class="mw-ref" id="cite_ref-Natural_and_drug_addictions_96-7"><a href="#cite_note-Natural_and_drug_addictions-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span><span class="mw-ref" id="cite_ref-Addiction_review_2016_126-2"><a href="#cite_note-Addiction_review_2016-126" style="counter-reset: mw-Ref 112;"><span class="mw-reflink-text">[112]</span></a></span> This is the opposite of pathological stimulant use, which induces decreased striatal DRD2 density.<span class="mw-ref" id="cite_ref-Natural_and_drug_addictions_96-8"><a href="#cite_note-Natural_and_drug_addictions-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span> One review noted that exercise may also prevent the development of a drug addiction by altering ΔFosB or <span class="nowrap">c-Fos</span> immunoreactivity in the striatum or other parts of the reward system.<span class="mw-ref" id="cite_ref-Exercise,_addiction_prevention,_and_ΔFosB_98-2"><a href="#cite_note-Exercise,_addiction_prevention,_and_ΔFosB-98" style="counter-reset: mw-Ref 91;"><span class="mw-reflink-text">[91]</span></a></span></p><span>
</span><table class="wikitable unsortable" style="width: 100%; text-align:center; margin-left: auto; margin-right: auto; border: none;">
<caption>Summary of addiction-related plasticity</caption>
<tbody><tr><th scope="col" style="width: 25%;" rowspan="2">Form of neuroplasticity<br> or behavioral plasticity</th>
<th scope="col" style="width: 25%;" colspan="6">Type of reinforcer</th>
<th scope="col" style="width: 15%;" rowspan="2"><small>Sources</small></th></tr>
<tr>
<th scope="col" style="width: 15%;">Opiates</th>
<th scope="col" style="width: 15%;">Psychostimulants</th>
<th scope="col" style="width: 15%;">High fat or sugar food</th>
<th scope="col" style="width: 15%;">Sexual intercourse</th>
<th scope="col" style="width: 15%;">Physical exercise<br>(aerobic)</th>
<th scope="col" style="width: 15%;">Environmental<br>enrichment</th></tr>
<tr>
<td scope="row" style="height: 40px">ΔFosB expression in<br>nucleus accumbens D1-type <abbr>MSNs</abbr></td>
<td>↑</td><td>↑</td><td>↑</td><td>↑</td><td>↑</td><td>↑</td><td><span class="mw-ref" id="cite_ref-Natural_and_drug_addictions_96-9"><a href="#cite_note-Natural_and_drug_addictions-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span></td></tr>
<tr>
<th scope="col" colspan="8">Behavioral plasticity</th></tr>
<tr>
<td scope="row" style="height: 40px">Escalation of intake</td>
<td>Yes</td><td>Yes</td><td>Yes</td><td></td><td></td><td></td><td><span class="mw-ref" id="cite_ref-Natural_and_drug_addictions_96-10"><a href="#cite_note-Natural_and_drug_addictions-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span></td></tr>
<tr>
<td scope="row" style="height: 40px">Psychostimulant<br>cross-sensitization</td>
<td>Yes</td><td>Not applicable</td><td>Yes</td><td>Yes</td><td>Attenuated</td><td>Attenuated</td><td><span class="mw-ref" id="cite_ref-Natural_and_drug_addictions_96-11"><a href="#cite_note-Natural_and_drug_addictions-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span></td></tr>
<tr>
<td scope="row" style="height: 40px">Psychostimulant<br>self-administration</td>
<td>↑</td><td>↑</td><td>↓</td><td></td><td>↓</td><td>↓</td><td><span class="mw-ref" id="cite_ref-Natural_and_drug_addictions_96-12"><a href="#cite_note-Natural_and_drug_addictions-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span></td></tr>
<tr>
<td scope="row" style="height: 40px">Psychostimulant<br>conditioned place preference</td>
<td>↑</td><td>↑</td><td>↓</td><td>↑</td><td>↓</td><td>↑</td><td><span class="mw-ref" id="cite_ref-Natural_and_drug_addictions_96-13"><a href="#cite_note-Natural_and_drug_addictions-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span></td></tr>
<tr>
<td scope="row" style="height: 40px">Reinstatement of drug-seeking behavior</td>
<td>↑</td><td>↑</td><td></td><td></td><td>↓</td><td>↓</td><td><span class="mw-ref" id="cite_ref-Natural_and_drug_addictions_96-14"><a href="#cite_note-Natural_and_drug_addictions-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span></td></tr>
<tr>
<th scope="col" colspan="8">Neurochemical plasticity</th></tr>
<tr>
<td scope="row" style="height: 40px"><abbr>CREB</abbr> phosphorylation<br>in the <span class="nowrap">nucleus accumbens</span></td>
<td>↓</td><td>↓</td><td>↓</td><td></td><td>↓</td><td>↓</td><td><span class="mw-ref" id="cite_ref-Natural_and_drug_addictions_96-15"><a href="#cite_note-Natural_and_drug_addictions-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span></td></tr>
<tr>
<td scope="row" style="height: 40px">Sensitized <a href="Dopamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dopamine" title="Dopamine">dopamine</a> response<br>in the <span class="nowrap">nucleus accumbens</span></td>
<td>No</td><td>Yes</td><td>No</td><td>Yes</td><td></td><td></td><td><span class="mw-ref" id="cite_ref-Natural_and_drug_addictions_96-16"><a href="#cite_note-Natural_and_drug_addictions-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span></td></tr>
<tr>
<td scope="row" style="height: 40px">Altered striatal dopamine signaling</td>
<td>↓DRD2, ↑DRD3</td><td>↑DRD1, ↓DRD2, ↑DRD3</td><td>↑DRD1, ↓DRD2, ↑DRD3</td><td></td><td>↑DRD2</td><td>↑DRD2</td><td><span class="mw-ref" id="cite_ref-Natural_and_drug_addictions_96-17"><a href="#cite_note-Natural_and_drug_addictions-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span></td></tr>
<tr>
<td scope="row" style="height: 40px">Altered striatal opioid signaling</td>
<td>No change or<br>↑μ-opioid receptors</td><td>↑μ-opioid receptors<br>↑κ-opioid receptors</td><td>↑μ-opioid receptors</td><td>↑μ-opioid receptors</td><td>No change</td><td>No change</td><td><span class="mw-ref" id="cite_ref-Natural_and_drug_addictions_96-18"><a href="#cite_note-Natural_and_drug_addictions-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span></td></tr>
<tr>
<td scope="row" style="height: 40px">Changes in striatal opioid peptides</td>
<td>↑dynorphin<br>No change: enkephalin</td><td>↑dynorphin</td><td>↓enkephalin</td><td></td><td>↑dynorphin</td><td>↑dynorphin</td><td><span class="mw-ref" id="cite_ref-Natural_and_drug_addictions_96-19"><a href="#cite_note-Natural_and_drug_addictions-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span></td></tr>
<tr>
<th scope="col" colspan="8">Mesocorticolimbic synaptic plasticity</th></tr>
<tr>
<td scope="row" style="height: 40px">Number of dendrites in the <span class="nowrap">nucleus accumbens</span></td>
<td>↓</td><td>↑</td><td></td><td>↑</td><td></td><td></td><td><span class="mw-ref" id="cite_ref-Natural_and_drug_addictions_96-20"><a href="#cite_note-Natural_and_drug_addictions-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span></td></tr>
<tr>
<td scope="row" style="height: 40px">Dendritic spine density in<br>the <span class="nowrap">nucleus accumbens</span></td>
<td>↓</td><td>↑</td><td></td><td>↑</td><td></td><td></td><td><span class="mw-ref" id="cite_ref-Natural_and_drug_addictions_96-21"><a href="#cite_note-Natural_and_drug_addictions-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span></td></tr>
<tr class="mw-empty-elt"></tr>
</tbody></table><span>

</span>
</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Dependence_and_withdrawal">Dependence and withdrawal</h4></summary>
    <span>
</span><p>Drug tolerance develops rapidly in amphetamine abuse (i.e., recreational amphetamine use), so periods of extended abuse require increasingly larger doses of the drug in order to achieve the same effect.<span class="mw-ref" id="cite_ref-Cochrane_2013_treatments_127-0"><a href="#cite_note-Cochrane_2013_treatments-127" style="counter-reset: mw-Ref 113;"><span class="mw-reflink-text">[113]</span></a></span><span class="mw-ref" id="cite_ref-128"><a href="#cite_note-128" style="counter-reset: mw-Ref 114;"><span class="mw-reflink-text">[114]</span></a></span>
According to a Cochrane review on withdrawal in individuals who compulsively use amphetamine and methamphetamine, "when chronic heavy users abruptly discontinue amphetamine use, many report a time-limited withdrawal syndrome that occurs within 24<span>&nbsp;</span>hours of their last dose."<span class="mw-ref" id="cite_ref-Cochrane_Withdrawal_129-0"><a href="#cite_note-Cochrane_Withdrawal-129" style="counter-reset: mw-Ref 115;"><span class="mw-reflink-text">[115]</span></a></span> This review noted that withdrawal symptoms in chronic, high-dose users are frequent, occurring in roughly 88% of cases, and persist for <span class="nowrap">3–4</span><span>&nbsp;</span>weeks with a marked "crash" phase occurring during the first week.<span class="mw-ref" id="cite_ref-Cochrane_Withdrawal_129-1"><a href="#cite_note-Cochrane_Withdrawal-129" style="counter-reset: mw-Ref 115;"><span class="mw-reflink-text">[115]</span></a></span> Amphetamine withdrawal symptoms can include anxiety, drug craving, depressed mood, fatigue, increased appetite, increased movement or decreased movement, lack of motivation, sleeplessness or sleepiness, and lucid dreams.<span class="mw-ref" id="cite_ref-Cochrane_Withdrawal_129-2"><a href="#cite_note-Cochrane_Withdrawal-129" style="counter-reset: mw-Ref 115;"><span class="mw-reflink-text">[115]</span></a></span> The review indicated that the severity of withdrawal symptoms is positively correlated with the age of the individual and the extent of their dependence.<span class="mw-ref" id="cite_ref-Cochrane_Withdrawal_129-3"><a href="#cite_note-Cochrane_Withdrawal-129" style="counter-reset: mw-Ref 115;"><span class="mw-reflink-text">[115]</span></a></span> Mild withdrawal symptoms from the discontinuation of amphetamine treatment at therapeutic doses can be avoided by tapering the dose.<span class="mw-ref" id="cite_ref-Stahl's_Essential_Psychopharmacology_60-3"><a href="#cite_note-Stahl's_Essential_Psychopharmacology-60" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Overdose">Overdose</h2></summary>
    

<p>An amphetamine overdose can lead to many different symptoms, but is rarely fatal with appropriate care.<span class="mw-ref" id="cite_ref-Stahl's_Essential_Psychopharmacology_60-4"><a href="#cite_note-Stahl's_Essential_Psychopharmacology-60" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></span><span class="mw-ref" id="cite_ref-International_55-2"><a href="#cite_note-International-55" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span><span class="mw-ref" id="cite_ref-Amphetamine_toxidrome_130-0"><a href="#cite_note-Amphetamine_toxidrome-130" style="counter-reset: mw-Ref 116;"><span class="mw-reflink-text">[116]</span></a></span> The severity of overdose symptoms increases with dosage and decreases with drug tolerance to amphetamine.<span class="mw-ref" id="cite_ref-Westfall_46-15"><a href="#cite_note-Westfall-46" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span><span class="mw-ref" id="cite_ref-International_55-3"><a href="#cite_note-International-55" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span> Tolerant individuals have been known to take as much as 5<span>&nbsp;</span>grams of amphetamine in a day, which is roughly 100<span>&nbsp;</span>times the maximum daily therapeutic dose.<span class="mw-ref" id="cite_ref-International_55-4"><a href="#cite_note-International-55" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span> Symptoms of a moderate and extremely large overdose are listed below; fatal amphetamine poisoning usually also involves convulsions and coma.<span class="mw-ref" id="cite_ref-FDA_54-11"><a href="#cite_note-FDA-54" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-Westfall_46-16"><a href="#cite_note-Westfall-46" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> In 2013, overdose on amphetamine, methamphetamine, and other compounds implicated in an "<span class="new">amphetamine use disorder</span>" resulted in an estimated 3,788<span>&nbsp;</span>deaths worldwide (<span class="nowrap">3,425–4,145</span><span>&nbsp;</span>deaths, 95%<span>&nbsp;</span>confidence).<span class="mw-ref" id="cite_ref-131"><a href="#cite_note-131" style="counter-reset: mw-Ref 7;" data-mw-group="note"><span class="mw-reflink-text">[note 7]</span></a></span><span class="mw-ref" id="cite_ref-GDB2013_132-0"><a href="#cite_note-GDB2013-132" style="counter-reset: mw-Ref 117;"><span class="mw-reflink-text">[117]</span></a></span></p><span>

</span><table class="wikitable unsortable center" style="margin: 1em auto;">
<caption>Overdose symptoms by system</caption>
<tbody><tr><th scope="col" style="text-align:center">System</th>
<th scope="col" style="width: 40%;">Minor or moderate overdose<span class="mw-ref" id="cite_ref-FDA_54-12"><a href="#cite_note-FDA-54" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-Westfall_46-17"><a href="#cite_note-Westfall-46" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span><span class="mw-ref" id="cite_ref-International_55-5"><a href="#cite_note-International-55" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span></th>
<th scope="col" style="width: 50%;">Severe overdose<span class="mw-ref" id="cite_ref-135"><a href="#cite_note-135" style="counter-reset: mw-Ref 8;" data-mw-group="sources"><span class="mw-reflink-text">[sources 8]</span></a></span></th></tr>
<tr>
<th scope="row">Cardiovascular</th>
<td>
<ul><li>Abnormal heartbeat</li>
<li>High or low blood pressure</li></ul></td>
<td>
<ul><li>Cardiogenic shock (heart not pumping enough blood)</li>
<li>Cerebral hemorrhage (bleeding in the brain)</li>
<li>Circulatory collapse (partial or complete failure of the circulatory system)</li></ul></td></tr>
<tr>
<th scope="row">Central nervous<br>system</th>
<td>
<ul><li>Confusion</li>
<li>Abnormally fast reflexes</li>
<li>Severe agitation</li>
<li>Tremor (involuntary muscle twitching)</li></ul></td>
<td>
<ul><li>Acute amphetamine psychosis (e.g., delusions and paranoia)</li>
<li>Compulsive and repetitive movement</li>
<li>Serotonin syndrome (excessive serotonergic nerve activity)</li>
<li>Sympathomimetic toxidrome (excessive adrenergic nerve activity)</li></ul></td></tr>
<tr>
<th scope="row">Musculoskeletal</th>
<td>
<ul><li>Muscle pain</li></ul></td>
<td>
<ul><li>Rhabdomyolysis (rapid muscle breakdown)</li></ul></td></tr>
<tr>
<th scope="row">Respiratory</th>
<td>
<ul><li>Rapid breathing</li></ul></td>
<td>
<ul><li>Pulmonary edema (fluid accumulation in the lungs)</li>
<li>Pulmonary hypertension (high blood pressure in the arteries of the lung)</li>
<li>Respiratory alkalosis (reduced blood <a href="Carbon_dioxide.htm" tppabs="https://ptable.com/wiki/compounds/A/Carbon_dioxide" title="Carbon dioxide">CO<sub>2</sub></a>)</li></ul></td></tr>
<tr>
<th scope="row">Urinary</th>
<td>
<ul><li>Painful urination</li>
<li>Urinary retention (inability to urinate)</li></ul></td>
<td>
<ul><li>No urine production</li>
<li>Kidney failure</li></ul></td></tr>
<tr>
<th scope="row">Other</th>
<td>
<ul><li>Elevated body temperature</li>
<li>Mydriasis (dilated pupils)</li></ul></td>
<td>
<ul><li>Elevated or low blood potassium</li>
<li>Hyperpyrexia (extremely elevated core body temperature)</li>
<li>Metabolic acidosis (excessively acidic bodily fluids)</li></ul></td></tr>
</tbody></table><span>

</span>
    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Toxicity">Toxicity</h3></summary>
    <span>
</span><p>In rodents and primates, sufficiently high doses of amphetamine cause dopaminergic neurotoxicity, or damage to dopamine neurons, which is characterized by dopamine terminal degeneration and reduced transporter and receptor function.<span class="mw-ref" id="cite_ref-Humans&amp;Animals_136-0"><a href="#cite_note-Humans&amp;Animals-136" style="counter-reset: mw-Ref 120;"><span class="mw-reflink-text">[120]</span></a></span><span class="mw-ref" id="cite_ref-Amph-induced_hyperthermia_and_neurotoxicity_review_137-0"><a href="#cite_note-Amph-induced_hyperthermia_and_neurotoxicity_review-137" style="counter-reset: mw-Ref 121;"><span class="mw-reflink-text">[121]</span></a></span> There is no evidence that amphetamine is directly neurotoxic in humans.<span class="mw-ref" id="cite_ref-138"><a href="#cite_note-138" style="counter-reset: mw-Ref 122;"><span class="mw-reflink-text">[122]</span></a></span><span class="mw-ref" id="cite_ref-Malenka_2009_02_139-0"><a href="#cite_note-Malenka_2009_02-139" style="counter-reset: mw-Ref 123;"><span class="mw-reflink-text">[123]</span></a></span> However, large doses of amphetamine may indirectly cause dopaminergic neurotoxicity as a result of hyperpyrexia, the excessive formation of reactive oxygen species, and increased autoxidation of dopamine.<span class="mw-ref" id="cite_ref-142"><a href="#cite_note-142" style="counter-reset: mw-Ref 9;" data-mw-group="sources"><span class="mw-reflink-text">[sources 9]</span></a></span> Animal models of neurotoxicity from high-dose amphetamine exposure indicate that the occurrence of hyperpyrexia (i.e., core body temperature<span>&nbsp;</span>≥<span>&nbsp;</span>40<span>&nbsp;</span>°C) is necessary for the development of amphetamine-induced neurotoxicity.<span class="mw-ref" id="cite_ref-Amph-induced_hyperthermia_and_neurotoxicity_review_137-2"><a href="#cite_note-Amph-induced_hyperthermia_and_neurotoxicity_review-137" style="counter-reset: mw-Ref 121;"><span class="mw-reflink-text">[121]</span></a></span> Prolonged elevations of brain temperature above 40<span>&nbsp;</span>°C likely promote the development of amphetamine-induced neurotoxicity in laboratory animals by facilitating the production of reactive oxygen species, disrupting cellular protein function, and transiently increasing blood–brain barrier permeability.<span class="mw-ref" id="cite_ref-Amph-induced_hyperthermia_and_neurotoxicity_review_137-3"><a href="#cite_note-Amph-induced_hyperthermia_and_neurotoxicity_review-137" style="counter-reset: mw-Ref 121;"><span class="mw-reflink-text">[121]</span></a></span></p><span>

</span>
</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Psychosis">Psychosis</h3></summary>
    <span>
</span><span>
</span><p>An amphetamine overdose can result in a stimulant psychosis that may involve a variety of symptoms, such as delusions and paranoia.<span class="mw-ref" id="cite_ref-Cochrane_73-1"><a href="#cite_note-Cochrane-73" style="counter-reset: mw-Ref 67;"><span class="mw-reflink-text">[67]</span></a></span><span class="mw-ref" id="cite_ref-Amphetamine-induced_psychosis_74-2"><a href="#cite_note-Amphetamine-induced_psychosis-74" style="counter-reset: mw-Ref 68;"><span class="mw-reflink-text">[68]</span></a></span> A Cochrane review on treatment for amphetamine, dextroamphetamine, and methamphetamine psychosis states that about <span class="nowrap">5–15%</span> of users fail to recover completely.<span class="mw-ref" id="cite_ref-Cochrane_73-2"><a href="#cite_note-Cochrane-73" style="counter-reset: mw-Ref 67;"><span class="mw-reflink-text">[67]</span></a></span><span class="mw-ref" id="cite_ref-Hofmann_143-0"><a href="#cite_note-Hofmann-143" style="counter-reset: mw-Ref 126;"><span class="mw-reflink-text">[126]</span></a></span> According to the same review, there is at least one trial that shows antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis.<span class="mw-ref" id="cite_ref-Cochrane_73-3"><a href="#cite_note-Cochrane-73" style="counter-reset: mw-Ref 67;"><span class="mw-reflink-text">[67]</span></a></span> Psychosis rarely arises from therapeutic use.<span class="mw-ref" id="cite_ref-FDA_54-14"><a href="#cite_note-FDA-54" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-Amphetamine-induced_psychosis_74-3"><a href="#cite_note-Amphetamine-induced_psychosis-74" style="counter-reset: mw-Ref 68;"><span class="mw-reflink-text">[68]</span></a></span><span class="mw-ref" id="cite_ref-Stimulant_Misuse_75-1"><a href="#cite_note-Stimulant_Misuse-75" style="counter-reset: mw-Ref 69;"><span class="mw-reflink-text">[69]</span></a></span></p><span>

</span>
</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Interactions">Interactions</h2></summary>
    
<ul><li>Acidifying Agents: Drugs that acidify the urine, such as <a href="Ascorbic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Ascorbic_acid" title="Ascorbic acid" class="mw-redirect">ascorbic acid</a>, increase urinary excretion of dextroamphetamine, thus decreasing the half-life of dextroamphetamine in the body.<span class="mw-ref" id="cite_ref-USVyvanselabel_14-4"><a href="#cite_note-USVyvanselabel-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-FDA_Interactions_144-0"><a href="#cite_note-FDA_Interactions-144" style="counter-reset: mw-Ref 127;"><span class="mw-reflink-text">[127]</span></a></span></li>
<li>Alkalinizing Agents: Drugs that alkalinize the urine, such as <a href="Sodium_bicarbonate.htm" tppabs="https://ptable.com/wiki/compounds/A/Sodium_bicarbonate" title="Sodium bicarbonate">sodium bicarbonate</a>, decrease urinary excretion of dextroamphetamine, thus increasing the half-life of dextroamphetamine in the body.<span class="mw-ref" id="cite_ref-USVyvanselabel_14-5"><a href="#cite_note-USVyvanselabel-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-FDA_Interactions_144-1"><a href="#cite_note-FDA_Interactions-144" style="counter-reset: mw-Ref 127;"><span class="mw-reflink-text">[127]</span></a></span></li>
<li>Monoamine Oxidase Inhibitors: Concomitant use of MAOIs and central nervous system stimulants such as lisdexamfetamine can cause a hypertensive crisis.<span class="mw-ref" id="cite_ref-USVyvanselabel_14-6"><a href="#cite_note-USVyvanselabel-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span></li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pharmacology">Pharmacology</h2></summary>
    
<div role="note" class="hatnote navigation-not-searchable">Main section: <a href="Amphetamine.htm#Pharmacodynamics" tppabs="https://ptable.com/wiki/compounds/A/Amphetamine#Pharmacodynamics" title="Amphetamine">Amphetamine §<span>&nbsp;</span>Pharmacodynamics</a></div>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Mechanism_of_action">Mechanism of action</h3></summary>
    
<span>
</span><table role="presentation" cellpadding="0" style="border-spacing:0; clear:right; float:right;">
<tbody><tr>
<td><div class="thumb tright">
<div class="thumbinner" style="width:542px; ">
<div style="clear: both; font-weight: bold; font-size: 106.4%; text-align: center; background-color: #F0F8FF;margin-bottom:3px;">Pharmacodynamics of amphetamine in a dopamine neuron<br></div>
<div style="position:relative; width:540px; height:685px; overflow:hidden; border:solid #ccc 1px; background-color:white;">
<div style="left:0px; top:0px; width:540px; position:absolute"> <figure-inline><img src="../I/m/TAAR1_Dopamine.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/TAAR1_Dopamine.svg.png" data-file-width="725" data-file-height="920" data-file-type="drawing" height="685" width="540"></figure-inline>
</div> 
<div style="text-align:center; font-size:14px; line-height:110%;">
<div style="background-color:transparent; color:black"><div id="annotation_190x45" style="position:absolute; left:190px; top:45px;      line-height:110% "><span style="background-color:transparent; ">via <b>AADC</b></span></div></div>
</div>
</div>
<div class="thumbcaption" style="clear:left"><div style="float:left;margin-right:0.5em"><figure-inline><span><img src="../I/m/Interactive_icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Interactive_icon.svg.png" data-file-width="133" data-file-height="200" data-file-type="drawing" height="27" width="18"></span></figure-inline></div>Amphetamine enters the presynaptic neuron across the neuronal membrane or through <abbr>DAT</abbr>.<span class="mw-ref" id="cite_ref-Miller_145-0"><a href="#cite_note-Miller-145" style="counter-reset: mw-Ref 128;"><span class="mw-reflink-text">[128]</span></a></span> Once inside, it binds to <abbr>TAAR1</abbr> or enters synaptic vesicles through <abbr>VMAT2</abbr>.<span class="mw-ref" id="cite_ref-Miller_145-1"><a href="#cite_note-Miller-145" style="counter-reset: mw-Ref 128;"><span class="mw-reflink-text">[128]</span></a></span><span class="mw-ref" id="cite_ref-E_Weihe_146-0"><a href="#cite_note-E_Weihe-146" style="counter-reset: mw-Ref 129;"><span class="mw-reflink-text">[129]</span></a></span> When amphetamine enters synaptic vesicles through VMAT2, it collapses the vesicular pH gradient, which in turn causes dopamine to be released into the cytosol (light tan-colored area) through VMAT2.<span class="mw-ref" id="cite_ref-E_Weihe_146-1"><a href="#cite_note-E_Weihe-146" style="counter-reset: mw-Ref 129;"><span class="mw-reflink-text">[129]</span></a></span><span class="mw-ref" id="cite_ref-Amphetamine_VMAT2_pH_gradient_147-0"><a href="#cite_note-Amphetamine_VMAT2_pH_gradient-147" style="counter-reset: mw-Ref 130;"><span class="mw-reflink-text">[130]</span></a></span> When amphetamine binds to TAAR1, it reduces the firing rate of the dopamine neuron via potassium channels and activates protein kinase A (PKA) and protein kinase C (PKC), which subsequently phosphorylate DAT.<span class="mw-ref" id="cite_ref-Miller_145-2"><a href="#cite_note-Miller-145" style="counter-reset: mw-Ref 128;"><span class="mw-reflink-text">[128]</span></a></span><span class="mw-ref" id="cite_ref-GIRK_148-0"><a href="#cite_note-GIRK-148" style="counter-reset: mw-Ref 131;"><span class="mw-reflink-text">[131]</span></a></span><span class="mw-ref" id="cite_ref-Genatlas_TAAR1_149-0"><a href="#cite_note-Genatlas_TAAR1-149" style="counter-reset: mw-Ref 132;"><span class="mw-reflink-text">[132]</span></a></span> <span class="nowrap">PKA-phosphorylation</span> causes DAT to withdraw into the presynaptic neuron (internalize) and cease transport.<span class="mw-ref" id="cite_ref-Miller_145-3"><a href="#cite_note-Miller-145" style="counter-reset: mw-Ref 128;"><span class="mw-reflink-text">[128]</span></a></span> <span class="nowrap">PKC-phosphorylated</span> DAT may either operate in reverse or, like <span class="nowrap">PKA-phosphorylated</span> DAT, internalize and cease transport.<span class="mw-ref" id="cite_ref-Miller_145-4"><a href="#cite_note-Miller-145" style="counter-reset: mw-Ref 128;"><span class="mw-reflink-text">[128]</span></a></span> Amphetamine is also known to increase intracellular calcium, an effect which is associated with DAT phosphorylation through a CAMKIIα-dependent pathway, in turn producing dopamine efflux.<span class="mw-ref" id="cite_ref-EAAT3_150-0"><a href="#cite_note-EAAT3-150" style="counter-reset: mw-Ref 133;"><span class="mw-reflink-text">[133]</span></a></span><span class="mw-ref" id="cite_ref-DAT_regulation_review_151-0"><a href="#cite_note-DAT_regulation_review-151" style="counter-reset: mw-Ref 134;"><span class="mw-reflink-text">[134]</span></a></span></div>
</div>
</div></td></tr>
</tbody></table>
<p>Lisdexamfetamine is an inactive prodrug that is converted in the body to dextroamphetamine, a pharmacologically active compound which is responsible for the drug's activity.<span class="mw-ref" id="cite_ref-Vyvanse_152-0"><a href="#cite_note-Vyvanse-152" style="counter-reset: mw-Ref 135;"><span class="mw-reflink-text">[135]</span></a></span> After oral ingestion, lisdexamfetamine is broken down by enzymes in red blood cells to form <a href="Lysine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lysine" title="Lysine"><small>L</small>-lysine</a>, a naturally occurring essential amino acid, and dextroamphetamine.<span class="mw-ref" id="cite_ref-USVyvanselabel_14-7"><a href="#cite_note-USVyvanselabel-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> The conversion of lisdexamfetamine to dextroamphetamine is not affected by gastrointestinal pH and is unlikely to be affected by alterations in normal gastrointestinal transit times.<span class="mw-ref" id="cite_ref-USVyvanselabel_14-8"><a href="#cite_note-USVyvanselabel-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-Jasinski_2009_153-0"><a href="#cite_note-Jasinski_2009-153" style="counter-reset: mw-Ref 136;"><span class="mw-reflink-text">[136]</span></a></span></p>

<p>The optical isomers of <a href="Amphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amphetamine" title="Amphetamine">amphetamine</a>, i.e., <a href="Dextroamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dextroamphetamine" title="Dextroamphetamine">dextroamphetamine</a> and <a href="Levoamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Levoamphetamine" title="Levoamphetamine">levoamphetamine</a>, are TAAR1 agonists and vesicular monoamine transporter 2 inhibitors that can enter monoamine neurons;<span class="mw-ref" id="cite_ref-Miller_145-5"><a href="#cite_note-Miller-145" style="counter-reset: mw-Ref 128;"><span class="mw-reflink-text">[128]</span></a></span><span class="mw-ref" id="cite_ref-E_Weihe_146-2"><a href="#cite_note-E_Weihe-146" style="counter-reset: mw-Ref 129;"><span class="mw-reflink-text">[129]</span></a></span> this allows them to release monoamine neurotransmitters (<a href="Dopamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dopamine" title="Dopamine">dopamine</a>, norepinephrine, and <a href="Serotonin.htm" tppabs="https://ptable.com/wiki/compounds/A/Serotonin" title="Serotonin">serotonin</a>, among others) from their storage sites in the presynaptic neuron, as well as prevent the reuptake of these neurotransmitters from the synaptic cleft.<span class="mw-ref" id="cite_ref-Miller_145-6"><a href="#cite_note-Miller-145" style="counter-reset: mw-Ref 128;"><span class="mw-reflink-text">[128]</span></a></span><span class="mw-ref" id="cite_ref-E_Weihe_146-3"><a href="#cite_note-E_Weihe-146" style="counter-reset: mw-Ref 129;"><span class="mw-reflink-text">[129]</span></a></span></p>

<p>Lisdexamfetamine was developed with the goal of providing a long duration of effect that is consistent throughout the day, with reduced potential for abuse. The attachment of the amino acid lysine slows down the relative amount of dextroamphetamine available to the blood stream. Because no free dextroamphetamine is present in lisdexamfetamine capsules, dextroamphetamine does not become available through mechanical manipulation, such as crushing or simple extraction. A relatively sophisticated biochemical process is needed to produce dextroamphetamine from lisdexamfetamine.<span class="mw-ref" id="cite_ref-Jasinski_2009_153-1"><a href="#cite_note-Jasinski_2009-153" style="counter-reset: mw-Ref 136;"><span class="mw-reflink-text">[136]</span></a></span> As opposed to Adderall, which contains roughly equal parts of racemic amphetamine and dextroamphetamine salts, lisdexamfetamine is a single-enantiomer dextroamphetamine formula.<span class="mw-ref" id="cite_ref-Vyvanse_152-1"><a href="#cite_note-Vyvanse-152" style="counter-reset: mw-Ref 135;"><span class="mw-reflink-text">[135]</span></a></span><span class="mw-ref" id="cite_ref-FDA_adderall_154-0"><a href="#cite_note-FDA_adderall-154" style="counter-reset: mw-Ref 137;"><span class="mw-reflink-text">[137]</span></a></span> Studies conducted show that lisdexamfetamine dimesylate may have less abuse potential than dextroamphetamine and an abuse profile similar to <a href="Amfepramone.htm" tppabs="https://ptable.com/wiki/compounds/A/Diethylpropion" title="Diethylpropion" class="mw-redirect">diethylpropion</a> at dosages that are FDA-approved for treatment of ADHD, but still has a high abuse potential when this dosage is exceeded by over 100%.<span class="mw-ref" id="cite_ref-Jasinski_2009_153-2"><a href="#cite_note-Jasinski_2009-153" style="counter-reset: mw-Ref 136;"><span class="mw-reflink-text">[136]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacokinetics">Pharmacokinetics</h3></summary>
    

<p>The oral bioavailability of amphetamine varies with gastrointestinal pH;<span class="mw-ref" id="cite_ref-FDA_54-15"><a href="#cite_note-FDA-54" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span> it is well absorbed from the gut, and bioavailability is typically over<span>&nbsp;</span>75% for dextroamphetamine.<span class="mw-ref" id="cite_ref-Drugbank-dexamph_155-0"><a href="#cite_note-Drugbank-dexamph-155" style="counter-reset: mw-Ref 138;"><span class="mw-reflink-text">[138]</span></a></span> Amphetamine is a weak base with a p<i>K</i><sub>a</sub> of 9.9;<span class="mw-ref" id="cite_ref-FDA_Pharmacokinetics_156-0"><a href="#cite_note-FDA_Pharmacokinetics-156" style="counter-reset: mw-Ref 139;"><span class="mw-reflink-text">[139]</span></a></span> consequently, when the pH is basic, more of the drug is in its lipid soluble free base form, and more is absorbed through the lipid-rich cell membranes of the gut epithelium.<span class="mw-ref" id="cite_ref-FDA_Pharmacokinetics_156-1"><a href="#cite_note-FDA_Pharmacokinetics-156" style="counter-reset: mw-Ref 139;"><span class="mw-reflink-text">[139]</span></a></span><span class="mw-ref" id="cite_ref-FDA_54-16"><a href="#cite_note-FDA-54" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span> Conversely, an acidic pH means the drug is predominantly in a water-soluble cationic (salt) form, and less is absorbed.<span class="mw-ref" id="cite_ref-FDA_Pharmacokinetics_156-2"><a href="#cite_note-FDA_Pharmacokinetics-156" style="counter-reset: mw-Ref 139;"><span class="mw-reflink-text">[139]</span></a></span> Approximately <span class="nowrap">15–40%</span> of amphetamine circulating in the bloodstream is bound to plasma proteins.<span class="mw-ref" id="cite_ref-Drugbank-amph_157-0"><a href="#cite_note-Drugbank-amph-157" style="counter-reset: mw-Ref 140;"><span class="mw-reflink-text">[140]</span></a></span> Following absorption, amphetamine readily distributes into most tissues in the body, with high concentrations occurring in cerebrospinal fluid and brain tissue.<span class="mw-ref" id="cite_ref-HSDB_Toxnet_October_2017_Full_archived_record_158-0"><a href="#cite_note-HSDB_Toxnet_October_2017_Full_archived_record-158" style="counter-reset: mw-Ref 141;"><span class="mw-reflink-text">[141]</span></a></span></p><span>

</span><p>The half-lives of amphetamine enantiomers differ and vary with urine pH.<span class="mw-ref" id="cite_ref-FDA_Pharmacokinetics_156-3"><a href="#cite_note-FDA_Pharmacokinetics-156" style="counter-reset: mw-Ref 139;"><span class="mw-reflink-text">[139]</span></a></span> At normal urine pH, the half-lives of dextroamphetamine and levoamphetamine are <span class="nowrap">9–11</span><span>&nbsp;</span>hours and <span class="nowrap">11–14</span><span>&nbsp;</span>hours, respectively.<span class="mw-ref" id="cite_ref-FDA_Pharmacokinetics_156-4"><a href="#cite_note-FDA_Pharmacokinetics-156" style="counter-reset: mw-Ref 139;"><span class="mw-reflink-text">[139]</span></a></span> Highly acidic urine will reduce the enantiomer half-lives to 7<span>&nbsp;</span>hours;<span class="mw-ref" id="cite_ref-HSDB_Toxnet_October_2017_Full_archived_record_158-1"><a href="#cite_note-HSDB_Toxnet_October_2017_Full_archived_record-158" style="counter-reset: mw-Ref 141;"><span class="mw-reflink-text">[141]</span></a></span> highly alkaline urine will increase the half-lives up to 34<span>&nbsp;</span>hours.<span class="mw-ref" id="cite_ref-HSDB_Toxnet_October_2017_Full_archived_record_158-2"><a href="#cite_note-HSDB_Toxnet_October_2017_Full_archived_record-158" style="counter-reset: mw-Ref 141;"><span class="mw-reflink-text">[141]</span></a></span> The immediate-release and extended release variants of salts of both isomers reach peak plasma concentrations at 3<span>&nbsp;</span>hours and 7<span>&nbsp;</span>hours post-dose respectively.<span class="mw-ref" id="cite_ref-FDA_Pharmacokinetics_156-5"><a href="#cite_note-FDA_Pharmacokinetics-156" style="counter-reset: mw-Ref 139;"><span class="mw-reflink-text">[139]</span></a></span> Amphetamine is eliminated via the kidneys, with <span class="nowrap">30–40%</span> of the drug being excreted unchanged at normal urinary pH.<span class="mw-ref" id="cite_ref-FDA_Pharmacokinetics_156-6"><a href="#cite_note-FDA_Pharmacokinetics-156" style="counter-reset: mw-Ref 139;"><span class="mw-reflink-text">[139]</span></a></span> When the urinary pH is basic, amphetamine is in its free base form, so less is excreted.<span class="mw-ref" id="cite_ref-FDA_Pharmacokinetics_156-7"><a href="#cite_note-FDA_Pharmacokinetics-156" style="counter-reset: mw-Ref 139;"><span class="mw-reflink-text">[139]</span></a></span> When urine pH is abnormal, the urinary recovery of amphetamine may range from a low of 1% to a high of 75%, depending mostly upon whether urine is too basic or acidic, respectively.<span class="mw-ref" id="cite_ref-FDA_Pharmacokinetics_156-8"><a href="#cite_note-FDA_Pharmacokinetics-156" style="counter-reset: mw-Ref 139;"><span class="mw-reflink-text">[139]</span></a></span> Following oral administration, amphetamine appears in urine within 3<span>&nbsp;</span>hours.<span class="mw-ref" id="cite_ref-HSDB_Toxnet_October_2017_Full_archived_record_158-3"><a href="#cite_note-HSDB_Toxnet_October_2017_Full_archived_record-158" style="counter-reset: mw-Ref 141;"><span class="mw-reflink-text">[141]</span></a></span> Roughly 90% of ingested amphetamine is eliminated 3<span>&nbsp;</span>days after the last oral dose.<span class="mw-ref" id="cite_ref-HSDB_Toxnet_October_2017_Full_archived_record_158-4"><a href="#cite_note-HSDB_Toxnet_October_2017_Full_archived_record-158" style="counter-reset: mw-Ref 141;"><span class="mw-reflink-text">[141]</span></a></span><span>&nbsp;</span></p><span>

</span><p>The prodrug lisdexamfetamine is not as sensitive to pH as amphetamine when being absorbed in the gastrointestinal tract;<span class="mw-ref" id="cite_ref-USVyvanselabel_14-9"><a href="#cite_note-USVyvanselabel-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> following absorption into the blood stream, it is converted by red blood cell-associated enzymes to dextroamphetamine via hydrolysis.<span class="mw-ref" id="cite_ref-USVyvanselabel_14-10"><a href="#cite_note-USVyvanselabel-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> The elimination half-life of lisdexamfetamine is generally less than 1<span>&nbsp;</span>hour.<span class="mw-ref" id="cite_ref-USVyvanselabel_14-11"><a href="#cite_note-USVyvanselabel-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span></p><span>

</span><p>CYP2D6, dopamine β-hydroxylase (DBH), flavin-containing monooxygenase 3 (FMO3), butyrate-CoA ligase (XM-ligase), and glycine <i>N</i>-acyltransferase (GLYAT) are the enzymes known to metabolize amphetamine or its metabolites in humans.<span class="mw-ref" id="cite_ref-amphetamine_metabolism_159-0"><a href="#cite_note-amphetamine_metabolism-159" style="counter-reset: mw-Ref 10;" data-mw-group="sources"><span class="mw-reflink-text">[sources 10]</span></a></span> Amphetamine has a variety of excreted metabolic products, including <span class="nowrap">4-hydroxyamphetamine</span>, <span class="nowrap">4-hydroxynorephedrine</span>, <span class="nowrap">4-hydroxyphenylacetone</span>, <a href="Benzoic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzoic_acid" title="Benzoic acid">benzoic acid</a>, <a href="Hippuric_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Hippuric_acid" title="Hippuric acid">hippuric acid</a>, <a href="Phenylpropanolamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Norephedrine" title="Norephedrine" class="mw-redirect">norephedrine</a>, and <a href="Phenylacetone.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenylacetone" title="Phenylacetone">phenylacetone</a>.<span class="mw-ref" id="cite_ref-FDA_Pharmacokinetics_156-9"><a href="#cite_note-FDA_Pharmacokinetics-156" style="counter-reset: mw-Ref 139;"><span class="mw-reflink-text">[139]</span></a></span><span class="mw-ref" id="cite_ref-Metabolites_160-0"><a href="#cite_note-Metabolites-160" style="counter-reset: mw-Ref 142;"><span class="mw-reflink-text">[142]</span></a></span> Among these metabolites, the active sympathomimetics are <span class="nowrap">4-hydroxyamphetamine</span>,<span class="mw-ref" id="cite_ref-161"><a href="#cite_note-161" style="counter-reset: mw-Ref 143;"><span class="mw-reflink-text">[143]</span></a></span> <span class="nowrap">4-hydroxynorephedrine</span>,<span class="mw-ref" id="cite_ref-162"><a href="#cite_note-162" style="counter-reset: mw-Ref 144;"><span class="mw-reflink-text">[144]</span></a></span> and norephedrine.<span class="mw-ref" id="cite_ref-163"><a href="#cite_note-163" style="counter-reset: mw-Ref 145;"><span class="mw-reflink-text">[145]</span></a></span> The main metabolic pathways involve aromatic para-hydroxylation, aliphatic alpha- and beta-hydroxylation, <i>N</i>-oxidation, <i>N</i>-dealkylation, and deamination.<span class="mw-ref" id="cite_ref-FDA_Pharmacokinetics_156-10"><a href="#cite_note-FDA_Pharmacokinetics-156" style="counter-reset: mw-Ref 139;"><span class="mw-reflink-text">[139]</span></a></span><span class="mw-ref" id="cite_ref-Pubchem_Kinetics_164-0"><a href="#cite_note-Pubchem_Kinetics-164" style="counter-reset: mw-Ref 146;"><span class="mw-reflink-text">[146]</span></a></span> The known metabolic pathways, detectable metabolites, and metabolizing enzymes in humans include the following:</p><span>

</span><table role="presentation" cellpadding="0" style="border-spacing:0; margin-left: auto; margin-right: auto; border: none;">
<tbody><tr>
<td><div class="thumb center" style="margin: 1em auto;">
<div class="thumbinner" style="width:687px; ">
<div style="clear: both; font-weight: bold; font-size: 106.4%; text-align: center; background-color: aliceblue;margin-bottom:3px;">Metabolic pathways of amphetamine in humans<span class="mw-ref" id="cite_ref-amphetamine_metabolism_159-1"><a href="#cite_note-amphetamine_metabolism-159" style="counter-reset: mw-Ref 10;" data-mw-group="sources"><span class="mw-reflink-text">[sources 10]</span></a></span></div>
<div style="position:relative; width:685px; height:375px; overflow:hidden; border:solid #ccc 1px; background-color:white;">
<div style="left:-10px; top:3px; width:700px; position:absolute"> <figure-inline><img src="../I/m/Amph_Pathway.png" tppabs="https://ptable.com/wiki/compounds/I/m/Amph_Pathway.png" data-file-width="725" data-file-height="400" data-file-type="bitmap" height="386" width="700"></figure-inline>
</div> 
<div style="text-align:center; font-size:16px; line-height:110%;">
<div style="background-color:transparent; color:black"><div id="annotation_2x350" style="position:absolute; left:2px; top:350px;      line-height:110% "><span style="background-color:transparent; ">4-Hydroxyphenylacetone</span></div>
<div id="annotation_210x350" style="position:absolute; left:210px; top:350px;      line-height:110% "><span style="background-color:transparent; "><a href="Phenylacetone.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenylacetone" title="Phenylacetone">Phenylacetone</a></span></div>
<div id="annotation_380x350" style="position:absolute; left:380px; top:350px;      line-height:110% "><span style="background-color:transparent; "><a href="Benzoic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzoic_acid" title="Benzoic acid">Benzoic acid</a></span></div>
<div id="annotation_560x350" style="position:absolute; left:560px; top:350px;      line-height:110% "><span style="background-color:transparent; "><a href="Hippuric_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Hippuric_acid" title="Hippuric acid">Hippuric acid</a></span></div>

<div id="annotation_45x220" style="position:absolute; left:45px; top:220px;      line-height:110% "><span style="background-color:transparent; "><a href="Amphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amphetamine" title="Amphetamine">Amphetamine</a> </span></div>
<div id="annotation_300x220" style="position:absolute; left:300px; top:220px;      line-height:110% "><span style="background-color:transparent; "><a href="Phenylpropanolamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenylpropanolamine" title="Phenylpropanolamine">Norephedrine</a></span></div>

<div id="annotation_255x90" style="position:absolute; left:255px; top:90px;      line-height:110% "><span style="background-color:transparent; ">4-Hydroxyamphetamine</span></div>
<div id="annotation_490x90" style="position:absolute; left:490px; top:90px;      line-height:110% "><span style="background-color:transparent; ">4-Hydroxynorephedrine</span></div>

<div id="annotation_145x115" style="position:absolute; left:145px; top:115px;   font-size:10px;   line-height:12px; "><span style="background-color:transparent; ">Para-<br>Hydroxylation</span></div>
<div id="annotation_384x115" style="position:absolute; left:384px; top:115px;   font-size:10px;   line-height:12px; "><span style="background-color:transparent; ">Para-<br>Hydroxylation</span></div>
<div id="annotation_150x294" style="position:absolute; left:150px; top:294px;   font-size:10px;   line-height:12px; "><span style="background-color:transparent; ">Para-<br>Hydroxylation</span></div>
<div id="annotation_151x138" style="position:absolute; left:151px; top:138px;   font-size:12px;   line-height:14px; "><span style="background-color:transparent; ">CYP2D6</span></div>
<div id="annotation_390x138" style="position:absolute; left:390px; top:138px;   font-size:12px;   line-height:14px; "><span style="background-color:transparent; ">CYP2D6</span></div>
<div id="annotation_150x330" style="position:absolute; left:150px; top:330px;   font-size:12px;   line-height:14px; "><span style="background-color:transparent; ">unidentified</span></div>

<div id="annotation_190x165" style="position:absolute; left:190px; top:165px;   font-size:10px;   line-height:12px; "><span style="background-color:transparent; ">Beta-<br>Hydroxylation</span></div>
<div id="annotation_415x25" style="position:absolute; left:415px; top:25px;   font-size:10px;   line-height:12px; "><span style="background-color:transparent; ">Beta-<br>Hydroxylation</span></div>
<div id="annotation_206x195" style="position:absolute; left:206px; top:195px;   font-size:12px;   line-height:14px; "><span style="background-color:transparent; ">DBH</span></div>
<div id="annotation_428x55" style="position:absolute; left:428px; top:55px;   font-size:12px;   line-height:14px; "><span style="background-color:transparent; ">DBH<br><span class="mw-ref" id="cite_ref-174"><a href="#cite_note-174" style="counter-reset: mw-Ref 8;" data-mw-group="note"><span class="mw-reflink-text">[note 8]</span></a></span></span></div>

<div id="annotation_210x220" style="position:absolute; left:210px; top:220px;   font-size:10px;   line-height:12px; "><span style="background-color:transparent; ">Oxidative<br>Deamination</span></div>
<div id="annotation_220x242" style="position:absolute; left:220px; top:242px;   font-size:12px;   line-height:14px; "><span style="background-color:transparent; ">FMO3</span></div>

<div id="annotation_330x307" style="position:absolute; left:330px; top:307px;   font-size:10px;   line-height:12px; "><span style="background-color:transparent; ">Oxidation</span></div>
<div id="annotation_323x330" style="position:absolute; left:323px; top:330px;   font-size:12px;   line-height:14px; "><span style="background-color:transparent; ">unidentified</span></div>
<div id="annotation_478x293" style="position:absolute; left:478px; top:293px;   font-size:10px;   line-height:12px; "><span style="background-color:transparent; ">Glycine<br>Conjugation</span></div>
<div id="annotation_480x330" style="position:absolute; left:480px; top:330px;   font-size:12px;   line-height:14px; "><span style="background-color:transparent; ">XM-ligase<br>GLYAT</span></div></div>
</div>
</div>
<div class="thumbcaption" style="clear:left"><div style="float:left;margin-right:0.5em"><figure-inline><span><img src="../I/m/Interactive_icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Interactive_icon.svg.png" data-file-width="133" data-file-height="200" data-file-type="drawing" height="27" width="18"></span></figure-inline></div>The primary active metabolites of amphetamine are <span class="nowrap">4-hydroxyamphetamine</span> and norephedrine;<span class="mw-ref" id="cite_ref-Metabolites_160-2"><a href="#cite_note-Metabolites-160" style="counter-reset: mw-Ref 142;"><span class="mw-reflink-text">[142]</span></a></span> at normal urine pH, about <span class="nowrap">30–40%</span> of amphetamine is excreted unchanged and roughly 50% is excreted as the inactive metabolites (bottom row).<span class="mw-ref" id="cite_ref-FDA_Pharmacokinetics_156-12"><a href="#cite_note-FDA_Pharmacokinetics-156" style="counter-reset: mw-Ref 139;"><span class="mw-reflink-text">[139]</span></a></span> The remaining <span class="nowrap">10–20%</span> is excreted as the active metabolites.<span class="mw-ref" id="cite_ref-FDA_Pharmacokinetics_156-13"><a href="#cite_note-FDA_Pharmacokinetics-156" style="counter-reset: mw-Ref 139;"><span class="mw-reflink-text">[139]</span></a></span> Benzoic acid is metabolized by <abbr>XM-ligase</abbr> into an intermediate product, <a href="Benzoyl-CoA.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzoyl-CoA" title="Benzoyl-CoA">benzoyl-CoA</a>, which is then metabolized by <abbr>GLYAT</abbr> into hippuric acid.<span class="mw-ref" id="cite_ref-Glycine_conjugation_review_170-1"><a href="#cite_note-Glycine_conjugation_review-170" style="counter-reset: mw-Ref 152;"><span class="mw-reflink-text">[152]</span></a></span></div>
</div>
</div></td></tr>
</tbody></table><span>
</span><div style="clear:both;"></div>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Chemistry">Chemistry</h2></summary>
    

<p>Lisdexamfetamine is a substituted amphetamine with an amide linkage formed by the condensation of <a href="Dextroamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dextroamphetamine" title="Dextroamphetamine">dextroamphetamine</a> with the carboxylate group of the essential amino acid <a href="Lysine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lysine" title="Lysine"><small>L</small>-lysine</a>.<span class="mw-ref" id="cite_ref-pmid17407369_9-2"><a href="#cite_note-pmid17407369-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span>  The reaction occurs with retention of stereochemistry, so the product lisdexamfetamine exists as a single stereoisomer.  There are many possible names for lisdexamfetamine based on IUPAC nomenclature, but it is usually named as <span class="nowrap"><i>N</i>-[(2<i>S</i>)-1-phenyl-2-propanyl]-<small>L</small>-lysinamide</span> or <span class="nowrap">(2<i>S</i>)-2,6-diamino-<i>N</i>-[(1<i>S</i>)-1-methyl-2-phenylethyl]hexanamide</span>.<span class="mw-ref" id="cite_ref-ChemSpider_175-0"><a href="#cite_note-ChemSpider-175" style="counter-reset: mw-Ref 156;"><span class="mw-reflink-text">[156]</span></a></span>  The condensation reaction occurs with loss of water:</p>

<dl><dd><a href="Dextroamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dextroamphetamine" title="Dextroamphetamine">(<i>S</i>)-<span class="chemf nowrap">PhCH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>CH(CH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">3</sub></span>)NH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span></span></a> <span>&nbsp;</span> + <span>&nbsp;</span> <a href="Lysine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lysine" title="Lysine">(<i>S</i>)-<span class="chemf nowrap">HOOCCH(NH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>)CH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>CH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>CH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>CH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>NH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span></span></a> <span>&nbsp;</span> <span>→</span> <span>&nbsp;</span> (<i>S</i>,<i>S</i>)-<span class="chemf nowrap">PhCH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>CH(CH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">3</sub></span>)NHC(O)CH(NH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>)CH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>CH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>CH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>CH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>NH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span></span> <span>&nbsp;</span> + <span>&nbsp;</span> <span class="chemf nowrap">H<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>O</span></dd></dl>

<p>Amine functional groups are vulnerable to oxidation in air and so pharmaceuticals containing them are usually formulated as salts where this moiety has been <a href="Protonation.htm" tppabs="https://ptable.com/wiki/compounds/A/Protonated" title="Protonated" class="mw-redirect">protonated</a>.  This increases stability, water solubility, and, by converting a molecular compound to an ionic compound, increases the melting point and thereby ensures a solid product.<span class="mw-ref" id="cite_ref-176"><a href="#cite_note-176" style="counter-reset: mw-Ref 157;"><span class="mw-reflink-text">[157]</span></a></span>  In the case of lisdexamfetamine, this is achieved by reacting with two equivalents of <a href="Methanesulfonic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Methanesulfonic_acid" title="Methanesulfonic acid">methanesulfonic acid</a> to produce the dimesylate salt, a water-soluble (792<span>&nbsp;</span>mg<span>&nbsp;</span>mL<sup><span>−</span>1</sup>) powder with a white to off-white color.<span class="mw-ref" id="cite_ref-USVyvanselabel_14-12"><a href="#cite_note-USVyvanselabel-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span></p>

<dl><dd><span class="chemf nowrap">PhCH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>CH(CH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">3</sub></span>)NHC(O)CH(NH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>)CH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>CH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>CH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>CH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>NH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span></span> <span>&nbsp;</span> + <span>&nbsp;</span> 2<span>&nbsp;</span><a href="Methanesulfonic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Methanesulfonic_acid" title="Methanesulfonic acid"><span class="chemf nowrap">CH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">3</sub></span>SO<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">3</sub></span>H</span></a> <span>&nbsp;</span> <span>→</span> <span>&nbsp;</span> <span class="chemf nowrap">[PhCH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>CH(CH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">3</sub></span>)NHC(O)CH(NH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline">+</sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">3</sub></span>)CH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>CH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>CH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>CH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span>NH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline">+</sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">3</sub></span>]</span><span class="chemf nowrap">[CH<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">3</sub></span>SO<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline">−</sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">3</sub></span>]<span style="display:inline-block;margin-bottom:-0.3em;vertical-align:-0.4em;line-height:1em;font-size:80%;text-align:left"><sup style="font-size:inherit;line-height:inherit;vertical-align:baseline"></sup><br><sub style="font-size:inherit;line-height:inherit;vertical-align:baseline">2</sub></span></span></dd></dl>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Comparison_to_other_formulations">Comparison to other formulations</h3></summary>
    
<p>Lisdexamfetamine dimesylate is one marketed formulation delivering dextroamphetamine. The following table compares the drug to other amphetamine pharmaceuticals.</p>

<div style="clear:both;"></div><span>
</span><table class="wikitable" style="clear:left; align:left">
<caption>Amphetamine base in marketed amphetamine medications</caption>
<tbody><tr><th colspan="2" rowspan="3">drug</th>
<th rowspan="3">formula</th>
<th colspan="2">molecular mass<br><span class="mw-ref" id="cite_ref-178"><a href="#cite_note-178" style="counter-reset: mw-Ref 9;" data-mw-group="note"><span class="mw-reflink-text">[note 9]</span></a></span></th>
<th colspan="3">amphetamine base<br><span class="mw-ref" id="cite_ref-179"><a href="#cite_note-179" style="counter-reset: mw-Ref 10;" data-mw-group="note"><span class="mw-reflink-text">[note 10]</span></a></span></th>
<th colspan="2">amphetamine base<br>in equal doses</th>
<th rowspan="3">doses with<br>equal base<br>content<br><span class="mw-ref" id="cite_ref-180"><a href="#cite_note-180" style="counter-reset: mw-Ref 11;" data-mw-group="note"><span class="mw-reflink-text">[note 11]</span></a></span></th></tr>
<tr>
<th colspan="2"><span class="nobold">(g/mol)</span></th>
<th colspan="3"><span class="nobold">(percent)</span></th>
<th colspan="2"><span class="nobold">(30<span>&nbsp;</span>mg dose)</span></th></tr>
<tr>
<th>total</th>
<th>base</th>
<th>total</th>
<th>dextro-</th>
<th>levo-</th>
<th>dextro-</th>
<th>levo-</th></tr>
<tr>
<td colspan="2"><b>dextroamphetamine sulfate</b><span class="mw-ref" id="cite_ref-damph1_181-0"><a href="#cite_note-damph1-181" style="counter-reset: mw-Ref 159;"><span class="mw-reflink-text">[159]</span></a></span><span class="mw-ref" id="cite_ref-damph2_182-0"><a href="#cite_note-damph2-182" style="counter-reset: mw-Ref 160;"><span class="mw-reflink-text">[160]</span></a></span></td>
<td>(C<sub>9</sub>H<sub>13</sub>N)<sub>2</sub>•H<sub>2</sub>SO<sub>4</sub></td>
<td><center>368.49</center></td>
<td><center>270.41</center></td>
<td><center>73.38%</center></td>
<td><center>73.38%</center></td>
<td><center>—</center></td>
<td><center>22.0<span>&nbsp;</span>mg</center></td>
<td><center>—</center></td>
<td><center>30.0<span>&nbsp;</span>mg</center></td></tr>
<tr>
<th colspan="11"></th></tr>
<tr>
<td colspan="2"><b>amphetamine sulfate</b><span class="mw-ref" id="cite_ref-Amph_sulfate_mass_183-0"><a href="#cite_note-Amph_sulfate_mass-183" style="counter-reset: mw-Ref 161;"><span class="mw-reflink-text">[161]</span></a></span></td>
<td>(C<sub>9</sub>H<sub>13</sub>N)<sub>2</sub>•H<sub>2</sub>SO<sub>4</sub></td>
<td><center>368.49</center></td>
<td><center>270.41</center></td>
<td><center>73.38%</center></td>
<td><center>36.69%</center></td>
<td><center>36.69%</center></td>
<td><center>11.0<span>&nbsp;</span>mg</center></td>
<td><center>11.0<span>&nbsp;</span>mg</center></td>
<td><center>30.0<span>&nbsp;</span>mg</center></td></tr>
<tr>
<th colspan="11"></th></tr>
<tr>
<td colspan="2"><b>Adderall</b></td>
<td></td>
<td></td>
<td></td>
<td><center>62.57%</center></td>
<td><center>47.49%</center></td>
<td><center>15.08%</center></td>
<td><center>14.2<span>&nbsp;</span>mg</center></td>
<td><center>4.5<span>&nbsp;</span>mg</center></td>
<td><center>35.2<span>&nbsp;</span>mg</center></td></tr>
<tr>
<td>25%</td>
<td>dextroamphetamine sulfate<span class="mw-ref" id="cite_ref-damph1_181-1"><a href="#cite_note-damph1-181" style="counter-reset: mw-Ref 159;"><span class="mw-reflink-text">[159]</span></a></span><span class="mw-ref" id="cite_ref-damph2_182-1"><a href="#cite_note-damph2-182" style="counter-reset: mw-Ref 160;"><span class="mw-reflink-text">[160]</span></a></span></td>
<td>(C<sub>9</sub>H<sub>13</sub>N)<sub>2</sub>•H<sub>2</sub>SO<sub>4</sub></td>
<td><center>368.49</center></td>
<td><center>270.41</center></td>
<td><center>73.38%</center></td>
<td><center>73.38%</center></td>
<td><center>—</center></td>
<td></td>
<td></td>
<td></td></tr>
<tr>
<td>25%</td>
<td>amphetamine sulfate<span class="mw-ref" id="cite_ref-Amph_sulfate_mass_183-1"><a href="#cite_note-Amph_sulfate_mass-183" style="counter-reset: mw-Ref 161;"><span class="mw-reflink-text">[161]</span></a></span></td>
<td>(C<sub>9</sub>H<sub>13</sub>N)<sub>2</sub>•H<sub>2</sub>SO<sub>4</sub></td>
<td><center>368.49</center></td>
<td><center>270.41</center></td>
<td><center>73.38%</center></td>
<td><center>36.69%</center></td>
<td><center>36.69%</center></td>
<td></td>
<td></td>
<td></td></tr>
<tr>
<td>25%</td>
<td>dextroamphetamine saccharate<span class="mw-ref" id="cite_ref-184"><a href="#cite_note-184" style="counter-reset: mw-Ref 162;"><span class="mw-reflink-text">[162]</span></a></span></td>
<td>(C<sub>9</sub>H<sub>13</sub>N)<sub>2</sub>•C<sub>6</sub>H<sub>10</sub>O<sub>8</sub></td>
<td><center>480.55</center></td>
<td><center>270.41</center></td>
<td><center>56.27%</center></td>
<td><center>56.27%</center></td>
<td><center>—</center></td>
<td></td>
<td></td>
<td></td></tr>
<tr>
<td>25%</td>
<td>amphetamine aspartate monohydrate<span class="mw-ref" id="cite_ref-amph2_185-0"><a href="#cite_note-amph2-185" style="counter-reset: mw-Ref 163;"><span class="mw-reflink-text">[163]</span></a></span></td>
<td>(C<sub>9</sub>H<sub>13</sub>N)•C<sub>4</sub>H<sub>7</sub>NO<sub>4</sub>•H<sub>2</sub>O</td>
<td><center>286.32</center></td>
<td><center>135.21</center></td>
<td><center>47.22%</center></td>
<td><center>23.61%</center></td>
<td><center>23.61%</center></td>
<td></td>
<td></td>
<td></td></tr>
<tr>
<th colspan="11"></th></tr>
<tr>
<td colspan="2"><b>lisdexamfetamine dimesylate</b><span class="mw-ref" id="cite_ref-USVyvanselabel_14-13"><a href="#cite_note-USVyvanselabel-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span></td>
<td>C<sub>15</sub>H<sub>25</sub>N<sub>3</sub>O•(CH<sub>4</sub>O<sub>3</sub>S)<sub>2</sub></td>
<td><center>455.49</center></td>
<td><center>135.21</center></td>
<td><center>29.68%</center></td>
<td><center>29.68%</center></td>
<td><center>—</center></td>
<td><center>8.9<span>&nbsp;</span>mg</center></td>
<td><center>—</center></td>
<td><center>74.2<span>&nbsp;</span>mg</center></td></tr>
<tr>
<th colspan="11"></th></tr>
<tr>
<td colspan="2"><b>amphetamine base suspension</b><span class="mw-ref" id="cite_ref-186"><a href="#cite_note-186" style="counter-reset: mw-Ref 12;" data-mw-group="note"><span class="mw-reflink-text">[note 12]</span></a></span><span class="mw-ref" id="cite_ref-Dyanavel_61-5"><a href="#cite_note-Dyanavel-61" style="counter-reset: mw-Ref 59;"><span class="mw-reflink-text">[59]</span></a></span></td>
<td>C<sub>9</sub>H<sub>13</sub>N</td>
<td><center>135.21</center></td>
<td><center>135.21</center></td>
<td><center>100%</center></td>
<td><center>76.19%</center></td>
<td><center>23.81%</center></td>
<td><center>22.9<span>&nbsp;</span>mg</center></td>
<td><center>7.1<span>&nbsp;</span>mg</center></td>
<td><center>22.0<span>&nbsp;</span>mg</center></td></tr>
</tbody></table>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History,_society,_and_culture">History, society, and culture</h2></summary>
    

<p>Lisdexamfetamine was developed by New River Pharmaceuticals, who were bought by Takeda Pharmaceuticals through its acquisition of Shire Pharmaceuticals, shortly before it began being marketed. It was developed with the intention of creating a longer-lasting and less-easily abused version of dextroamphetamine, as the requirement of conversion into dextroamphetamine via enzymes in the red blood cells delays its onset of action, regardless of the route of administration.<span class="mw-ref" id="cite_ref-CNS_Spectrums_187-0"><a href="#cite_note-CNS_Spectrums-187" style="counter-reset: mw-Ref 164;"><span class="mw-reflink-text">[164]</span></a></span></p>

<p>On 23 April 2008, the FDA approved lisdexamfetamine for treatment of ADHD in adults.<span class="mw-ref" id="cite_ref-FDAAdultApproval_188-0"><a href="#cite_note-FDAAdultApproval-188" style="counter-reset: mw-Ref 165;"><span class="mw-reflink-text">[165]</span></a></span> On 19 February 2009, Health Canada approved 30<span>&nbsp;</span>mg and 50<span>&nbsp;</span>mg capsules of lisdexamfetamine for treatment of ADHD.<span class="mw-ref" id="cite_ref-189"><a href="#cite_note-189" style="counter-reset: mw-Ref 166;"><span class="mw-reflink-text">[166]</span></a></span></p>

<p>In January 2015, lisdexamfetamine was approved by the U.S. Food and Drug Administration for treatment of binge eating disorder in adults.<span class="mw-ref" id="cite_ref-190"><a href="#cite_note-190" style="counter-reset: mw-Ref 167;"><span class="mw-reflink-text">[167]</span></a></span></p>

<p>Production quotas for 2016 in the United States were 29,750 kilograms.<span class="mw-ref" id="cite_ref-191"><a href="#cite_note-191" style="counter-reset: mw-Ref 168;"><span class="mw-reflink-text">[168]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Names">Names</h3></summary>
    
<p><i>Lisdexamfetamine</i> is a contraction of <a href="Lysine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lysine" title="Lysine"><small>L</small>-lysine</a>-<a href="Dextroamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dextroamphetamine" title="Dextroamphetamine">dextroamphetamine</a>.</p>

<p>As of July 2014 lisdexamfetamine was sold under the following brands: Elvanse, Samexid, Tyvense, Venvanse, and Vyvanse.<span class="mw-ref" id="cite_ref-192"><a href="#cite_note-192" style="counter-reset: mw-Ref 169;"><span class="mw-reflink-text">[169]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Research">Research</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Depression">Depression</h3></summary>
    
<p>Some clinical trials that used lisdexamfetamine as an add-on therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for treatment-resistant depression indicated that this is no more effective than the use of an SSRI or SNRI alone.<span class="mw-ref" id="cite_ref-LDX_adjunct_therapy_193-0"><a href="#cite_note-LDX_adjunct_therapy-193" style="counter-reset: mw-Ref 170;"><span class="mw-reflink-text">[170]</span></a></span> Other studies indicated that psychostimulants potentiated antidepressants, and were under-prescribed for treatment resistant depression. In those studies, patients showed significant improvement in energy, mood, and psychomotor activity.<span class="mw-ref" id="cite_ref-Psychostimulants_in_the_therapy_of_treatment-resistant_depression_Review_of_the_literature_and_findings_from_a_retrospective_study_in_65_depressed_patients_194-0"><a href="#cite_note-Psychostimulants_in_the_therapy_of_treatment-resistant_depression_Review_of_the_literature_and_findings_from_a_retrospective_study_in_65_depressed_patients-194" style="counter-reset: mw-Ref 171;"><span class="mw-reflink-text">[171]</span></a></span>   In February 2014, Shire announced that two late-stage clinical trials had shown that Vyvanse was not an effective treatment for depression.<span class="mw-ref" id="cite_ref-195"><a href="#cite_note-195" style="counter-reset: mw-Ref 172;"><span class="mw-reflink-text">[172]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Notes">Notes</h2></summary>
    

<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references" data-mw-group="note"><li id="cite_note-23"> <span id="mw-reference-text-cite_note-23" class="mw-reference-text">The ADHD-related outcome domains with the greatest proportion of significantly improved outcomes from long-term continuous stimulant therapy include academics (≈55% of academic outcomes improved), driving (100% of driving outcomes improved), non-medical drug use (47% of addiction-related outcomes improved), obesity (≈65% of obesity-related outcomes improved), self-esteem (50% of self-esteem outcomes improved), and social function (67% of social function outcomes improved).<span class="mw-ref" id="cite_ref-Long-term_2015_22-1"><a href="#cite_note-Long-term_2015-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span><br><br>The largest effect sizes for outcome improvements from long-term stimulant therapy occur in the domains involving academics (e.g., grade point average, achievement test scores, length of education, and education level), self-esteem (e.g., self-esteem questionnaire assessments, number of suicide attempts, and suicide rates), and social function (e.g., peer nomination scores, social skills, and quality of peer, family, and romantic relationships).<span class="mw-ref" id="cite_ref-Long-term_2015_22-2"><a href="#cite_note-Long-term_2015-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span><br><br>Long-term combination therapy for ADHD (i.e., treatment with both a stimulant and behavioral therapy) produces even larger effect sizes for outcome improvements and improves a larger proportion of outcomes across each domain compared to long-term stimulant therapy alone.<span class="mw-ref" id="cite_ref-Long-term_2015_22-3"><a href="#cite_note-Long-term_2015-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span></span></li><li id="cite_note-31"> <span id="mw-reference-text-cite_note-31" class="mw-reference-text">Cochrane reviews are high quality meta-analytic systematic reviews of randomized controlled trials.<span class="mw-ref" id="cite_ref-pmid16052183_30-0"><a href="#cite_note-pmid16052183-30" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span></span></li><li id="cite_note-104"> <span id="mw-reference-text-cite_note-104" class="mw-reference-text">Transcription factors are proteins that increase or decrease the expression of specific genes.<span class="mw-ref" id="cite_ref-NHM-Transcription_factor_103-0"><a href="#cite_note-NHM-Transcription_factor-103" style="counter-reset: mw-Ref 95;"><span class="mw-reflink-text">[95]</span></a></span></span></li><li id="cite_note-105"> <span id="mw-reference-text-cite_note-105" class="mw-reference-text">In simpler terms, this <i>necessary and sufficient</i> relationship means that ΔFosB overexpression in the nucleus accumbens and addiction-related behavioral and neural adaptations always occur together and never occur alone.</span></li><li id="cite_note-123"> <span id="mw-reference-text-cite_note-123" class="mw-reference-text">NMDA receptors are voltage-dependent ligand-gated ion channels that requires simultaneous binding of glutamate and a co-agonist (<span class="nowrap"><span class="smallcaps"><span style="font-variant: small-caps; text-transform: lowercase;">D</span></span>-serine</span> or <a href="Glycine.htm" tppabs="https://ptable.com/wiki/compounds/A/Glycine" title="Glycine">glycine</a>) to open the ion channel.<span class="mw-ref" id="cite_ref-NHM-NMDA_122-0"><a href="#cite_note-NHM-NMDA-122" style="counter-reset: mw-Ref 110;"><span class="mw-reflink-text">[110]</span></a></span></span></li><li id="cite_note-124"> <span id="mw-reference-text-cite_note-124" class="mw-reference-text">The review indicated that magnesium <span class="nowrap">L-aspartate</span> and <a href="Magnesium_chloride.htm" tppabs="https://ptable.com/wiki/compounds/A/Magnesium_chloride" title="Magnesium chloride">magnesium chloride</a> produce significant changes in addictive behavior;<span class="mw-ref" id="cite_ref-Magnesium_93-4"><a href="#cite_note-Magnesium-93" style="counter-reset: mw-Ref 86;"><span class="mw-reflink-text">[86]</span></a></span> other forms of magnesium were not mentioned.</span></li><li id="cite_note-131"> <span id="mw-reference-text-cite_note-131" class="mw-reference-text">The 95%<span>&nbsp;</span>confidence interval indicates that there is a 95%<span>&nbsp;</span>probability that the true number of deaths lies between 3,425 and 4,145.</span></li><li id="cite_note-174"> <span id="mw-reference-text-cite_note-174" class="mw-reference-text"><span class="nowrap">4-Hydroxyamphetamine</span> has been shown to be metabolized into <span class="nowrap">4-hydroxynorephedrine</span> by dopamine beta-hydroxylase (DBH) <i>in vitro</i> and it is presumed to be metabolized similarly <i>in vivo</i>.<span class="mw-ref" id="cite_ref-Substituted_amphetamines,_FMO,_and_DBH_165-1"><a href="#cite_note-Substituted_amphetamines,_FMO,_and_DBH-165" style="counter-reset: mw-Ref 147;"><span class="mw-reflink-text">[147]</span></a></span><span class="mw-ref" id="cite_ref-pmid13977820_169-1"><a href="#cite_note-pmid13977820-169" style="counter-reset: mw-Ref 151;"><span class="mw-reflink-text">[151]</span></a></span> Evidence from studies that measured the effect of serum DBH concentrations on <span class="nowrap">4-hydroxyamphetamine</span> metabolism in humans suggests that a different enzyme may mediate the conversion of <span class="nowrap">4-hydroxyamphetamine</span> to <span class="nowrap">4-hydroxynorephedrine</span>;<span class="mw-ref" id="cite_ref-pmid13977820_169-2"><a href="#cite_note-pmid13977820-169" style="counter-reset: mw-Ref 151;"><span class="mw-reflink-text">[151]</span></a></span><span class="mw-ref" id="cite_ref-DBH_4-HA_primary_171-0"><a href="#cite_note-DBH_4-HA_primary-171" style="counter-reset: mw-Ref 153;"><span class="mw-reflink-text">[153]</span></a></span> however, other evidence from animal studies suggests that this reaction is catalyzed by DBH in synaptic vesicles within noradrenergic neurons in the brain.<span class="mw-ref" id="cite_ref-pmid4457764_172-0"><a href="#cite_note-pmid4457764-172" style="counter-reset: mw-Ref 154;"><span class="mw-reflink-text">[154]</span></a></span><span class="mw-ref" id="cite_ref-pmid2600821_173-0"><a href="#cite_note-pmid2600821-173" style="counter-reset: mw-Ref 155;"><span class="mw-reflink-text">[155]</span></a></span></span></li><li id="cite_note-178"> <span id="mw-reference-text-cite_note-178" class="mw-reference-text">For uniformity, molecular masses were calculated using the Lenntech Molecular Weight Calculator<span class="mw-ref" id="cite_ref-177"><a href="#cite_note-177" style="counter-reset: mw-Ref 158;"><span class="mw-reflink-text">[158]</span></a></span> and were within 0.01g/mol of published pharmaceutical values.</span></li><li id="cite_note-179"> <span id="mw-reference-text-cite_note-179" class="mw-reference-text">Amphetamine base percentage = molecular mass<sub>base</sub> / molecular mass<sub>total</sub>. Amphetamine base percentage for Adderall = sum of component percentages / 4.</span></li><li id="cite_note-180"> <span id="mw-reference-text-cite_note-180" class="mw-reference-text">dose = (1 / amphetamine base percentage) <span>×</span> scaling factor = (molecular mass<sub>total</sub> / molecular mass<sub>base</sub>) <span>×</span> scaling factor. The values in this column were scaled to a 30<span>&nbsp;</span>mg dose of dextroamphetamine sulfate. <i>Due to pharmacological differences between these medications (e.g., differences in the release, absorption, conversion, concentration, differing effects of enantiomers, half-life, etc.), the listed values should not be considered equipotent doses.</i> </span></li><li id="cite_note-186"> <span id="mw-reference-text-cite_note-186" class="mw-reference-text">This product (Dyanavel XR) is an oral suspension (i.e., a drug that is suspended in a liquid and taken by mouth) that contains 2.5<span>&nbsp;</span>mg/mL of amphetamine base.<span class="mw-ref" id="cite_ref-Dyanavel_61-2"><a href="#cite_note-Dyanavel-61" style="counter-reset: mw-Ref 59;"><span class="mw-reflink-text">[59]</span></a></span><span>&nbsp;</span>The amphetamine base contains dextro- to levo-amphetamine in a ratio of 3.2:1,<span class="mw-ref" id="cite_ref-Dyanavel_61-3"><a href="#cite_note-Dyanavel-61" style="counter-reset: mw-Ref 59;"><span class="mw-reflink-text">[59]</span></a></span> which is approximately the ratio in Adderall. The product uses an ion exchange resin to achieve extended release of the amphetamine base.<span class="mw-ref" id="cite_ref-Dyanavel_61-4"><a href="#cite_note-Dyanavel-61" style="counter-reset: mw-Ref 59;"><span class="mw-reflink-text">[59]</span></a></span> </span></li></ol></div></div>
<dl><dt>Image legend</dt></dl>
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap"><ol class="mw-references references" data-mw-group="Color legend"><li id="cite_note-81"> <span id="mw-reference-text-cite_note-81" class="mw-reference-text"><div class="legend" style="-webkit-column-break-inside: avoid;page-break-inside: avoid;break-inside: avoid-column"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color:
#00ffff; color:black; font-size:100%; text-align:center;"><span>&nbsp;</span></span><span>&nbsp;</span>Ion channel</div><div class="legend" style="-webkit-column-break-inside: avoid;page-break-inside: avoid;break-inside: avoid-column"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color:
#b2df8a; color:black; font-size:100%; text-align:center;"><span>&nbsp;</span></span><span>&nbsp;</span>G proteins &amp; linked receptors</div><div class="legend" style="-webkit-column-break-inside: avoid;page-break-inside: avoid;break-inside: avoid-column"><span class="legend-color" style="display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color:MediumVioletRed; color:black; font-size:100%; text-align:center;"><span>&nbsp;</span></span><span>&nbsp;</span>(Text color) Transcription factors</div></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Reference_notes">Reference notes</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap"><ol class="mw-references references" data-mw-group="sources"><li id="cite_note-63"> <span id="mw-reference-text-cite_note-63" class="mw-reference-text"><span class="mw-ref" id="cite_ref-Stahl's_Essential_Psychopharmacology_60-1"><a href="#cite_note-Stahl's_Essential_Psychopharmacology-60" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></span><span class="mw-ref" id="cite_ref-FDA_54-4"><a href="#cite_note-FDA-54" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-Westfall_46-2"><a href="#cite_note-Westfall-46" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span><span class="mw-ref" id="cite_ref-pmid18295156_59-1"><a href="#cite_note-pmid18295156-59" style="counter-reset: mw-Ref 57;"><span class="mw-reflink-text">[57]</span></a></span><span class="mw-ref" id="cite_ref-Dyanavel_61-1"><a href="#cite_note-Dyanavel-61" style="counter-reset: mw-Ref 59;"><span class="mw-reflink-text">[59]</span></a></span><span class="mw-ref" id="cite_ref-rhinitis_62-0"><a href="#cite_note-rhinitis-62" style="counter-reset: mw-Ref 60;"><span class="mw-reflink-text">[60]</span></a></span></span></li><li id="cite_note-68"> <span id="mw-reference-text-cite_note-68" class="mw-reference-text"><span class="mw-ref" id="cite_ref-FDA_-_cardiovascular_effects_in_young_individuals_64-0"><a href="#cite_note-FDA_-_cardiovascular_effects_in_young_individuals-64" style="counter-reset: mw-Ref 61;"><span class="mw-reflink-text">[61]</span></a></span><span class="mw-ref" id="cite_ref-pmid22043968_65-0"><a href="#cite_note-pmid22043968-65" style="counter-reset: mw-Ref 62;"><span class="mw-reflink-text">[62]</span></a></span><span class="mw-ref" id="cite_ref-FDA_-_cardiovascular_effects_in_adults_66-0"><a href="#cite_note-FDA_-_cardiovascular_effects_in_adults-66" style="counter-reset: mw-Ref 63;"><span class="mw-reflink-text">[63]</span></a></span><span class="mw-ref" id="cite_ref-pmid22161946_67-0"><a href="#cite_note-pmid22161946-67" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></span></span></li><li id="cite_note-69"> <span id="mw-reference-text-cite_note-69" class="mw-reference-text"><span class="mw-ref" id="cite_ref-FDA_54-5"><a href="#cite_note-FDA-54" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-International_55-1"><a href="#cite_note-International-55" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span><span class="mw-ref" id="cite_ref-FDA_-_cardiovascular_effects_in_young_individuals_64-1"><a href="#cite_note-FDA_-_cardiovascular_effects_in_young_individuals-64" style="counter-reset: mw-Ref 61;"><span class="mw-reflink-text">[61]</span></a></span><span class="mw-ref" id="cite_ref-FDA_-_cardiovascular_effects_in_adults_66-1"><a href="#cite_note-FDA_-_cardiovascular_effects_in_adults-66" style="counter-reset: mw-Ref 63;"><span class="mw-reflink-text">[63]</span></a></span></span></li><li id="cite_note-72"> <span id="mw-reference-text-cite_note-72" class="mw-reference-text"><span class="mw-ref" id="cite_ref-Libido_70-0"><a href="#cite_note-Libido-70" style="counter-reset: mw-Ref 65;"><span class="mw-reflink-text">[65]</span></a></span><span class="mw-ref" id="cite_ref-FDA_54-7"><a href="#cite_note-FDA-54" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-Westfall_46-13"><a href="#cite_note-Westfall-46" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span><span class="mw-ref" id="cite_ref-Merck_Manual_Amphetamines_71-0"><a href="#cite_note-Merck_Manual_Amphetamines-71" style="counter-reset: mw-Ref 66;"><span class="mw-reflink-text">[66]</span></a></span></span></li><li id="cite_note-Exercise_therapy-99"> <span id="mw-reference-text-cite_note-Exercise_therapy-99" class="mw-reference-text"><span class="mw-ref" id="cite_ref-Natural_and_drug_addictions_96-6"><a href="#cite_note-Natural_and_drug_addictions-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span><span class="mw-ref" id="cite_ref-Running_vs_addiction_97-2"><a href="#cite_note-Running_vs_addiction-97" style="counter-reset: mw-Ref 90;"><span class="mw-reflink-text">[90]</span></a></span><span class="mw-ref" id="cite_ref-Exercise,_addiction_prevention,_and_ΔFosB_98-1"><a href="#cite_note-Exercise,_addiction_prevention,_and_ΔFosB-98" style="counter-reset: mw-Ref 91;"><span class="mw-reflink-text">[91]</span></a></span><span class="mw-ref" id="cite_ref-Exercise_Rev_3_100-1"><a href="#cite_note-Exercise_Rev_3-100" style="counter-reset: mw-Ref 92;"><span class="mw-reflink-text">[92]</span></a></span><span class="mw-ref" id="cite_ref-Addiction_review_2016_126-0"><a href="#cite_note-Addiction_review_2016-126" style="counter-reset: mw-Ref 112;"><span class="mw-reflink-text">[112]</span></a></span></span></li><li id="cite_note-108"> <span id="mw-reference-text-cite_note-108" class="mw-reference-text"><span class="mw-ref" id="cite_ref-What_the_ΔFosB?_94-4"><a href="#cite_note-What_the_ΔFosB?-94" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></span><span class="mw-ref" id="cite_ref-Natural_and_drug_addictions_96-1"><a href="#cite_note-Natural_and_drug_addictions-96" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span><span class="mw-ref" id="cite_ref-Nestler_95-4"><a href="#cite_note-Nestler-95" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span><span class="mw-ref" id="cite_ref-Alcoholism_ΔFosB_106-0"><a href="#cite_note-Alcoholism_ΔFosB-106" style="counter-reset: mw-Ref 96;"><span class="mw-reflink-text">[96]</span></a></span><span class="mw-ref" id="cite_ref-MPH_ΔFosB_107-0"><a href="#cite_note-MPH_ΔFosB-107" style="counter-reset: mw-Ref 97;"><span class="mw-reflink-text">[97]</span></a></span></span></li><li id="cite_note-113"> <span id="mw-reference-text-cite_note-113" class="mw-reference-text"><span class="mw-ref" id="cite_ref-Nestler_95-7"><a href="#cite_note-Nestler-95" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span><span class="mw-ref" id="cite_ref-G9a_reverses_ΔFosB_plasticity_110-0"><a href="#cite_note-G9a_reverses_ΔFosB_plasticity-110" style="counter-reset: mw-Ref 99;"><span class="mw-reflink-text">[99]</span></a></span><span class="mw-ref" id="cite_ref-HDACi-induced_G9a+H3K9me2_primary_source_111-0"><a href="#cite_note-HDACi-induced_G9a+H3K9me2_primary_source-111" style="counter-reset: mw-Ref 100;"><span class="mw-reflink-text">[100]</span></a></span><span class="mw-ref" id="cite_ref-A_feat_of_epigenetic_engineering_112-0"><a href="#cite_note-A_feat_of_epigenetic_engineering-112" style="counter-reset: mw-Ref 101;"><span class="mw-reflink-text">[101]</span></a></span></span></li><li id="cite_note-135"> <span id="mw-reference-text-cite_note-135" class="mw-reference-text"><span class="mw-ref" id="cite_ref-Acute_amph_toxicity_133-0"><a href="#cite_note-Acute_amph_toxicity-133" style="counter-reset: mw-Ref 118;"><span class="mw-reflink-text">[118]</span></a></span><span class="mw-ref" id="cite_ref-FDA_54-13"><a href="#cite_note-FDA-54" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-Westfall_46-18"><a href="#cite_note-Westfall-46" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span><span class="mw-ref" id="cite_ref-Amphetamine_toxidrome_130-1"><a href="#cite_note-Amphetamine_toxidrome-130" style="counter-reset: mw-Ref 116;"><span class="mw-reflink-text">[116]</span></a></span><span class="mw-ref" id="cite_ref-Albertson_2011_134-0"><a href="#cite_note-Albertson_2011-134" style="counter-reset: mw-Ref 119;"><span class="mw-reflink-text">[119]</span></a></span></span></li><li id="cite_note-142"> <span id="mw-reference-text-cite_note-142" class="mw-reference-text"><span class="mw-ref" id="cite_ref-pmid22392347_15-1"><a href="#cite_note-pmid22392347-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span><span class="mw-ref" id="cite_ref-Amph-induced_hyperthermia_and_neurotoxicity_review_137-1"><a href="#cite_note-Amph-induced_hyperthermia_and_neurotoxicity_review-137" style="counter-reset: mw-Ref 121;"><span class="mw-reflink-text">[121]</span></a></span><span class="mw-ref" id="cite_ref-Autoxidation1_140-0"><a href="#cite_note-Autoxidation1-140" style="counter-reset: mw-Ref 124;"><span class="mw-reflink-text">[124]</span></a></span><span class="mw-ref" id="cite_ref-Autoxidation2_141-0"><a href="#cite_note-Autoxidation2-141" style="counter-reset: mw-Ref 125;"><span class="mw-reflink-text">[125]</span></a></span></span></li><li id="cite_note-amphetamine_metabolism-159"> <span id="mw-reference-text-cite_note-amphetamine_metabolism-159" class="mw-reference-text"><span class="mw-ref" id="cite_ref-FDA_Pharmacokinetics_156-11"><a href="#cite_note-FDA_Pharmacokinetics-156" style="counter-reset: mw-Ref 139;"><span class="mw-reflink-text">[139]</span></a></span><span class="mw-ref" id="cite_ref-Substituted_amphetamines,_FMO,_and_DBH_165-0"><a href="#cite_note-Substituted_amphetamines,_FMO,_and_DBH-165" style="counter-reset: mw-Ref 147;"><span class="mw-reflink-text">[147]</span></a></span><span class="mw-ref" id="cite_ref-DBH_amph_primary_166-0"><a href="#cite_note-DBH_amph_primary-166" style="counter-reset: mw-Ref 148;"><span class="mw-reflink-text">[148]</span></a></span><span class="mw-ref" id="cite_ref-FMO_167-0"><a href="#cite_note-FMO-167" style="counter-reset: mw-Ref 149;"><span class="mw-reflink-text">[149]</span></a></span><span class="mw-ref" id="cite_ref-FMO3-Primary_168-0"><a href="#cite_note-FMO3-Primary-168" style="counter-reset: mw-Ref 150;"><span class="mw-reflink-text">[150]</span></a></span><span class="mw-ref" id="cite_ref-Metabolites_160-1"><a href="#cite_note-Metabolites-160" style="counter-reset: mw-Ref 142;"><span class="mw-reflink-text">[142]</span></a></span><span class="mw-ref" id="cite_ref-pmid13977820_169-0"><a href="#cite_note-pmid13977820-169" style="counter-reset: mw-Ref 151;"><span class="mw-reflink-text">[151]</span></a></span><span class="mw-ref" id="cite_ref-Glycine_conjugation_review_170-0"><a href="#cite_note-Glycine_conjugation_review-170" style="counter-reset: mw-Ref 152;"><span class="mw-reflink-text">[152]</span></a></span></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-AHFS2019-1"> <span id="mw-reference-text-cite_note-AHFS2019-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/monograph/lisdexamfetamine-dimesylate.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/lisdexamfetamine-dimesylate.html'" tppabs="https://www.drugs.com/monograph/lisdexamfetamine-dimesylate.html" class="external text external">"Lisdexamfetamine Dimesylate Monograph for Professionals"</a>. <i>Drugs.com</i>. American Society of Health-System Pharmacists<span class="reference-accessdate">. Retrieved <span class="nowrap">15 April</span> 2019</span>.</cite></span></li><li id="cite_note-Stahl's_Essential_Psychopharmacology_-_Lisdexamfetamine-2"> <span id="mw-reference-text-cite_note-Stahl's_Essential_Psychopharmacology_-_Lisdexamfetamine-2" class="mw-reference-text"><cite id="CITEREFStahl2017" class="citation book cs1">Stahl SM (March 2017). "Lisdexamfetamine". <i>Prescriber's Guide: Stahl's Essential Psychopharmacology</i> (6th ed.). Cambridge, United Kingdom: Cambridge University Press. pp.<span>&nbsp;</span>379–384. ISBN<span>&nbsp;</span><bdi>9781108228749</bdi>.</cite></span></li><li id="cite_note-3"> <span id="mw-reference-text-cite_note-3" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con261790.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con261790.pdf'" tppabs="http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con261790.pdf" class="external text external">"Public Assessment Report Decentralised Procedure"</a> <span class="cs1-format">(PDF)</span>. MHRA. p.<span>&nbsp;</span>14<span class="reference-accessdate">. Retrieved <span class="nowrap">23 August</span> 2014</span>.</cite></span></li><li id="cite_note-Millichap:_onset,_peak,_and_duration-4"> <span id="mw-reference-text-cite_note-Millichap:_onset,_peak,_and_duration-4" class="mw-reference-text"><cite id="CITEREFMillichap_JG2010" class="citation book cs1">Millichap JG (2010). "Chapter 9: Medications for ADHD".  In Millichap JG (ed.). <i>Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD</i> (2nd ed.). New York, USA: Springer. p.<span>&nbsp;</span>112. ISBN<span>&nbsp;</span><bdi>9781441913968</bdi>. <q><br>Table 9.2 Dextroamphetamine formulations of stimulant medication<br>Dexedrine [Peak:2–3<span>&nbsp;</span>h] [Duration:5–6<span>&nbsp;</span>h]<span>&nbsp;</span>...<br>Adderall [Peak:2–3<span>&nbsp;</span>h] [Duration:5–7<span>&nbsp;</span>h]<br>Dexedrine spansules [Peak:7–8<span>&nbsp;</span>h] [Duration:12<span>&nbsp;</span>h]<span>&nbsp;</span>...<br>Adderall XR [Peak:7–8<span>&nbsp;</span>h] [Duration:12<span>&nbsp;</span>h]<br>Vyvanse [Peak:3–4<span>&nbsp;</span>h] [Duration:12<span>&nbsp;</span>h]</q></cite></span></li><li id="cite_note-XR_onset-duration-5"> <span id="mw-reference-text-cite_note-XR_onset-duration-5" class="mw-reference-text"><cite id="CITEREFBramsMaoDoyle2008" class="citation journal cs1">Brams M, Mao AR, Doyle RL (September 2008). "Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder". <i>Postgrad. Med</i>. <b>120</b> (3): 69–88. doi:<a href="javascript:if(confirm('https://doi.org/10.3810%2Fpgm.2008.09.1909  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3810%2Fpgm.2008.09.1909'" tppabs="https://doi.org/10.3810%2Fpgm.2008.09.1909" class="external text external">10.3810/pgm.2008.09.1909</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18824827  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18824827'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18824827" class="external text external">18824827</a>. <q>Onset of efficacy was earliest for d-MPH-ER at 0.5 hours, followed by d, l-MPH-LA at 1 to 2 hours, MCD at 1.5 hours, d, l-MPH-OR at 1 to 2 hours, MAS-XR at 1.5 to 2 hours, MTS at 2 hours, and LDX at approximately 2 hours.<span>&nbsp;</span>... MAS-XR, and LDX have a long duration of action at 12 hours postdose</q></cite></span></li><li id="cite_note-DailyMed2019-6"> <span id="mw-reference-text-cite_note-DailyMed2019-6" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/pregnancy/lisdexamfetamine.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/pregnancy/lisdexamfetamine.html'" tppabs="https://www.drugs.com/pregnancy/lisdexamfetamine.html" class="external text external">"Lisdexamfetamine (Vyvanse) Use During Pregnancy"</a>. <i>Drugs.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">16 April</span> 2019</span>.</cite></span></li><li id="cite_note-BNF76-7"> <span id="mw-reference-text-cite_note-BNF76-7" class="mw-reference-text"><cite class="citation book cs1"><i>British national formulary: BNF 76</i> (76 ed.). Pharmaceutical Press. 2018. pp.<span>&nbsp;</span>348–349. ISBN<span>&nbsp;</span><bdi>9780857113382</bdi>.</cite></span></li><li id="cite_note-Amp2013-8"> <span id="mw-reference-text-cite_note-Amp2013-8" class="mw-reference-text"><cite id="CITEREFHealSmithGosdenNutt2013" class="citation journal cs1">Heal DJ, Smith SL, Gosden J, Nutt DJ (June 2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666194  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666194'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666194" class="external text external">"Amphetamine, past and present – a pharmacological and clinical perspective"</a>. <i>J. Psychopharmacol</i>. <b>27</b> (6): 479–496. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F0269881113482532  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F0269881113482532'" tppabs="https://doi.org/10.1177%2F0269881113482532" class="external text external">10.1177/0269881113482532</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666194  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666194'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666194" class="external text external">3666194</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23539642  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23539642'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23539642" class="external text external">23539642</a>.</cite></span></li><li id="cite_note-pmid17407369-9"> <span id="mw-reference-text-cite_note-pmid17407369-9" class="mw-reference-text"><cite id="CITEREFBlickKeating2007" class="citation journal cs1">Blick SK, Keating GM (2007). "Lisdexamfetamine". <i>Paediatric Drugs</i>. <b>9</b> (2): 129–135, discussion 136–138. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00148581-200709020-00007  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00148581-200709020-00007'" tppabs="https://doi.org/10.2165%2F00148581-200709020-00007" class="external text external">10.2165/00148581-200709020-00007</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17407369  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17407369'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17407369" class="external text external">17407369</a>.</cite></span></li><li id="cite_note-NADAC2019-10"> <span id="mw-reference-text-cite_note-NADAC2019-10" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://data.medicaid.gov/Drug-Pricing-and-Payment/NADAC-as-of-2019-02-27/s7c9-pfa6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://data.medicaid.gov/Drug-Pricing-and-Payment/NADAC-as-of-2019-02-27/s7c9-pfa6'" tppabs="https://data.medicaid.gov/Drug-Pricing-and-Payment/NADAC-as-of-2019-02-27/s7c9-pfa6" class="external text external">"NADAC as of 2019-02-27"</a>. <i>Centers for Medicare and Medicaid Services</i><span class="reference-accessdate">. Retrieved <span class="nowrap">3 March</span> 2019</span>.</cite></span></li><li id="cite_note-11"> <span id="mw-reference-text-cite_note-11" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://clincalc.com/DrugStats/Top300Drugs.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://clincalc.com/DrugStats/Top300Drugs.aspx'" tppabs="https://clincalc.com/DrugStats/Top300Drugs.aspx" class="external text external">"The Top 300 of 2020"</a>. <i>ClinCalc</i><span class="reference-accessdate">. Retrieved <span class="nowrap">11 April</span> 2020</span>.</cite></span></li><li id="cite_note-12"> <span id="mw-reference-text-cite_note-12" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://clincalc.com/DrugStats/Drugs/LisdexamfetamineDimesylate  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://clincalc.com/DrugStats/Drugs/LisdexamfetamineDimesylate'" tppabs="https://clincalc.com/DrugStats/Drugs/LisdexamfetamineDimesylate" class="external text external">"Lisdexamfetamine Dimesylate - Drug Usage Statistics"</a>. <i>ClinCalc</i><span class="reference-accessdate">. Retrieved <span class="nowrap">11 April</span> 2020</span>.</cite></span></li><li id="cite_note-DEA2017-13"> <span id="mw-reference-text-cite_note-DEA2017-13" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://www.dea.gov/sites/default/files/2018-06/drug_of_abuse.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.dea.gov/sites/default/files/2018-06/drug_of_abuse.pdf'" tppabs="https://www.dea.gov/sites/default/files/2018-06/drug_of_abuse.pdf" class="external text external"><i>Drugs of Abuse</i></a> <span class="cs1-format">(PDF)</span>. Drug Enforcement Administration • U.S. Department of Justice. 2017. p.<span>&nbsp;</span>22<span class="reference-accessdate">. Retrieved <span class="nowrap">16 April</span> 2019</span>.</cite></span></li><li id="cite_note-USVyvanselabel-14"> <span id="mw-reference-text-cite_note-USVyvanselabel-14" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=704e4378-ca83-445c-8b45-3cfa51c1ecad  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=704e4378-ca83-445c-8b45-3cfa51c1ecad'" tppabs="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=704e4378-ca83-445c-8b45-3cfa51c1ecad" class="external text external">"Vyvanse- lisdexamfetamine dimesylate capsule Vyvanse- lisdexamfetamine dimesylate tablet, chewable"</a>. <i>DailyMed</i>. Shire US Inc. 30 October 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">22 December</span> 2019</span>.</cite></span></li><li id="cite_note-pmid22392347-15"> <span id="mw-reference-text-cite_note-pmid22392347-15" class="mw-reference-text"><cite id="CITEREFCarvalhoCarmoCostaCapela2012" class="citation journal cs1">Carvalho M, Carmo H, Costa VM, Capela JP, Pontes H, Remião F, Carvalho F, Bastos Mde L (August 2012). "Toxicity of amphetamines: an update". <i>Archives of Toxicology</i>. <b>86</b> (8): 1167–1231. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs00204-012-0815-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs00204-012-0815-5'" tppabs="https://doi.org/10.1007%2Fs00204-012-0815-5" class="external text external">10.1007/s00204-012-0815-5</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22392347  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22392347'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22392347" class="external text external">22392347</a>.</cite></span></li><li id="cite_note-AbuseAndAbnormalities-16"> <span id="mw-reference-text-cite_note-AbuseAndAbnormalities-16" class="mw-reference-text"><cite id="CITEREFBermanO'NeillFearsBartzokis2008" class="citation journal cs1">Berman S, O'Neill J, Fears S, Bartzokis G, London ED (October 2008). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769923  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769923'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769923" class="external text external">"Abuse of amphetamines and structural abnormalities in the brain"</a>. <i>Annals of the New York Academy of Sciences</i>. <b>1141</b> (1): 195–220. doi:<a href="javascript:if(confirm('https://doi.org/10.1196%2Fannals.1441.031  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1196%2Fannals.1441.031'" tppabs="https://doi.org/10.1196%2Fannals.1441.031" class="external text external">10.1196/annals.1441.031</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769923  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769923'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769923" class="external text external">2769923</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18991959  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18991959'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18991959" class="external text external">18991959</a>.</cite></span></li><li id="cite_note-Neuroplasticity_1-17"> <span id="mw-reference-text-cite_note-Neuroplasticity_1-17" class="mw-reference-text"><cite id="CITEREFHartRaduaNakaoMataix-Cols2013" class="citation journal cs1">Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K (February 2013). "Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects". <i>JAMA Psychiatry</i>. <b>70</b> (2): 185–198. doi:<a href="javascript:if(confirm('https://doi.org/10.1001%2Fjamapsychiatry.2013.277  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Fjamapsychiatry.2013.277'" tppabs="https://doi.org/10.1001%2Fjamapsychiatry.2013.277" class="external text external">10.1001/jamapsychiatry.2013.277</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23247506  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23247506'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23247506" class="external text external">23247506</a>.</cite></span></li><li id="cite_note-Neuroplasticity_2-18"> <span id="mw-reference-text-cite_note-Neuroplasticity_2-18" class="mw-reference-text"><cite id="CITEREFSpencerBrownSeidmanValera2013" class="citation journal cs1">Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A, Faraone SV, Biederman J (September 2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801446  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801446'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801446" class="external text external">"Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies"</a>. <i>The Journal of Clinical Psychiatry</i>. <b>74</b> (9): 902–917. doi:<a href="javascript:if(confirm('https://doi.org/10.4088%2FJCP.12r08287  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4088%2FJCP.12r08287'" tppabs="https://doi.org/10.4088%2FJCP.12r08287" class="external text external">10.4088/JCP.12r08287</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801446  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801446'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801446" class="external text external">3801446</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24107764  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24107764'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24107764" class="external text external">24107764</a>.</cite></span></li><li id="cite_note-Neuroplasticity_3-19"> <span id="mw-reference-text-cite_note-Neuroplasticity_3-19" class="mw-reference-text"><cite id="CITEREFFrodlSkokauskas2012" class="citation journal cs1">Frodl T, Skokauskas N (February 2012). "Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects". <i>Acta Psychiatrica Scandinavica</i>. <b>125</b> (2): 114–126. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1600-0447.2011.01786.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1600-0447.2011.01786.x'" tppabs="https://doi.org/10.1111%2Fj.1600-0447.2011.01786.x" class="external text external">10.1111/j.1600-0447.2011.01786.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22118249  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22118249'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22118249" class="external text external">22118249</a>. <q>Basal ganglia regions like the right globus pallidus, the right putamen, and the nucleus caudatus are structurally affected in children with ADHD. These changes and alterations in limbic regions like ACC and amygdala are more pronounced in non-treated populations and seem to diminish over time from child to adulthood. Treatment seems to have positive effects on brain structure.</q></cite></span></li><li id="cite_note-Long-Term_Outcomes_Medications-20"> <span id="mw-reference-text-cite_note-Long-Term_Outcomes_Medications-20" class="mw-reference-text"><cite id="CITEREFHuangTsai2011" class="citation journal cs1">Huang YS, Tsai MH (July 2011). "Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge". <i>CNS Drugs</i>. <b>25</b> (7): 539–554. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F11589380-000000000-00000  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F11589380-000000000-00000'" tppabs="https://doi.org/10.2165%2F11589380-000000000-00000" class="external text external">10.2165/11589380-000000000-00000</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21699268  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21699268'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21699268" class="external text external">21699268</a>. <q>Several other studies,<sup>[97-101]</sup> including a meta-analytic review<sup>[98]</sup> and a retrospective study,<sup>[97]</sup> suggested that stimulant therapy in childhood is associated with a reduced risk of subsequent substance use, cigarette smoking and alcohol use disorders.<span>&nbsp;</span>... Recent studies have demonstrated that stimulants, along with the non-stimulants atomoxetine and extended-release guanfacine, are continuously effective for more than 2-year treatment periods with few and tolerable adverse effects. The effectiveness of long-term therapy includes not only the core symptoms of ADHD, but also improved quality of life and academic achievements. The most concerning short-term adverse effects of stimulants, such as elevated blood pressure and heart rate, waned in long-term follow-up studies.<span>&nbsp;</span>... The current data do not support the potential impact of stimulants on the worsening or development of tics or substance abuse into adulthood. In the longest follow-up study (of more than 10<span>&nbsp;</span>years), lifetime stimulant treatment for ADHD was effective and protective against the development of adverse psychiatric disorders.</q></cite></span></li><li id="cite_note-Millichap-21"> <span id="mw-reference-text-cite_note-Millichap-21" class="mw-reference-text"><cite class="citation book cs1">Millichap JG (2010). "Chapter 9: Medications for ADHD".  In Millichap JG (ed.). <i>Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD</i> (2nd ed.). New York, USA: Springer. pp.<span>&nbsp;</span>121–123, 125–127. ISBN<span>&nbsp;</span><bdi>9781441913968</bdi>. <q>Ongoing research has provided answers to many of the parents' concerns, and has confirmed the effectiveness and safety of the long-term use of medication.</q></cite></span></li><li id="cite_note-Long-term_2015-22"> <span id="mw-reference-text-cite_note-Long-term_2015-22" class="mw-reference-text"><cite id="CITEREFArnoldHodgkinsCaciKahle2015" class="citation journal cs1">Arnold LE, Hodgkins P, Caci H, Kahle J, Young S (February 2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340791  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340791'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340791" class="external text external">"Effect of treatment modality on long-term outcomes in attention-deficit/hyperactivity disorder: a systematic review"</a>. <i>PLOS ONE</i>. <b>10</b> (2): e0116407. doi:<a href="javascript:if(confirm('https://doi.org/10.1371%2Fjournal.pone.0116407  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1371%2Fjournal.pone.0116407'" tppabs="https://doi.org/10.1371%2Fjournal.pone.0116407" class="external text external">10.1371/journal.pone.0116407</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340791  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340791'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340791" class="external text external">4340791</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25714373  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25714373'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25714373" class="external text external">25714373</a>. <q>The highest proportion of improved outcomes was reported with combination treatment (83% of outcomes). Among significantly improved outcomes, the largest effect sizes were found for combination treatment. The greatest improvements were associated with academic, self-esteem, or social function outcomes.</q></cite><br><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340791/figure/pone.0116407.g003/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340791/figure/pone.0116407.g003/'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340791/figure/pone.0116407.g003/" class="external text external">Figure 3: Treatment benefit by treatment type and outcome group</a></span></li><li id="cite_note-Malenka_2009_03-24"> <span id="mw-reference-text-cite_note-Malenka_2009_03-24" class="mw-reference-text"><cite id="CITEREFMalenkaNestlerHyman2009" class="citation book cs1">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 6: Widely Projecting Systems: Monoamines, Acetylcholine, and Orexin".  In Sydor A, Brown RY (eds.). <i>Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York, USA: McGraw-Hill Medical. pp.<span>&nbsp;</span>154–157. ISBN<span>&nbsp;</span><bdi>9780071481274</bdi>.</cite></span></li><li id="cite_note-Malenka_2009-25"> <span id="mw-reference-text-cite_note-Malenka_2009-25" class="mw-reference-text"><cite class="citation book cs1">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 13: Higher Cognitive Function and Behavioral Control".  In Sydor A, Brown RY (eds.). <i>Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York, USA: McGraw-Hill Medical. pp.<span>&nbsp;</span>318, 321. ISBN<span>&nbsp;</span><bdi>9780071481274</bdi>. <q>Therapeutic (relatively low) doses of psychostimulants, such as methylphenidate and amphetamine, improve performance on working memory tasks both in normal subjects and those with ADHD.<span>&nbsp;</span>... stimulants act not only on working memory function, but also on general levels of arousal and, within the nucleus accumbens, improve the saliency of tasks. Thus, stimulants improve performance on effortful but tedious tasks<span>&nbsp;</span>... through indirect stimulation of dopamine and norepinephrine receptors.<span>&nbsp;</span>...<br>Beyond these general permissive effects, dopamine (acting via D1 receptors) and norepinephrine (acting at several receptors) can, at optimal levels, enhance working memory and aspects of attention.</q></cite></span></li><li id="cite_note-cognition_enhancers-26"> <span id="mw-reference-text-cite_note-cognition_enhancers-26" class="mw-reference-text"><cite id="CITEREFBidwellMcClernonKollins2011" class="citation journal cs1">Bidwell LC, McClernon FJ, Kollins SH (August 2011). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353150  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353150'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353150" class="external text external">"Cognitive enhancers for the treatment of ADHD"</a>. <i>Pharmacology Biochemistry and Behavior</i>. <b>99</b> (2): 262–274. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.pbb.2011.05.002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.pbb.2011.05.002'" tppabs="https://doi.org/10.1016%2Fj.pbb.2011.05.002" class="external text external">10.1016/j.pbb.2011.05.002</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353150  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353150'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353150" class="external text external">3353150</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21596055  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21596055'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21596055" class="external text external">21596055</a>.</cite></span></li><li id="cite_note-Long-term_36-27"> <span id="mw-reference-text-cite_note-Long-term_36-27" class="mw-reference-text"><cite id="CITEREFParkerWalesChalhoubHarpin2013" class="citation journal cs1">Parker J, Wales G, Chalhoub N, Harpin V (September 2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3785407  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3785407'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3785407" class="external text external">"The long-term outcomes of interventions for the management of attention-deficit hyperactivity disorder in children and adolescents: a systematic review of randomized controlled trials"</a>. <i>Psychology Research and Behavior Management</i>. <b>6</b>: 87–99. doi:<a href="javascript:if(confirm('https://doi.org/10.2147%2FPRBM.S49114  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2147%2FPRBM.S49114'" tppabs="https://doi.org/10.2147%2FPRBM.S49114" class="external text external">10.2147/PRBM.S49114</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3785407  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3785407'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3785407" class="external text external">3785407</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24082796  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24082796'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24082796" class="external text external">24082796</a>. <q>Only one paper<sup>53</sup> examining outcomes beyond 36 months met the review criteria.<span>&nbsp;</span>... There is high level evidence suggesting that pharmacological treatment can have a major beneficial effect on the core symptoms of ADHD (hyperactivity, inattention, and impulsivity) in approximately 80% of cases compared with placebo controls, in the short term.</q></cite></span></li><li id="cite_note-Millichap_3-28"> <span id="mw-reference-text-cite_note-Millichap_3-28" class="mw-reference-text"><cite class="citation book cs1">Millichap JG (2010). "Chapter 9: Medications for ADHD".  In Millichap JG (ed.). <i>Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD</i> (2nd ed.). New York, USA: Springer. pp.<span>&nbsp;</span>111–113. ISBN<span>&nbsp;</span><bdi>9781441913968</bdi>.</cite></span></li><li id="cite_note-ADHD-29"> <span id="mw-reference-text-cite_note-ADHD-29" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.webmd.com/add-adhd/childhood-adhd/stimulants-for-attention-deficit-hyperactivity-disorder  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.webmd.com/add-adhd/childhood-adhd/stimulants-for-attention-deficit-hyperactivity-disorder'" tppabs="http://www.webmd.com/add-adhd/childhood-adhd/stimulants-for-attention-deficit-hyperactivity-disorder" class="external text external">"Stimulants for Attention Deficit Hyperactivity Disorder"</a>. <i>WebMD</i>. Healthwise. 12 April 2010<span class="reference-accessdate">. Retrieved <span class="nowrap">12 November</span> 2013</span>.</cite></span></li><li id="cite_note-pmid16052183-30"> <span id="mw-reference-text-cite_note-pmid16052183-30" class="mw-reference-text"><cite id="CITEREFScholtenClarkeHetherington2005" class="citation journal cs1">Scholten RJ, Clarke M, Hetherington J (August 2005). "The Cochrane Collaboration". <i>European Journal of Clinical Nutrition</i>. <b>59</b> (Suppl 1): S147–S149, discussion S195–S196. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fsj.ejcn.1602188  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fsj.ejcn.1602188'" tppabs="https://doi.org/10.1038%2Fsj.ejcn.1602188" class="external text external">10.1038/sj.ejcn.1602188</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16052183  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16052183'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16052183" class="external text external">16052183</a>.</cite></span></li><li id="cite_note-Cochrane_Amphetamines_ADHD-32"> <span id="mw-reference-text-cite_note-Cochrane_Amphetamines_ADHD-32" class="mw-reference-text"><cite id="CITEREFCastellsBlanco-SilventeCunill2018" class="citation journal cs1">Castells X, Blanco-Silvente L, Cunill R (August 2018). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513464  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513464'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513464" class="external text external">"Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults"</a>. <i>Cochrane Database of Systematic Reviews</i>. <b>8</b>: CD007813. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD007813.pub3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD007813.pub3'" tppabs="https://doi.org/10.1002%2F14651858.CD007813.pub3" class="external text external">10.1002/14651858.CD007813.pub3</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513464  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513464'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513464" class="external text external">6513464</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/30091808  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/30091808'" tppabs="https://pubmed.ncbi.nlm.nih.gov/30091808" class="external text external">30091808</a>.</cite></span></li><li id="cite_note-pmid26844979-33"> <span id="mw-reference-text-cite_note-pmid26844979-33" class="mw-reference-text"><cite id="CITEREFPunjaShamseerHartlingUrichuk2016" class="citation journal cs1">Punja S, Shamseer L, Hartling L, Urichuk L, Vandermeer B, Nikles J, Vohra S (February 2016). "Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents". <i>Cochrane Database of Systematic Reviews</i>. <b>2</b>: CD009996. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD009996.pub2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD009996.pub2'" tppabs="https://doi.org/10.1002%2F14651858.CD009996.pub2" class="external text external">10.1002/14651858.CD009996.pub2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26844979  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26844979'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26844979" class="external text external">26844979</a>.</cite></span></li><li id="cite_note-pmid29944175-34"> <span id="mw-reference-text-cite_note-pmid29944175-34" class="mw-reference-text"><cite id="CITEREFOslandSteevesPringsheim2018" class="citation journal cs1">Osland ST, Steeves TD, Pringsheim T (June 2018). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513283  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513283'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513283" class="external text external">"Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders"</a>. <i>Cochrane Database of Systematic Reviews</i>. <b>6</b>: CD007990. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD007990.pub3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD007990.pub3'" tppabs="https://doi.org/10.1002%2F14651858.CD007990.pub3" class="external text external">10.1002/14651858.CD007990.pub3</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513283  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513283'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513283" class="external text external">6513283</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29944175  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29944175'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29944175" class="external text external">29944175</a>.</cite></span></li><li id="cite_note-Unambiguous_PFC_D1_A2-35"> <span id="mw-reference-text-cite_note-Unambiguous_PFC_D1_A2-35" class="mw-reference-text"><cite id="CITEREFSpencerDevilbissBerridge2015" class="citation journal cs1">Spencer RC, Devilbiss DM, Berridge CW (June 2015). <a href="javascript:if(confirm('https://rdw.rowan.edu/cgi/viewcontent.cgi?article=1056&context=som_facpub  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://rdw.rowan.edu/cgi/viewcontent.cgi?article=1056&context=som_facpub'" tppabs="https://rdw.rowan.edu/cgi/viewcontent.cgi?article=1056&context=som_facpub" class="external text external">"The Cognition-Enhancing Effects of Psychostimulants Involve Direct Action in the Prefrontal Cortex"</a>. <i>Biological Psychiatry</i>. <b>77</b> (11): 940–950. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.biopsych.2014.09.013  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.biopsych.2014.09.013'" tppabs="https://doi.org/10.1016%2Fj.biopsych.2014.09.013" class="external text external">10.1016/j.biopsych.2014.09.013</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377121  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377121'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377121" class="external text external">4377121</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25499957  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25499957'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25499957" class="external text external">25499957</a>. <q>The procognitive actions of psychostimulants are only associated with low doses. Surprisingly, despite nearly 80 years of clinical use, the neurobiology of the procognitive actions of psychostimulants has only recently been systematically investigated. Findings from this research unambiguously demonstrate that the cognition-enhancing effects of psychostimulants involve the preferential elevation of catecholamines in the PFC and the subsequent activation of norepinephrine α2 and dopamine D1 receptors.<span>&nbsp;</span>... This differential modulation of PFC-dependent processes across dose appears to be associated with the differential involvement of noradrenergic α2 versus α1 receptors. Collectively, this evidence indicates that at low, clinically relevant doses, psychostimulants are devoid of the behavioral and neurochemical actions that define this class of drugs and instead act largely as cognitive enhancers (improving PFC-dependent function).<span>&nbsp;</span>... In particular, in both animals and humans, lower doses maximally improve performance in tests of working memory and response inhibition, whereas maximal suppression of overt behavior and facilitation of attentional processes occurs at higher doses.</q></cite></span></li><li id="cite_note-Cognitive_and_motivational_effects-36"> <span id="mw-reference-text-cite_note-Cognitive_and_motivational_effects-36" class="mw-reference-text"><cite id="CITEREFIlievaHookFarah2015" class="citation journal cs1">Ilieva IP, Hook CJ, Farah MJ (June 2015). <a href="javascript:if(confirm('https://repository.upenn.edu/neuroethics_pubs/130  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://repository.upenn.edu/neuroethics_pubs/130'" tppabs="https://repository.upenn.edu/neuroethics_pubs/130" class="external text external">"Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis"</a>. <i>Journal of Cognitive Neuroscience</i>. <b>27</b> (6): 1069–1089. doi:<a href="javascript:if(confirm('https://doi.org/10.1162%2Fjocn_a_00776  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1162%2Fjocn_a_00776'" tppabs="https://doi.org/10.1162%2Fjocn_a_00776" class="external text external">10.1162/jocn_a_00776</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25591060  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25591060'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25591060" class="external text external">25591060</a>. <q>Specifically, in a set of experiments limited to high-quality designs, we found significant enhancement of several cognitive abilities.<span>&nbsp;</span>... The results of this meta-analysis<span>&nbsp;</span>... do confirm the reality of cognitive enhancing effects for normal healthy adults in general, while also indicating that these effects are modest in size.</q></cite></span></li><li id="cite_note-Cognition_enhancement_2014_systematic_review-37"> <span id="mw-reference-text-cite_note-Cognition_enhancement_2014_systematic_review-37" class="mw-reference-text"><cite id="CITEREFBagotKaminer2014" class="citation journal cs1">Bagot KS, Kaminer Y (April 2014). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471173  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471173'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471173" class="external text external">"Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review"</a>. <i>Addiction</i>. <b>109</b> (4): 547–557. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fadd.12460  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fadd.12460'" tppabs="https://doi.org/10.1111%2Fadd.12460" class="external text external">10.1111/add.12460</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471173  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471173'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471173" class="external text external">4471173</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24749160  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24749160'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24749160" class="external text external">24749160</a>. <q>Amphetamine has been shown to improve consolidation of information (0.02<span>&nbsp;</span>≥<span>&nbsp;</span>P<span>&nbsp;</span>≤<span>&nbsp;</span>0.05), leading to improved recall.</q></cite></span></li><li id="cite_note-pmid11337538-38"> <span id="mw-reference-text-cite_note-pmid11337538-38" class="mw-reference-text"><cite id="CITEREFDevousTrivediRush2001" class="citation journal cs1">Devous MD, Trivedi MH, Rush AJ (April 2001). "Regional cerebral blood flow response to oral amphetamine challenge in healthy volunteers". <i>Journal of Nuclear Medicine</i>. <b>42</b> (4): 535–542. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11337538  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11337538'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11337538" class="external text external">11337538</a>.</cite></span></li><li id="cite_note-Malenka_NAcc-39"> <span id="mw-reference-text-cite_note-Malenka_NAcc-39" class="mw-reference-text"><cite class="citation book cs1">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 10: Neural and Neuroendocrine Control of the Internal Milieu".  In Sydor A, Brown RY (eds.). <i>Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York, USA: McGraw-Hill Medical. p.<span>&nbsp;</span>266. ISBN<span>&nbsp;</span><bdi>9780071481274</bdi>. <q>Dopamine acts in the nucleus accumbens to attach motivational significance to stimuli associated with reward.</q></cite></span></li><li id="cite_note-Continuum-40"> <span id="mw-reference-text-cite_note-Continuum-40" class="mw-reference-text"><cite id="CITEREFWoodSageShumanAnagnostaras2014" class="citation journal cs1">Wood S, Sage JR, Shuman T, Anagnostaras SG (January 2014). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880463  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880463'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880463" class="external text external">"Psychostimulants and cognition: a continuum of behavioral and cognitive activation"</a>. <i>Pharmacological Reviews</i>. <b>66</b> (1): 193–221. doi:<a href="javascript:if(confirm('https://doi.org/10.1124%2Fpr.112.007054  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1124%2Fpr.112.007054'" tppabs="https://doi.org/10.1124%2Fpr.112.007054" class="external text external">10.1124/pr.112.007054</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880463  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880463'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880463" class="external text external">3880463</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24344115  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24344115'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24344115" class="external text external">24344115</a>.</cite></span></li><li id="cite_note-Test_taking_aid-41"> <span id="mw-reference-text-cite_note-Test_taking_aid-41" class="mw-reference-text"><cite id="CITEREFTwohey_M2006" class="citation web cs1">Twohey M (26 March 2006). <a href="javascript:if(confirm('https://web.archive.org/web/20070815200239/http://www.jsonline.com/story/index.aspx?id=410902  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20070815200239/http://www.jsonline.com/story/index.aspx?id=410902'" tppabs="https://web.archive.org/web/20070815200239/http://www.jsonline.com/story/index.aspx?id=410902" class="external text external">"Pills become an addictive study aid"</a>. <i>JS Online</i>. Archived from <a href="javascript:if(confirm('http://www.jsonline.com/story/index.aspx?id=410902  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.jsonline.com/story/index.aspx?id=410902'" tppabs="http://www.jsonline.com/story/index.aspx?id=410902" class="external text external">the original</a> on 15 August 2007<span class="reference-accessdate">. Retrieved <span class="nowrap">2 December</span> 2007</span>.</cite></span></li><li id="cite_note-pmid16999660-42"> <span id="mw-reference-text-cite_note-pmid16999660-42" class="mw-reference-text"><cite id="CITEREFTeterMcCabeLaGrangeCranford2006" class="citation journal cs1">Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ (October 2006). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1794223  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1794223'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1794223" class="external text external">"Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration"</a>. <i>Pharmacotherapy</i>. <b>26</b> (10): 1501–1510. doi:<a href="javascript:if(confirm('https://doi.org/10.1592%2Fphco.26.10.1501  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1592%2Fphco.26.10.1501'" tppabs="https://doi.org/10.1592%2Fphco.26.10.1501" class="external text external">10.1592/phco.26.10.1501</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1794223  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1794223'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1794223" class="external text external">1794223</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16999660  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16999660'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16999660" class="external text external">16999660</a>.</cite></span></li><li id="cite_note-Diversion_prevalence_1-43"> <span id="mw-reference-text-cite_note-Diversion_prevalence_1-43" class="mw-reference-text"><cite id="CITEREFWeyandtOsterMarracciniGudmundsdottir2014" class="citation journal cs1">Weyandt LL, Oster DR, Marraccini ME, Gudmundsdottir BG, Munro BA, Zavras BM, Kuhar B (September 2014). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164338  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164338'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164338" class="external text external">"Pharmacological interventions for adolescents and adults with ADHD: stimulant and nonstimulant medications and misuse of prescription stimulants"</a>. <i>Psychology Research and Behavior Management</i>. <b>7</b>: 223–249. doi:<a href="javascript:if(confirm('https://doi.org/10.2147%2FPRBM.S47013  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2147%2FPRBM.S47013'" tppabs="https://doi.org/10.2147%2FPRBM.S47013" class="external text external">10.2147/PRBM.S47013</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164338  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164338'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164338" class="external text external">4164338</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25228824  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25228824'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25228824" class="external text external">25228824</a>. <q>misuse of prescription stimulants has become a serious problem on college campuses across the US and has been recently documented in other countries as well.<span>&nbsp;</span>... Indeed, large numbers of students claim to have engaged in the nonmedical use of prescription stimulants, which is reflected in lifetime prevalence rates of prescription stimulant misuse ranging from 5% to nearly 34% of students.</q></cite></span></li><li id="cite_note-Diversion_prevalence_2-44"> <span id="mw-reference-text-cite_note-Diversion_prevalence_2-44" class="mw-reference-text"><cite id="CITEREFClemowWalker2014" class="citation journal cs1">Clemow DB, Walker DJ (September 2014). "The potential for misuse and abuse of medications in ADHD: a review". <i>Postgraduate Medicine</i>. <b>126</b> (5): 64–81. doi:<a href="javascript:if(confirm('https://doi.org/10.3810%2Fpgm.2014.09.2801  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3810%2Fpgm.2014.09.2801'" tppabs="https://doi.org/10.3810%2Fpgm.2014.09.2801" class="external text external">10.3810/pgm.2014.09.2801</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25295651  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25295651'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25295651" class="external text external">25295651</a>. <q>Overall, the data suggest that ADHD medication misuse and diversion are common health care problems for stimulant medications, with the prevalence believed to be approximately 5% to 10% of high school students and 5% to 35% of college students, depending on the study.</q></cite></span></li><li id="cite_note-Ergogenics-45"> <span id="mw-reference-text-cite_note-Ergogenics-45" class="mw-reference-text"><cite id="CITEREFLiddleConnor2013" class="citation journal cs1">Liddle DG, Connor DJ (June 2013). "Nutritional supplements and ergogenic AIDS". <i>Primary Care: Clinics in Office Practice</i>. <b>40</b> (2): 487–505. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.pop.2013.02.009  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.pop.2013.02.009'" tppabs="https://doi.org/10.1016%2Fj.pop.2013.02.009" class="external text external">10.1016/j.pop.2013.02.009</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23668655  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23668655'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23668655" class="external text external">23668655</a>. <q>Amphetamines and caffeine are stimulants that increase alertness, improve focus, decrease reaction time, and delay fatigue, allowing for an increased intensity and duration of training<span>&nbsp;</span>...<br>Physiologic and performance effects<br><span>&nbsp;</span><span>•</span><span> </span>Amphetamines increase dopamine/norepinephrine release and inhibit their reuptake, leading to central nervous system (CNS) stimulation<br><span>&nbsp;</span><span>•</span><span> </span>Amphetamines seem to enhance athletic performance in anaerobic conditions 39 40<br><span>&nbsp;</span><span>•</span><span> </span>Improved reaction time<br><span>&nbsp;</span><span>•</span><span> </span>Increased muscle strength and delayed muscle fatigue<br><span>&nbsp;</span><span>•</span><span> </span>Increased acceleration<br><span>&nbsp;</span><span>•</span><span> </span>Increased alertness and attention to task</q></cite></span></li><li id="cite_note-Westfall-46"> <span id="mw-reference-text-cite_note-Westfall-46" class="mw-reference-text"><cite id="CITEREFWestfallWestfall2010" class="citation book cs1">Westfall DP, Westfall TC (2010). "Miscellaneous Sympathomimetic Agonists".  In Brunton LL, Chabner BA, Knollmann BC (eds.). <i>Goodman &amp; Gilman's Pharmacological Basis of Therapeutics</i> (12th ed.). New York, USA: McGraw-Hill. ISBN<span>&nbsp;</span><bdi>9780071624428</bdi>.</cite></span></li><li id="cite_note-NCAA-47"> <span id="mw-reference-text-cite_note-NCAA-47" class="mw-reference-text"><cite id="CITEREFBracken_NM2012" class="citation web cs1">Bracken NM (January 2012). <a href="javascript:if(confirm('http://www.ncaapublications.com/productdownloads/SAHS09.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ncaapublications.com/productdownloads/SAHS09.pdf'" tppabs="http://www.ncaapublications.com/productdownloads/SAHS09.pdf" class="external text external">"National Study of Substance Use Trends Among NCAA College Student-Athletes"</a> <span class="cs1-format">(PDF)</span>. <i>NCAA Publications</i>. National Collegiate Athletic Association<span class="reference-accessdate">. Retrieved <span class="nowrap">8 October</span> 2013</span>.</cite></span></li><li id="cite_note-WADA_&amp;_AD_regulation-48"> <span id="mw-reference-text-cite_note-WADA_&amp;_AD_regulation-48" class="mw-reference-text"><cite id="CITEREFDocherty_JR2008" class="citation journal cs1">Docherty JR (June 2008). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2439527  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2439527'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2439527" class="external text external">"Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)"</a>. <i>British Journal of Pharmacology</i>. <b>154</b> (3): 606–622. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fbjp.2008.124  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fbjp.2008.124'" tppabs="https://doi.org/10.1038%2Fbjp.2008.124" class="external text external">10.1038/bjp.2008.124</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2439527  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2439527'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2439527" class="external text external">2439527</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18500382  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18500382'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18500382" class="external text external">18500382</a>.</cite></span></li><li id="cite_note-Ergogenics2-49"> <span id="mw-reference-text-cite_note-Ergogenics2-49" class="mw-reference-text"><cite id="CITEREFParr_JW2011" class="citation journal cs1">Parr JW (July 2011). "Attention-deficit hyperactivity disorder and the athlete: new advances and understanding". <i>Clinics in Sports Medicine</i>. <b>30</b> (3): 591–610. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.csm.2011.03.007  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.csm.2011.03.007'" tppabs="https://doi.org/10.1016%2Fj.csm.2011.03.007" class="external text external">10.1016/j.csm.2011.03.007</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21658550  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21658550'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21658550" class="external text external">21658550</a>. <q>In 1980, Chandler and Blair<sup>47</sup> showed significant increases in knee extension strength, acceleration, anaerobic capacity, time to exhaustion during exercise, pre-exercise and maximum heart rates, and time to exhaustion during maximal oxygen consumption (VO2 max) testing after administration of 15 mg of dextroamphetamine versus placebo. Most of the information to answer this question has been obtained in the past decade through studies of fatigue rather than an attempt to systematically investigate the effect of ADHD drugs on exercise.</q></cite></span></li><li id="cite_note-Roelands_2013-50"> <span id="mw-reference-text-cite_note-Roelands_2013-50" class="mw-reference-text"><cite id="CITEREFRoelandsde_KoningFosterHettinga2013" class="citation journal cs1">Roelands B, de Koning J, Foster C, Hettinga F, Meeusen R (May 2013). "Neurophysiological determinants of theoretical concepts and mechanisms involved in pacing". <i>Sports Medicine</i>. <b>43</b> (5): 301–311. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs40279-013-0030-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs40279-013-0030-4'" tppabs="https://doi.org/10.1007%2Fs40279-013-0030-4" class="external text external">10.1007/s40279-013-0030-4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23456493  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23456493'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23456493" class="external text external">23456493</a>. <q>In high-ambient temperatures, dopaminergic manipulations clearly improve performance. The distribution of the power output reveals that after dopamine reuptake inhibition, subjects are able to maintain a higher power output compared with placebo.<span>&nbsp;</span>... Dopaminergic drugs appear to override a safety switch and allow athletes to use a reserve capacity that is 'off-limits' in a normal (placebo) situation.</q></cite></span></li><li id="cite_note-Amph-DA_reaction_time-51"> <span id="mw-reference-text-cite_note-Amph-DA_reaction_time-51" class="mw-reference-text"><cite id="CITEREFParkerLamichhaneCaetanoNarayanan2013" class="citation journal cs1">Parker KL, Lamichhane D, Caetano MS, Narayanan NS (October 2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813949  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813949'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813949" class="external text external">"Executive dysfunction in Parkinson's disease and timing deficits"</a>. <i>Frontiers in Integrative Neuroscience</i>. <b>7</b>: 75. doi:<a href="javascript:if(confirm('https://doi.org/10.3389%2Ffnint.2013.00075  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3389%2Ffnint.2013.00075'" tppabs="https://doi.org/10.3389%2Ffnint.2013.00075" class="external text external">10.3389/fnint.2013.00075</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813949  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813949'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813949" class="external text external">3813949</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24198770  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24198770'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24198770" class="external text external">24198770</a>. <q>Manipulations of dopaminergic signaling profoundly influence interval timing, leading to the hypothesis that dopamine influences internal pacemaker, or "clock," activity. For instance, amphetamine, which increases concentrations of dopamine at the synaptic cleft advances the start of responding during interval timing, whereas antagonists of D2 type dopamine receptors typically slow timing;... Depletion of dopamine in healthy volunteers impairs timing, while amphetamine releases synaptic dopamine and speeds up timing.</q></cite></span></li><li id="cite_note-Central_mechanisms_affecting_exertion-52"> <span id="mw-reference-text-cite_note-Central_mechanisms_affecting_exertion-52" class="mw-reference-text"><cite id="CITEREFRattrayArgusMartinNorthey2015" class="citation journal cs1">Rattray B, Argus C, Martin K, Northey J, Driller M (March 2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362407  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362407'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362407" class="external text external">"Is it time to turn our attention toward central mechanisms for post-exertional recovery strategies and performance?"</a>. <i>Frontiers in Physiology</i>. <b>6</b>: 79. doi:<a href="javascript:if(confirm('https://doi.org/10.3389%2Ffphys.2015.00079  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3389%2Ffphys.2015.00079'" tppabs="https://doi.org/10.3389%2Ffphys.2015.00079" class="external text external">10.3389/fphys.2015.00079</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362407  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362407'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362407" class="external text external">4362407</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25852568  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25852568'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25852568" class="external text external">25852568</a>. <q>Aside from accounting for the reduced performance of mentally fatigued participants, this model rationalizes the reduced RPE and hence improved cycling time trial performance of athletes using a glucose mouthwash (Chambers et al., 2009) and the greater power output during a RPE matched cycling time trial following amphetamine ingestion (Swart, 2009).<span>&nbsp;</span>... Dopamine stimulating drugs are known to enhance aspects of exercise performance (Roelands et al., 2008)</q></cite></span></li><li id="cite_note-Monoamine+drug_effects_on_exercise_-_fatigue_and_heat-53"> <span id="mw-reference-text-cite_note-Monoamine+drug_effects_on_exercise_-_fatigue_and_heat-53" class="mw-reference-text"><cite id="CITEREFRoelandsDe_PauwMeeusen2015" class="citation journal cs1">Roelands B, De Pauw K, Meeusen R (June 2015). "Neurophysiological effects of exercise in the heat". <i>Scandinavian Journal of Medicine &amp; Science in Sports</i>. <b>25</b> (Suppl 1): 65–78. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fsms.12350  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fsms.12350'" tppabs="https://doi.org/10.1111%2Fsms.12350" class="external text external">10.1111/sms.12350</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25943657  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25943657'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25943657" class="external text external">25943657</a>. <q>This indicates that subjects did not feel they were producing more power and consequently more heat. The authors concluded that the "safety switch" or the mechanisms existing in the body to prevent harmful effects are overridden by the drug administration (Roelands et al., 2008b). Taken together, these data indicate strong ergogenic effects of an increased DA concentration in the brain, without any change in the perception of effort.</q></cite></span></li><li id="cite_note-FDA-54"> <span id="mw-reference-text-cite_note-FDA-54" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aff45863-ffe1-4d4f-8acf-c7081512a6c0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aff45863-ffe1-4d4f-8acf-c7081512a6c0'" tppabs="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aff45863-ffe1-4d4f-8acf-c7081512a6c0" class="external text external">"Adderall XR- dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine sulfate and amphetamine aspartate capsule, extended release"</a>. <i>DailyMed</i>. Shire US Inc. 17 July 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">22 December</span> 2019</span>.</cite></span></li><li id="cite_note-International-55"> <span id="mw-reference-text-cite_note-International-55" class="mw-reference-text"><cite id="CITEREFHeedesAilakis" class="citation web cs1">Heedes G, Ailakis J. <a href="javascript:if(confirm('http://www.inchem.org/documents/pims/pharm/pim934.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.inchem.org/documents/pims/pharm/pim934.htm'" tppabs="http://www.inchem.org/documents/pims/pharm/pim934.htm" class="external text external">"Amphetamine (PIM 934)"</a>. <i>INCHEM</i>. International Programme on Chemical Safety<span class="reference-accessdate">. Retrieved <span class="nowrap">24 June</span> 2014</span>.</cite></span></li><li id="cite_note-FDA_Contra_Warnings-56"> <span id="mw-reference-text-cite_note-FDA_Contra_Warnings-56" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf'" tppabs="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf" class="external text external">"Adderall XR Prescribing Information"</a> <span class="cs1-format">(PDF)</span>. <i>United States Food and Drug Administration</i>. Shire US Inc. December 2013. pp.<span>&nbsp;</span>4–6<span class="reference-accessdate">. Retrieved <span class="nowrap">30 December</span> 2013</span>.</cite></span></li><li id="cite_note-57"> <span id="mw-reference-text-cite_note-57" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20101214112356/http://depts.washington.edu/druginfo/Formulary/Pregnancy.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20101214112356/http://depts.washington.edu/druginfo/Formulary/Pregnancy.pdf'" tppabs="https://web.archive.org/web/20101214112356/http://depts.washington.edu/druginfo/Formulary/Pregnancy.pdf" class="external text external">"FDA Pregnancy Categories"</a> <span class="cs1-format">(PDF)</span>. <i>United States Food and Drug Administration</i>. 21 October 2004. Archived from <a href="javascript:if(confirm('http://depts.washington.edu/druginfo/Formulary/Pregnancy.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://depts.washington.edu/druginfo/Formulary/Pregnancy.pdf'" tppabs="http://depts.washington.edu/druginfo/Formulary/Pregnancy.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 14 December 2010<span class="reference-accessdate">. Retrieved <span class="nowrap">31 October</span> 2013</span>.</cite></span></li><li id="cite_note-58"> <span id="mw-reference-text-cite_note-58" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2009-PI-00828-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2009-PI-00828-3'" tppabs="https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2009-PI-00828-3" class="external text external">"Dexamphetamine tablets"</a>. <i>Therapeutic Goods Administration</i><span class="reference-accessdate">. Retrieved <span class="nowrap">12 April</span> 2014</span>.</cite></span></li><li id="cite_note-pmid18295156-59"> <span id="mw-reference-text-cite_note-pmid18295156-59" class="mw-reference-text"><cite id="CITEREFVitiello_B2008" class="citation journal cs1">Vitiello B (April 2008). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408826  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408826'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408826" class="external text external">"Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function"</a>. <i>Child and Adolescent Psychiatric Clinics of North America</i>. <b>17</b> (2): 459–474. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.chc.2007.11.010  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.chc.2007.11.010'" tppabs="https://doi.org/10.1016%2Fj.chc.2007.11.010" class="external text external">10.1016/j.chc.2007.11.010</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408826  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408826'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408826" class="external text external">2408826</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18295156  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18295156'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18295156" class="external text external">18295156</a>.</cite></span></li><li id="cite_note-Stahl's_Essential_Psychopharmacology-60"> <span id="mw-reference-text-cite_note-Stahl's_Essential_Psychopharmacology-60" class="mw-reference-text"><cite class="citation book cs1">Stahl SM (March 2017). <a href="javascript:if(confirm('https://books.google.com/books?id=9hssDwAAQBAJ&pg=PA45  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=9hssDwAAQBAJ&pg=PA45#v=onepage'" tppabs="https://books.google.com/books?id=9hssDwAAQBAJ&pg=PA45#v=onepage" class="external text external">"Amphetamine (D,L)"</a>. <i>Prescriber's Guide: Stahl's Essential Psychopharmacology</i> (6th ed.). Cambridge, United Kingdom: Cambridge University Press. pp.<span>&nbsp;</span>45–51. ISBN<span>&nbsp;</span><bdi>9781108228749</bdi><span class="reference-accessdate">. Retrieved <span class="nowrap">5 August</span> 2017</span>.</cite></span></li><li id="cite_note-Dyanavel-61"> <span id="mw-reference-text-cite_note-Dyanavel-61" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8a7eb93-4192-4826-bbf1-82c06634f553  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8a7eb93-4192-4826-bbf1-82c06634f553'" tppabs="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8a7eb93-4192-4826-bbf1-82c06634f553" class="external text external">"Dyanavel XR- amphetamine suspension, extended release"</a>. <i>DailyMed</i>. Tris Pharma, Inc. 6 February 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">22 December</span> 2019</span>. <q>DYANAVEL XR contains d-amphetamine and l-amphetamine in a ratio of 3.2 to 1<span>&nbsp;</span>... The most common (≥2% in the DYANAVEL XR group and greater than placebo) adverse reactions reported in the Phase 3 controlled study conducted in 108 patients with ADHD (aged 6 to 12 years) were: epistaxis, allergic rhinitis and upper abdominal pain.<span>&nbsp;</span>... <br>DOSAGE FORMS AND STRENGTHS<br>Extended-release oral suspension contains 2.5 mg amphetamine base equivalents per mL.</q></cite></span></li><li id="cite_note-rhinitis-62"> <span id="mw-reference-text-cite_note-rhinitis-62" class="mw-reference-text"><cite id="CITEREFRameyBailenLockey2006" class="citation journal cs1">Ramey JT, Bailen E, Lockey RF (2006). <a href="javascript:if(confirm('http://www.jiaci.org/issues/vol16issue03/1.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.jiaci.org/issues/vol16issue03/1.pdf'" tppabs="http://www.jiaci.org/issues/vol16issue03/1.pdf" class="external text external">"Rhinitis medicamentosa"</a> <span class="cs1-format">(PDF)</span>. <i>Journal of Investigational Allergology &amp; Clinical Immunology</i>. <b>16</b> (3): 148–155. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16784007  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16784007'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16784007" class="external text external">16784007</a><span class="reference-accessdate">. Retrieved <span class="nowrap">29 April</span> 2015</span>. <q>Table 2. Decongestants Causing Rhinitis Medicamentosa<br> – Nasal decongestants:<br><span>&nbsp;</span>– Sympathomimetic:<br><span>&nbsp;</span><span>&nbsp;</span> • Amphetamine</q></cite></span></li><li id="cite_note-FDA_-_cardiovascular_effects_in_young_individuals-64"> <span id="mw-reference-text-cite_note-FDA_-_cardiovascular_effects_in_young_individuals-64" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-medications-used-treat-attention  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-medications-used-treat-attention'" tppabs="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-medications-used-treat-attention" class="external text external">"FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults"</a>. <i>United States Food and Drug Administration</i>. 1 November 2011. <a href="javascript:if(confirm('https://web.archive.org/web/20190825032123/https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-medications-used-treat-attention  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20190825032123/https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-medications-used-treat-attention'" tppabs="https://web.archive.org/web/20190825032123/https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-medications-used-treat-attention" class="external text external">Archived</a> from the original on 25 August 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">24 December</span> 2019</span>.</cite></span></li><li id="cite_note-pmid22043968-65"> <span id="mw-reference-text-cite_note-pmid22043968-65" class="mw-reference-text"><cite id="CITEREFCooperHabelSoxChan2011" class="citation journal cs1">Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA (November 2011). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943074  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943074'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943074" class="external text external">"ADHD drugs and serious cardiovascular events in children and young adults"</a>. <i>New England Journal of Medicine</i>. <b>365</b> (20): 1896–1904. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa1110212  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa1110212'" tppabs="https://doi.org/10.1056%2FNEJMoa1110212" class="external text external">10.1056/NEJMoa1110212</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943074  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943074'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943074" class="external text external">4943074</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22043968  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22043968'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22043968" class="external text external">22043968</a>.</cite></span></li><li id="cite_note-FDA_-_cardiovascular_effects_in_adults-66"> <span id="mw-reference-text-cite_note-FDA_-_cardiovascular_effects_in_adults-66" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-medications-used-treat-attention-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-medications-used-treat-attention-0'" tppabs="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-medications-used-treat-attention-0" class="external text external">"FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults"</a>. <i>United States Food and Drug Administration</i>. 12 December 2011. <a href="javascript:if(confirm('https://web.archive.org/web/20191214114954/https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-medications-used-treat-attention-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191214114954/https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-medications-used-treat-attention-0'" tppabs="https://web.archive.org/web/20191214114954/https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-medications-used-treat-attention-0" class="external text external">Archived</a> from the original on 14 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">24 December</span> 2013</span>.</cite></span></li><li id="cite_note-pmid22161946-67"> <span id="mw-reference-text-cite_note-pmid22161946-67" class="mw-reference-text"><cite id="CITEREFHabelCooperSoxChan2011" class="citation journal cs1">Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV (December 2011). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3350308  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3350308'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3350308" class="external text external">"ADHD medications and risk of serious cardiovascular events in young and middle-aged adults"</a>. <i>JAMA</i>. <b>306</b> (24): 2673–2683. doi:<a href="javascript:if(confirm('https://doi.org/10.1001%2Fjama.2011.1830  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Fjama.2011.1830'" tppabs="https://doi.org/10.1001%2Fjama.2011.1830" class="external text external">10.1001/jama.2011.1830</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3350308  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3350308'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3350308" class="external text external">3350308</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22161946  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22161946'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22161946" class="external text external">22161946</a>.</cite></span></li><li id="cite_note-Libido-70"> <span id="mw-reference-text-cite_note-Libido-70" class="mw-reference-text"><cite id="CITEREFMontgomery_KA2008" class="citation journal cs1">Montgomery KA (June 2008). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695750  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695750'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695750" class="external text external">"Sexual desire disorders"</a>. <i>Psychiatry</i>. <b>5</b> (6): 50–55. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695750  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695750'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695750" class="external text external">2695750</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19727285  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19727285'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19727285" class="external text external">19727285</a>.</cite></span></li><li id="cite_note-Merck_Manual_Amphetamines-71"> <span id="mw-reference-text-cite_note-Merck_Manual_Amphetamines-71" class="mw-reference-text"><cite id="CITEREFO'Connor_PG2012" class="citation web cs1">O'Connor PG (February 2012). <a href="javascript:if(confirm('http://www.merckmanuals.com/professional/special_subjects/drug_use_and_dependence/amphetamines.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.merckmanuals.com/professional/special_subjects/drug_use_and_dependence/amphetamines.html'" tppabs="http://www.merckmanuals.com/professional/special_subjects/drug_use_and_dependence/amphetamines.html" class="external text external">"Amphetamines"</a>. <i>Merck Manual for Health Care Professionals</i>. Merck<span class="reference-accessdate">. Retrieved <span class="nowrap">8 May</span> 2012</span>.</cite></span></li><li id="cite_note-Cochrane-73"> <span id="mw-reference-text-cite_note-Cochrane-73" class="mw-reference-text"><cite id="CITEREFShoptawKaoLing2009" class="citation journal cs1">Shoptaw SJ, Kao U, Ling W (January 2009).  Shoptaw SJ, Ali R (ed.). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004251  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004251'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004251" class="external text external">"Treatment for amphetamine psychosis"</a>. <i>Cochrane Database of Systematic Reviews</i> (1): CD003026. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD003026.pub3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD003026.pub3'" tppabs="https://doi.org/10.1002%2F14651858.CD003026.pub3" class="external text external">10.1002/14651858.CD003026.pub3</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004251  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004251'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004251" class="external text external">7004251</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19160215  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19160215'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19160215" class="external text external">19160215</a>. <q>A minority of individuals who use amphetamines develop full-blown psychosis requiring care at emergency departments or psychiatric hospitals. In such cases, symptoms of amphetamine psychosis commonly include paranoid and persecutory delusions as well as auditory and visual hallucinations in the presence of extreme agitation. More common (about 18%) is for frequent amphetamine users to report psychotic symptoms that are sub-clinical and that do not require high-intensity intervention<span>&nbsp;</span>...<br>About 5–15% of the users who develop an amphetamine psychosis fail to recover completely (Hofmann 1983)<span>&nbsp;</span>...<br>Findings from one trial indicate use of antipsychotic medications effectively resolves symptoms of acute amphetamine psychosis.<br>psychotic symptoms of individuals with amphetamine psychosis may be due exclusively to heavy use of the drug or heavy use of the drug may exacerbate an underlying vulnerability to schizophrenia.</q></cite></span></li><li id="cite_note-Amphetamine-induced_psychosis-74"> <span id="mw-reference-text-cite_note-Amphetamine-induced_psychosis-74" class="mw-reference-text"><cite id="CITEREFBramnessGundersenGuterstamRognli2012" class="citation journal cs1">Bramness JG, Gundersen ØH, Guterstam J, Rognli EB, Konstenius M, Løberg EM, Medhus S, Tanum L, Franck J (December 2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554477  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554477'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554477" class="external text external">"Amphetamine-induced psychosis—a separate diagnostic entity or primary psychosis triggered in the vulnerable?"</a>. <i>BMC Psychiatry</i>. <b>12</b>: 221. doi:<a href="javascript:if(confirm('https://doi.org/10.1186%2F1471-244X-12-221  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1186%2F1471-244X-12-221'" tppabs="https://doi.org/10.1186%2F1471-244X-12-221" class="external text external">10.1186/1471-244X-12-221</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554477  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554477'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554477" class="external text external">3554477</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23216941  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23216941'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23216941" class="external text external">23216941</a>. <q>In these studies, amphetamine was given in consecutively higher doses until psychosis was precipitated, often after 100–300 mg of amphetamine<span>&nbsp;</span>... Secondly, psychosis has been viewed as an adverse event, although rare, in children with ADHD who have been treated with amphetamine</q></cite></span></li><li id="cite_note-Stimulant_Misuse-75"> <span id="mw-reference-text-cite_note-Stimulant_Misuse-75" class="mw-reference-text"><cite id="CITEREFGreydanus_D" class="citation web cs1">Greydanus D. <a href="javascript:if(confirm('https://web.archive.org/web/20131103155156/http://www.acha.org/prof_dev/ADHD_docs/ADHD_PDprogram_Article2.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20131103155156/http://www.acha.org/prof_dev/ADHD_docs/ADHD_PDprogram_Article2.pdf'" tppabs="https://web.archive.org/web/20131103155156/http://www.acha.org/prof_dev/ADHD_docs/ADHD_PDprogram_Article2.pdf" class="external text external">"Stimulant Misuse: Strategies to Manage a Growing Problem"</a> <span class="cs1-format">(PDF)</span>. <i>American College Health Association</i> (Review Article). ACHA Professional Development Program. p.<span>&nbsp;</span>20. Archived from <a href="javascript:if(confirm('http://www.acha.org/prof_dev/ADHD_docs/ADHD_PDprogram_Article2.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.acha.org/prof_dev/ADHD_docs/ADHD_PDprogram_Article2.pdf'" tppabs="http://www.acha.org/prof_dev/ADHD_docs/ADHD_PDprogram_Article2.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 3 November 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">2 November</span> 2013</span>.</cite></span></li><li id="cite_note-Human_CPP-76"> <span id="mw-reference-text-cite_note-Human_CPP-76" class="mw-reference-text"><cite id="CITEREFChildsde_Wit2009" class="citation journal cs1">Childs E, de Wit H (May 2009). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693956  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693956'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693956" class="external text external">"Amphetamine-induced place preference in humans"</a>. <i>Biological Psychiatry</i>. <b>65</b> (10): 900–904. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.biopsych.2008.11.016  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.biopsych.2008.11.016'" tppabs="https://doi.org/10.1016%2Fj.biopsych.2008.11.016" class="external text external">10.1016/j.biopsych.2008.11.016</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693956  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693956'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693956" class="external text external">2693956</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19111278  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19111278'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19111278" class="external text external">19111278</a>. <q>This study demonstrates that humans, like nonhumans, prefer a place associated with amphetamine administration. These findings support the idea that subjective responses to a drug contribute to its ability to establish place conditioning.</q></cite></span></li><li id="cite_note-Addiction_glossary-77"> <span id="mw-reference-text-cite_note-Addiction_glossary-77" class="mw-reference-text"><cite class="citation book cs1">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 15: Reinforcement and Addictive Disorders".  In Sydor A, Brown RY (eds.). <i>Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York: McGraw-Hill Medical. pp.<span>&nbsp;</span>364–375. ISBN<span>&nbsp;</span><bdi>9780071481274</bdi>.</cite></span></li><li id="cite_note-Cellular_basis-78"> <span id="mw-reference-text-cite_note-Cellular_basis-78" class="mw-reference-text"><cite id="CITEREFNestler_EJ2013" class="citation journal cs1">Nestler EJ (December 2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898681  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898681'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898681" class="external text external">"Cellular basis of memory for addiction"</a>. <i>Dialogues in Clinical Neuroscience</i>. <b>15</b> (4): 431–443. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898681  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898681'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898681" class="external text external">3898681</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24459410  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24459410'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24459410" class="external text external">24459410</a>. <q>Despite the importance of numerous psychosocial factors, at its core, drug addiction involves a biological process: the ability of repeated exposure to a drug of abuse to induce changes in a vulnerable brain that drive the compulsive seeking and taking of drugs, and loss of control over drug use, that define a state of addiction.<span>&nbsp;</span>... A large body of literature has demonstrated that such ΔFosB induction in D1-type [nucleus accumbens] neurons increases an animal's sensitivity to drug as well as natural rewards and promotes drug self-administration, presumably through a process of positive reinforcement<span>&nbsp;</span>... Another ΔFosB target is cFos: as ΔFosB accumulates with repeated drug exposure it represses c-Fos and contributes to the molecular switch whereby ΔFosB is selectively induced in the chronic drug-treated state.<sup>41</sup>.<span>&nbsp;</span>... Moreover, there is increasing evidence that, despite a range of genetic risks for addiction across the population, exposure to sufficiently high doses of a drug for long periods of time can transform someone who has relatively lower genetic loading into an addict.</q></cite></span></li><li id="cite_note-Nestler_Labs_Glossary-79"> <span id="mw-reference-text-cite_note-Nestler_Labs_Glossary-79" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://neuroscience.mssm.edu/nestler/glossary.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://neuroscience.mssm.edu/nestler/glossary.html'" tppabs="http://neuroscience.mssm.edu/nestler/glossary.html" class="external text external">"Glossary of Terms"</a>. <i>Mount Sinai School of Medicine</i>. Department of Neuroscience<span class="reference-accessdate">. Retrieved <span class="nowrap">9 February</span> 2015</span>.</cite></span></li><li id="cite_note-Brain_disease-80"> <span id="mw-reference-text-cite_note-Brain_disease-80" class="mw-reference-text"><cite id="CITEREFVolkowKoobMcLellan2016" class="citation journal cs1">Volkow ND, Koob GF, McLellan AT (January 2016). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135257  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135257'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135257" class="external text external">"Neurobiologic Advances from the Brain Disease Model of Addiction"</a>. <i>New England Journal of Medicine</i>. <b>374</b> (4): 363–371. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMra1511480  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMra1511480'" tppabs="https://doi.org/10.1056%2FNEJMra1511480" class="external text external">10.1056/NEJMra1511480</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135257  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135257'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135257" class="external text external">6135257</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26816013  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26816013'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26816013" class="external text external">26816013</a>. <q>Substance-use disorder: A diagnostic term in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) referring to recurrent use of alcohol or other drugs that causes clinically and functionally significant impairment, such as health problems, disability, and failure to meet major responsibilities at work, school, or home. Depending on the level of severity, this disorder is classified as mild, moderate, or severe.<br>Addiction: A term used to indicate the most severe, chronic stage of substance-use disorder, in which there is a substantial loss of self-control, as indicated by compulsive drug taking despite the desire to stop taking the drug. In the DSM-5, the term addiction is synonymous with the classification of severe substance-use disorder.</q></cite></span></li><li id="cite_note-Nestler-Renthal_Figure_2-82"> <span id="mw-reference-text-cite_note-Nestler-Renthal_Figure_2-82" class="mw-reference-text"><cite id="CITEREFRenthal_W,_Nestler_EJ2009" class="citation journal cs1">Renthal W, Nestler EJ (September 2009). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834246  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834246'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834246" class="external text external">"Chromatin regulation in drug addiction and depression"</a>. <i>Dialogues in Clinical Neuroscience</i>. <b>11</b> (3): 257–268. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834246  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834246'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834246" class="external text external">2834246</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19877494  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19877494'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19877494" class="external text external">19877494</a>. <q>[Psychostimulants] increase cAMP levels in striatum, which activates protein kinase A (PKA) and leads to phosphorylation of its targets. This includes the cAMP response element binding protein (CREB), the phosphorylation of which induces its association with the histone acetyltransferase, CREB binding protein (CBP) to acetylate histones and facilitate gene activation. This is known to occur on many genes including fosB and <span class="nowrap">c-fos</span> in response to psychostimulant exposure. ΔFosB is also upregulated by chronic psychostimulant treatments, and is known to activate certain genes (eg, cdk5) and repress others (eg, <span class="nowrap">c-fos</span>) where it recruits HDAC1 as a corepressor.<span>&nbsp;</span>... Chronic exposure to psychostimulants increases glutamatergic [signaling] from the prefrontal cortex to the NAc. Glutamatergic signaling elevates Ca2+ levels in NAc postsynaptic elements where it activates CaMK (calcium/calmodulin protein kinases) signaling, which, in addition to phosphorylating CREB, also phosphorylates HDAC5.</q></cite><br><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834246/figure/DialoguesClinNeurosci-11-257-g002/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834246/figure/DialoguesClinNeurosci-11-257-g002/'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834246/figure/DialoguesClinNeurosci-11-257-g002/" class="external text external">Figure 2: Psychostimulant-induced signaling events</a></span></li><li id="cite_note-Glutamate-dopamine_cotransmission_review-83"> <span id="mw-reference-text-cite_note-Glutamate-dopamine_cotransmission_review-83" class="mw-reference-text"><cite id="CITEREFBroussard2012" class="citation journal cs1">Broussard JI (January 2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250102  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250102'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250102" class="external text external">"Co-transmission of dopamine and glutamate"</a>. <i>The Journal of General Physiology</i>. <b>139</b> (1): 93–96. doi:<a href="javascript:if(confirm('https://doi.org/10.1085%2Fjgp.201110659  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1085%2Fjgp.201110659'" tppabs="https://doi.org/10.1085%2Fjgp.201110659" class="external text external">10.1085/jgp.201110659</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250102  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250102'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250102" class="external text external">3250102</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22200950  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22200950'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22200950" class="external text external">22200950</a>. <q>Coincident and convergent input often induces plasticity on a postsynaptic neuron. The NAc integrates processed information about the environment from basolateral amygdala, hippocampus, and prefrontal cortex (PFC), as well as projections from midbrain dopamine neurons. Previous studies have demonstrated how dopamine modulates this integrative process. For example, high frequency stimulation potentiates hippocampal inputs to the NAc while simultaneously depressing PFC synapses (Goto and Grace, 2005). The converse was also shown to be true; stimulation at PFC potentiates PFC–NAc synapses but depresses hippocampal–NAc synapses. In light of the new functional evidence of midbrain dopamine/glutamate co-transmission (references above), new experiments of NAc function will have to test whether midbrain glutamatergic inputs bias or filter either limbic or cortical inputs to guide goal-directed behavior.</q></cite></span></li><li id="cite_note-Amphetamine_KEGG_ΔFosB-84"> <span id="mw-reference-text-cite_note-Amphetamine_KEGG_ΔFosB-84" class="mw-reference-text"><cite id="CITEREFKanehisa_Laboratories2014" class="citation web cs1">Kanehisa Laboratories (10 October 2014). <a href="javascript:if(confirm('http://www.genome.jp/kegg-bin/show_pathway?hsa05031+2354  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.genome.jp/kegg-bin/show_pathway?hsa05031+2354'" tppabs="http://www.genome.jp/kegg-bin/show_pathway?hsa05031+2354" class="external text external">"Amphetamine – Homo sapiens (human)"</a>. <i>KEGG Pathway</i><span class="reference-accessdate">. Retrieved <span class="nowrap">31 October</span> 2014</span>. <q>Most addictive drugs increase extracellular concentrations of dopamine (DA) in nucleus accumbens (NAc) and medial prefrontal cortex (mPFC), projection areas of mesocorticolimbic DA neurons and key components of the "brain reward circuit". Amphetamine achieves this elevation in extracellular levels of DA by promoting efflux from synaptic terminals.<span>&nbsp;</span>... Chronic exposure to amphetamine induces a unique transcription factor delta FosB, which plays an essential role in long-term adaptive changes in the brain.</q></cite></span></li><li id="cite_note-Meth_cAMP/calcium-dependent_cascade-85"> <span id="mw-reference-text-cite_note-Meth_cAMP/calcium-dependent_cascade-85" class="mw-reference-text"><cite id="CITEREFCadetBrannockJayanthiKrasnova2015" class="citation journal cs1">Cadet JL, Brannock C, Jayanthi S, Krasnova IN (2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359351  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359351'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359351" class="external text external">"Transcriptional and epigenetic substrates of methamphetamine addiction and withdrawal: evidence from a long-access self-administration model in the rat"</a>. <i>Molecular Neurobiology</i>. <b>51</b> (2): 696–717. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs12035-014-8776-8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs12035-014-8776-8'" tppabs="https://doi.org/10.1007%2Fs12035-014-8776-8" class="external text external">10.1007/s12035-014-8776-8</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359351  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359351'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359351" class="external text external">4359351</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24939695  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24939695'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24939695" class="external text external">24939695</a>. <q><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359351/figure/Fig1/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359351/figure/Fig1/'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359351/figure/Fig1/" class="external text external">Figure 1</a></q></cite></span></li><li id="cite_note-Nestler1-86"> <span id="mw-reference-text-cite_note-Nestler1-86" class="mw-reference-text"><cite id="CITEREFRobison_AJ,_Nestler_EJ2011" class="citation journal cs1">Robison AJ, Nestler EJ (November 2011). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277" class="external text external">"Transcriptional and epigenetic mechanisms of addiction"</a>. <i>Nature Reviews Neuroscience</i>. <b>12</b> (11): 623–637. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnrn3111  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnrn3111'" tppabs="https://doi.org/10.1038%2Fnrn3111" class="external text external">10.1038/nrn3111</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277" class="external text external">3272277</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21989194  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21989194'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21989194" class="external text external">21989194</a>. <q>ΔFosB serves as one of the master control proteins governing this structural plasticity.<span>&nbsp;</span>... ΔFosB also represses G9a expression, leading to reduced repressive histone methylation at the cdk5 gene. The net result is gene activation and increased CDK5 expression.<span>&nbsp;</span>... In contrast, ΔFosB binds to the <span class="nowrap">c-fos</span> gene and recruits several co-repressors, including HDAC1 (histone deacetylase 1) and SIRT 1 (sirtuin 1).<span>&nbsp;</span>... The net result is <span class="nowrap">c-fos</span> gene repression.</q></cite><br><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277/figure/F4/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277/figure/F4/'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277/figure/F4/" class="external text external">Figure 4: Epigenetic basis of drug regulation of gene expression</a></span></li><li id="cite_note-Nestler2-87"> <span id="mw-reference-text-cite_note-Nestler2-87" class="mw-reference-text"><cite id="CITEREFNestler_EJ2012" class="citation journal cs1">Nestler EJ (December 2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3569166  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3569166'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3569166" class="external text external">"Transcriptional mechanisms of drug addiction"</a>. <i>Clinical Psychopharmacology and Neuroscience</i>. <b>10</b> (3): 136–143. doi:<a href="javascript:if(confirm('https://doi.org/10.9758%2Fcpn.2012.10.3.136  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.9758%2Fcpn.2012.10.3.136'" tppabs="https://doi.org/10.9758%2Fcpn.2012.10.3.136" class="external text external">10.9758/cpn.2012.10.3.136</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3569166  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3569166'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3569166" class="external text external">3569166</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23430970  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23430970'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23430970" class="external text external">23430970</a>. <q>The 35-37 kD ΔFosB isoforms accumulate with chronic drug exposure due to their extraordinarily long half-lives.<span>&nbsp;</span>... As a result of its stability, the ΔFosB protein persists in neurons for at least several weeks after cessation of drug exposure.<span>&nbsp;</span>... ΔFosB overexpression in nucleus accumbens induces NFκB<span>&nbsp;</span>...  In contrast, the ability of ΔFosB to repress the <span class="nowrap">c-Fos</span> gene occurs in concert with the recruitment of a histone deacetylase and presumably several other repressive proteins such as a repressive histone methyltransferase</q></cite></span></li><li id="cite_note-c-Fos_repression-88"> <span id="mw-reference-text-cite_note-c-Fos_repression-88" class="mw-reference-text"><cite id="CITEREFNestler_EJ2008" class="citation journal cs1">Nestler EJ (October 2008). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607320  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607320'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607320" class="external text external">"Transcriptional mechanisms of addiction: Role of ΔFosB"</a>. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i>. <b>363</b> (1507): 3245–3255. doi:<a href="javascript:if(confirm('https://doi.org/10.1098%2Frstb.2008.0067  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1098%2Frstb.2008.0067'" tppabs="https://doi.org/10.1098%2Frstb.2008.0067" class="external text external">10.1098/rstb.2008.0067</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607320  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607320'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607320" class="external text external">2607320</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18640924  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18640924'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18640924" class="external text external">18640924</a>. <q>Recent evidence has shown that ΔFosB also represses the <span class="nowrap">c-fos</span> gene that helps create the molecular switch—from the induction of several short-lived Fos family proteins after acute drug exposure to the predominant accumulation of ΔFosB after chronic drug exposure</q></cite></span></li><li id="cite_note-NHMH_3e-Addiction_doses-89"> <span id="mw-reference-text-cite_note-NHMH_3e-Addiction_doses-89" class="mw-reference-text"><cite id="CITEREFMalenkaNestlerHymanHoltzman2015" class="citation book cs1">Malenka RC, Nestler EJ, Hyman SE, Holtzman DM (2015). "Chapter 16: Reinforcement and Addictive Disorders". <i>Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (3rd ed.). New York: McGraw-Hill Medical. ISBN<span>&nbsp;</span><bdi>9780071827706</bdi>. <q>Such agents also have important therapeutic uses; cocaine, for example, is used as a local anesthetic (Chapter 2), and amphetamines and methylphenidate are used in low doses to treat attention deficit hyperactivity disorder and in higher doses to treat narcolepsy (Chapter 12). Despite their clinical uses, these drugs are strongly reinforcing, and their long-term use at high doses is linked with potential addiction, especially when they are rapidly administered or when high-potency forms are given.</q></cite></span></li><li id="cite_note-Addiction_risk-90"> <span id="mw-reference-text-cite_note-Addiction_risk-90" class="mw-reference-text"><cite id="CITEREFKollins2008" class="citation journal cs1">Kollins SH (May 2008). "A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders". <i>Current Medical Research and Opinion</i>. <b>24</b> (5): 1345–1357. doi:<a href="javascript:if(confirm('https://doi.org/10.1185%2F030079908X280707  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1185%2F030079908X280707'" tppabs="https://doi.org/10.1185%2F030079908X280707" class="external text external">10.1185/030079908X280707</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18384709  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18384709'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18384709" class="external text external">18384709</a>. <q>When oral formulations of psychostimulants are used at recommended doses and frequencies, they are unlikely to yield effects consistent with abuse potential in patients with ADHD.</q></cite></span></li><li id="cite_note-LDX_abuse-91"> <span id="mw-reference-text-cite_note-LDX_abuse-91" class="mw-reference-text"><cite id="CITEREFCoghillCaballeroSorooshianCivil2014" class="citation journal cs1">Coghill DR, Caballero B, Sorooshian S, Civil R (June 2014). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057639  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057639'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057639" class="external text external">"A systematic review of the safety of lisdexamfetamine dimesylate"</a>. <i>CNS Drugs</i>. <b>28</b> (6): 497–511. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs40263-014-0166-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs40263-014-0166-2'" tppabs="https://doi.org/10.1007%2Fs40263-014-0166-2" class="external text external">10.1007/s40263-014-0166-2</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057639  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057639'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057639" class="external text external">4057639</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24788672  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24788672'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24788672" class="external text external">24788672</a>. <q>The prodrug formulation of LDX may also lead to reduced abuse potential of LDX compared with immediate-release d-AMP.</q></cite></span></li><li id="cite_note-Amphetamine_KEGG_–_ΔFosB-92"> <span id="mw-reference-text-cite_note-Amphetamine_KEGG_–_ΔFosB-92" class="mw-reference-text"><cite class="citation web cs1">Kanehisa Laboratories (10 October 2014). <a href="javascript:if(confirm('http://www.genome.jp/kegg-bin/show_pathway?hsa05031  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.genome.jp/kegg-bin/show_pathway?hsa05031'" tppabs="http://www.genome.jp/kegg-bin/show_pathway?hsa05031" class="external text external">"Amphetamine – Homo sapiens (human)"</a>. <i>KEGG Pathway</i><span class="reference-accessdate">. Retrieved <span class="nowrap">31 October</span> 2014</span>.</cite></span></li><li id="cite_note-Magnesium-93"> <span id="mw-reference-text-cite_note-Magnesium-93" class="mw-reference-text"><cite id="CITEREFNechifor_M2008" class="citation journal cs1">Nechifor M (March 2008). <a href="javascript:if(confirm('https://www.jle.com/10.1684/mrh.2008.0124  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.jle.com/10.1684/mrh.2008.0124'" tppabs="https://www.jle.com/10.1684/mrh.2008.0124" class="external text external">"Magnesium in drug dependences"</a>. <i>Magnesium Research</i>. <b>21</b> (1): 5–15. doi:<a href="javascript:if(confirm('https://doi.org/10.1684%2Fmrh.2008.0124  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1684%2Fmrh.2008.0124'" tppabs="https://doi.org/10.1684%2Fmrh.2008.0124" class="external text external">10.1684/mrh.2008.0124</a> (inactive 3 June 2020). PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18557129  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18557129'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18557129" class="external text external">18557129</a>.</cite></span></li><li id="cite_note-What_the_ΔFosB?-94"> <span id="mw-reference-text-cite_note-What_the_ΔFosB?-94" class="mw-reference-text"><cite id="CITEREFRuffle_JK2014" class="citation journal cs1">Ruffle JK (November 2014). "Molecular neurobiology of addiction: what's all the (Δ)FosB about?". <i>The American Journal of Drug and Alcohol Abuse</i>. <b>40</b> (6): 428–437. doi:<a href="javascript:if(confirm('https://doi.org/10.3109%2F00952990.2014.933840  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3109%2F00952990.2014.933840'" tppabs="https://doi.org/10.3109%2F00952990.2014.933840" class="external text external">10.3109/00952990.2014.933840</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25083822  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25083822'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25083822" class="external text external">25083822</a>. <q>ΔFosB is an essential transcription factor implicated in the molecular and behavioral pathways of addiction following repeated drug exposure.</q></cite></span></li><li id="cite_note-Nestler-95"> <span id="mw-reference-text-cite_note-Nestler-95" class="mw-reference-text"><cite id="CITEREFRobisonNestler2011" class="citation journal cs1">Robison AJ, Nestler EJ (November 2011). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277" class="external text external">"Transcriptional and epigenetic mechanisms of addiction"</a>. <i>Nature Reviews Neuroscience</i>. <b>12</b> (11): 623–637. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnrn3111  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnrn3111'" tppabs="https://doi.org/10.1038%2Fnrn3111" class="external text external">10.1038/nrn3111</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272277" class="external text external">3272277</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21989194  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21989194'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21989194" class="external text external">21989194</a>. <q>ΔFosB has been linked directly to several addiction-related behaviors<span>&nbsp;</span>... Importantly, genetic or viral overexpression of ΔJunD, a dominant negative mutant of JunD which antagonizes ΔFosB- and other AP-1-mediated transcriptional activity, in the NAc or OFC blocks these key effects of drug exposure<sup>14,22–24</sup>. This indicates that ΔFosB is both necessary and sufficient for many of the changes wrought in the brain by chronic drug exposure. ΔFosB is also induced in D1-type NAc MSNs by chronic consumption of several natural rewards, including sucrose, high fat food, sex, wheel running, where it promotes that consumption<sup>14,26–30</sup>. This implicates ΔFosB in the regulation of natural rewards under normal conditions and perhaps during pathological addictive-like states.<span>&nbsp;</span>... ΔFosB serves as one of the master control proteins governing this structural plasticity.</q></cite></span></li><li id="cite_note-Natural_and_drug_addictions-96"> <span id="mw-reference-text-cite_note-Natural_and_drug_addictions-96" class="mw-reference-text"><cite id="CITEREFOlsen_CM2011" class="citation journal cs1">Olsen CM (December 2011). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139704  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139704'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139704" class="external text external">"Natural rewards, neuroplasticity, and non-drug addictions"</a>. <i>Neuropharmacology</i>. <b>61</b> (7): 1109–1122. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.neuropharm.2011.03.010  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.neuropharm.2011.03.010'" tppabs="https://doi.org/10.1016%2Fj.neuropharm.2011.03.010" class="external text external">10.1016/j.neuropharm.2011.03.010</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139704  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139704'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139704" class="external text external">3139704</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21459101  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21459101'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21459101" class="external text external">21459101</a>. <q>Similar to environmental enrichment, studies have found that exercise reduces self-administration and relapse to drugs of abuse (Cosgrove et al., 2002; Zlebnik et al., 2010). There is also some evidence that these preclinical findings translate to human populations, as exercise reduces withdrawal symptoms and relapse in abstinent smokers (Daniel et al., 2006; Prochaska et al., 2008), and one drug recovery program has seen success in participants that train for and compete in a marathon as part of the program (Butler, 2005).<span>&nbsp;</span>... In humans, the role of dopamine signaling in incentive-sensitization processes has recently been highlighted by the observation of a dopamine dysregulation syndrome in some patients taking dopaminergic drugs. This syndrome is characterized by a medication-induced increase in (or compulsive) engagement in non-drug rewards such as gambling, shopping, or sex (Evans et al., 2006; Aiken, 2007; Lader, 2008).</q></cite></span></li><li id="cite_note-Running_vs_addiction-97"> <span id="mw-reference-text-cite_note-Running_vs_addiction-97" class="mw-reference-text"><cite id="CITEREFLynchPetersonSanchezAbel2013" class="citation journal cs1">Lynch WJ, Peterson AB, Sanchez V, Abel J, Smith MA (September 2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788047  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788047'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788047" class="external text external">"Exercise as a novel treatment for drug addiction: a neurobiological and stage-dependent hypothesis"</a>. <i>Neuroscience &amp; Biobehavioral Reviews</i>. <b>37</b> (8): 1622–1644. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.neubiorev.2013.06.011  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.neubiorev.2013.06.011'" tppabs="https://doi.org/10.1016%2Fj.neubiorev.2013.06.011" class="external text external">10.1016/j.neubiorev.2013.06.011</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788047  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788047'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788047" class="external text external">3788047</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23806439  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23806439'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23806439" class="external text external">23806439</a>. <q>These findings suggest that exercise may "magnitude"-dependently prevent the development of an addicted phenotype possibly by blocking/reversing behavioral and neuroadaptive changes that develop during and following extended access to the drug.<span>&nbsp;</span>... Exercise has been proposed as a treatment for drug addiction that may reduce drug craving and risk of relapse. Although few clinical studies have investigated the efficacy of exercise for preventing relapse, the few studies that have been conducted generally report a reduction in drug craving and better treatment outcomes<span>&nbsp;</span>... Taken together, these data suggest that the potential benefits of exercise during relapse, particularly for relapse to psychostimulants, may be mediated via chromatin remodeling and possibly lead to greater treatment outcomes.</q></cite></span></li><li id="cite_note-Exercise,_addiction_prevention,_and_ΔFosB-98"> <span id="mw-reference-text-cite_note-Exercise,_addiction_prevention,_and_ΔFosB-98" class="mw-reference-text"><cite id="CITEREFZhouZhaoZhouLi2015" class="citation journal cs1">Zhou Y, Zhao M, Zhou C, Li R (July 2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712120  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712120'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712120" class="external text external">"Sex differences in drug addiction and response to exercise intervention: From human to animal studies"</a>. <i>Frontiers in Neuroendocrinology</i>. <b>40</b>: 24–41. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.yfrne.2015.07.001  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.yfrne.2015.07.001'" tppabs="https://doi.org/10.1016%2Fj.yfrne.2015.07.001" class="external text external">10.1016/j.yfrne.2015.07.001</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712120  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712120'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712120" class="external text external">4712120</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26182835  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26182835'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26182835" class="external text external">26182835</a>. <q>Collectively, these findings demonstrate that exercise may serve as a substitute or competition for drug abuse by changing ΔFosB or cFos immunoreactivity in the reward system to protect against later or previous drug use.<span>&nbsp;</span>... The postulate that exercise serves as an ideal intervention for drug addiction has been widely recognized and used in human and animal rehabilitation.</q></cite></span></li><li id="cite_note-Exercise_Rev_3-100"> <span id="mw-reference-text-cite_note-Exercise_Rev_3-100" class="mw-reference-text"><cite id="CITEREFLinkeUssher2015" class="citation journal cs1">Linke SE, Ussher M (January 2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831948  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831948'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831948" class="external text external">"Exercise-based treatments for substance use disorders: evidence, theory, and practicality"</a>. <i>The American Journal of Drug and Alcohol Abuse</i>. <b>41</b> (1): 7–15. doi:<a href="javascript:if(confirm('https://doi.org/10.3109%2F00952990.2014.976708  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3109%2F00952990.2014.976708'" tppabs="https://doi.org/10.3109%2F00952990.2014.976708" class="external text external">10.3109/00952990.2014.976708</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831948  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831948'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831948" class="external text external">4831948</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25397661  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25397661'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25397661" class="external text external">25397661</a>. <q>The limited research conducted suggests that exercise may be an effective adjunctive treatment for SUDs. In contrast to the scarce intervention trials to date, a relative abundance of literature on the theoretical and practical reasons supporting the investigation of this topic has been published.<span>&nbsp;</span>... numerous theoretical and practical reasons support exercise-based treatments for SUDs, including psychological, behavioral, neurobiological, nearly universal safety profile, and overall positive health effects.</q></cite></span></li><li id="cite_note-Nestler,_Hyman,_and_Malenka_2-101"> <span id="mw-reference-text-cite_note-Nestler,_Hyman,_and_Malenka_2-101" class="mw-reference-text"><cite id="CITEREFHymanMalenkaNestler2006" class="citation journal cs1">Hyman SE, Malenka RC, Nestler EJ (July 2006). "Neural mechanisms of addiction: the role of reward-related learning and memory". <i>Annual Review of Neuroscience</i>. <b>29</b>: 565–598. doi:<a href="javascript:if(confirm('https://doi.org/10.1146%2Fannurev.neuro.29.051605.113009  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1146%2Fannurev.neuro.29.051605.113009'" tppabs="https://doi.org/10.1146%2Fannurev.neuro.29.051605.113009" class="external text external">10.1146/annurev.neuro.29.051605.113009</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16776597  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16776597'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16776597" class="external text external">16776597</a>.</cite></span></li><li id="cite_note-Addiction_genetics-102"> <span id="mw-reference-text-cite_note-Addiction_genetics-102" class="mw-reference-text"><cite id="CITEREFSteinerVan_Waes2013" class="citation journal cs1">Steiner H, Van Waes V (January 2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525776  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525776'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525776" class="external text external">"Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulants"</a>. <i>Progress in Neurobiology</i>. <b>100</b>: 60–80. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.pneurobio.2012.10.001  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.pneurobio.2012.10.001'" tppabs="https://doi.org/10.1016%2Fj.pneurobio.2012.10.001" class="external text external">10.1016/j.pneurobio.2012.10.001</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525776  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525776'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525776" class="external text external">3525776</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23085425  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23085425'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23085425" class="external text external">23085425</a>.</cite></span></li><li id="cite_note-NHM-Transcription_factor-103"> <span id="mw-reference-text-cite_note-NHM-Transcription_factor-103" class="mw-reference-text"><cite class="citation book cs1">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 4: Signal Transduction in the Brain".  In Sydor A, Brown RY (eds.). <i>Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York, USA: McGraw-Hill Medical. p.<span>&nbsp;</span>94. ISBN<span>&nbsp;</span><bdi>9780071481274</bdi>.</cite></span></li><li id="cite_note-Alcoholism_ΔFosB-106"> <span id="mw-reference-text-cite_note-Alcoholism_ΔFosB-106" class="mw-reference-text"><cite class="citation web cs1">Kanehisa Laboratories (29 October 2014). <a href="javascript:if(confirm('http://www.genome.jp/kegg-bin/show_pathway?hsa05034+2354  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.genome.jp/kegg-bin/show_pathway?hsa05034+2354'" tppabs="http://www.genome.jp/kegg-bin/show_pathway?hsa05034+2354" class="external text external">"Alcoholism – Homo sapiens (human)"</a>. <i>KEGG Pathway</i><span class="reference-accessdate">. Retrieved <span class="nowrap">31 October</span> 2014</span>.</cite></span></li><li id="cite_note-MPH_ΔFosB-107"> <span id="mw-reference-text-cite_note-MPH_ΔFosB-107" class="mw-reference-text"><cite id="CITEREFKimTeylanBaronSands2009" class="citation journal cs1">Kim Y, Teylan MA, Baron M, Sands A, Nairn AC, Greengard P (February 2009). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2650365  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2650365'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2650365" class="external text external">"Methylphenidate-induced dendritic spine formation and DeltaFosB expression in nucleus accumbens"</a>. <i>Proceedings of the National Academy of Sciences</i>. <b>106</b> (8): 2915–2920. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/2009PNAS..106.2915K  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/2009PNAS..106.2915K'" tppabs="https://ui.adsabs.harvard.edu/abs/2009PNAS..106.2915K" class="external text external">2009PNAS..106.2915K</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1073%2Fpnas.0813179106  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1073%2Fpnas.0813179106'" tppabs="https://doi.org/10.1073%2Fpnas.0813179106" class="external text external">10.1073/pnas.0813179106</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2650365  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2650365'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2650365" class="external text external">2650365</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19202072  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19202072'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19202072" class="external text external">19202072</a>.</cite></span></li><li id="cite_note-Nestler_2014_epigenetics-109"> <span id="mw-reference-text-cite_note-Nestler_2014_epigenetics-109" class="mw-reference-text"><cite id="CITEREFNestler2014" class="citation journal cs1">Nestler EJ (January 2014). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766384  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766384'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766384" class="external text external">"Epigenetic mechanisms of drug addiction"</a>. <i>Neuropharmacology</i>. 76 Pt B: 259–268. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.neuropharm.2013.04.004  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.neuropharm.2013.04.004'" tppabs="https://doi.org/10.1016%2Fj.neuropharm.2013.04.004" class="external text external">10.1016/j.neuropharm.2013.04.004</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766384  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766384'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766384" class="external text external">3766384</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23643695  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23643695'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23643695" class="external text external">23643695</a>.</cite></span></li><li id="cite_note-G9a_reverses_ΔFosB_plasticity-110"> <span id="mw-reference-text-cite_note-G9a_reverses_ΔFosB_plasticity-110" class="mw-reference-text"><cite id="CITEREFBilińskiWojtyłaKapka-SkrzypczakChwedorowicz2012" class="citation journal cs1">Biliński P, Wojtyła A, Kapka-Skrzypczak L, Chwedorowicz R, Cyranka M, Studziński T (2012). <a href="javascript:if(confirm('http://www.aaem.pl/Epigenetic-regulation-in-drug-addiction,71809,0,2.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.aaem.pl/Epigenetic-regulation-in-drug-addiction,71809,0,2.html'" tppabs="http://www.aaem.pl/Epigenetic-regulation-in-drug-addiction,71809,0,2.html" class="external text external">"Epigenetic regulation in drug addiction"</a>. <i>Annals of Agricultural and Environmental Medicine</i>. <b>19</b> (3): 491–496. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23020045  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23020045'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23020045" class="external text external">23020045</a>.</cite></span></li><li id="cite_note-HDACi-induced_G9a+H3K9me2_primary_source-111"> <span id="mw-reference-text-cite_note-HDACi-induced_G9a+H3K9me2_primary_source-111" class="mw-reference-text"><cite id="CITEREFKennedyFengRobisonMaze2013" class="citation journal cs1">Kennedy PJ, Feng J, Robison AJ, Maze I, Badimon A, Mouzon E, Chaudhury D, Damez-Werno DM, Haggarty SJ, Han MH, Bassel-Duby R, Olson EN, Nestler EJ (April 2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609040  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609040'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609040" class="external text external">"Class I HDAC inhibition blocks cocaine-induced plasticity by targeted changes in histone methylation"</a>. <i>Nature Neuroscience</i>. <b>16</b> (4): 434–440. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnn.3354  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnn.3354'" tppabs="https://doi.org/10.1038%2Fnn.3354" class="external text external">10.1038/nn.3354</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609040  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609040'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609040" class="external text external">3609040</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23475113  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23475113'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23475113" class="external text external">23475113</a>.</cite></span></li><li id="cite_note-A_feat_of_epigenetic_engineering-112"> <span id="mw-reference-text-cite_note-A_feat_of_epigenetic_engineering-112" class="mw-reference-text"><cite id="CITEREFWhalley2014" class="citation journal cs1">Whalley K (December 2014). "Psychiatric disorders: a feat of epigenetic engineering". <i>Nature Reviews. Neuroscience</i>. <b>15</b> (12): 768–769. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnrn3869  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnrn3869'" tppabs="https://doi.org/10.1038%2Fnrn3869" class="external text external">10.1038/nrn3869</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25409693  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25409693'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25409693" class="external text external">25409693</a>.</cite></span></li><li id="cite_note-ΔFosB_reward-114"> <span id="mw-reference-text-cite_note-ΔFosB_reward-114" class="mw-reference-text"><cite id="CITEREFBlumWernerCarnesCarnes2012" class="citation journal cs1">Blum K, Werner T, Carnes S, Carnes P, Bowirrat A, Giordano J, Oscar-Berman M, Gold M (March 2012). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040958  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040958'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040958" class="external text external">"Sex, drugs, and rock 'n' roll: hypothesizing common mesolimbic activation as a function of reward gene polymorphisms"</a>. <i>Journal of Psychoactive Drugs</i>. <b>44</b> (1): 38–55. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F02791072.2012.662112  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F02791072.2012.662112'" tppabs="https://doi.org/10.1080%2F02791072.2012.662112" class="external text external">10.1080/02791072.2012.662112</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040958  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040958'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040958" class="external text external">4040958</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22641964  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22641964'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22641964" class="external text external">22641964</a>. <q>It has been found that deltaFosB gene in the NAc is critical for reinforcing effects of sexual reward. Pitchers and colleagues (2010) reported that sexual experience was shown to cause DeltaFosB accumulation in several limbic brain regions including the NAc, medial pre-frontal cortex, VTA, caudate, and putamen, but not the medial preoptic nucleus.<span>&nbsp;</span>... these findings support a critical role for DeltaFosB expression in the NAc in the reinforcing effects of sexual behavior and sexual experience-induced facilitation of sexual performance.<span>&nbsp;</span>... both drug addiction and sexual addiction represent pathological forms of neuroplasticity along with the emergence of aberrant behaviors involving a cascade of neurochemical changes mainly in the brain's rewarding circuitry.</q></cite></span></li><li id="cite_note-Amph-Sex_X-sensitization_through_D1_signaling-115"> <span id="mw-reference-text-cite_note-Amph-Sex_X-sensitization_through_D1_signaling-115" class="mw-reference-text"><cite id="CITEREFPitchersVialouNestlerLaviolette2013" class="citation journal cs1">Pitchers KK, Vialou V, Nestler EJ, Laviolette SR, Lehman MN, Coolen LM (February 2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865508  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865508'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865508" class="external text external">"Natural and drug rewards act on common neural plasticity mechanisms with ΔFosB as a key mediator"</a>. <i>The Journal of Neuroscience</i>. <b>33</b> (8): 3434–3442. doi:<a href="javascript:if(confirm('https://doi.org/10.1523%2FJNEUROSCI.4881-12.2013  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1523%2FJNEUROSCI.4881-12.2013'" tppabs="https://doi.org/10.1523%2FJNEUROSCI.4881-12.2013" class="external text external">10.1523/JNEUROSCI.4881-12.2013</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865508  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865508'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3865508" class="external text external">3865508</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23426671  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23426671'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23426671" class="external text external">23426671</a>.</cite></span></li><li id="cite_note-Amph-Sex_X-sensitization_through_NMDA_signaling-116"> <span id="mw-reference-text-cite_note-Amph-Sex_X-sensitization_through_NMDA_signaling-116" class="mw-reference-text"><cite id="CITEREFBeloateWeemsCaseyWebb2016" class="citation journal cs1">Beloate LN, Weems PW, Casey GR, Webb IC, Coolen LM (February 2016). "Nucleus accumbens NMDA receptor activation regulates amphetamine cross-sensitization and deltaFosB expression following sexual experience in male rats". <i>Neuropharmacology</i>. <b>101</b>: 154–164. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.neuropharm.2015.09.023  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.neuropharm.2015.09.023'" tppabs="https://doi.org/10.1016%2Fj.neuropharm.2015.09.023" class="external text external">10.1016/j.neuropharm.2015.09.023</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26391065  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26391065'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26391065" class="external text external">26391065</a>.</cite></span></li><li id="cite_note-NHMH_3e-Physical_dependence_+_psychostimulant_addiction_treatment-117"> <span id="mw-reference-text-cite_note-NHMH_3e-Physical_dependence_+_psychostimulant_addiction_treatment-117" class="mw-reference-text"><cite class="citation book cs1">Malenka RC, Nestler EJ, Hyman SE, Holtzman DM (2015). "Chapter 16: Reinforcement and Addictive Disorders". <i>Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (3rd ed.). New York: McGraw-Hill Medical. ISBN<span>&nbsp;</span><bdi>9780071827706</bdi>. <q>Pharmacologic treatment for psychostimulant addiction is generally unsatisfactory. As previously discussed, cessation of cocaine use and the use of other psychostimulants in dependent individuals does not produce a physical withdrawal syndrome but may produce dysphoria, anhedonia, and an intense desire to reinitiate drug use.</q></cite></span></li><li id="cite_note-SystRev-Meta_analysis_amphetamine_addiction_pharmacotherapy-118"> <span id="mw-reference-text-cite_note-SystRev-Meta_analysis_amphetamine_addiction_pharmacotherapy-118" class="mw-reference-text"><cite id="CITEREFChanFreemanKondoAyers2019" class="citation journal cs1">Chan B, Freeman M, Kondo K, Ayers C, Montgomery J, Paynter R, Kansagara D (December 2019). "Pharmacotherapy for methamphetamine/amphetamine use disorder-a systematic review and meta-analysis". <i>Addiction (Abingdon, England)</i>. <b>114</b> (12): 2122–2136. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fadd.14755  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fadd.14755'" tppabs="https://doi.org/10.1111%2Fadd.14755" class="external text external">10.1111/add.14755</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/31328345  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/31328345'" tppabs="https://pubmed.ncbi.nlm.nih.gov/31328345" class="external text external">31328345</a>.</cite></span></li><li id="cite_note-pmid24716825-119"> <span id="mw-reference-text-cite_note-pmid24716825-119" class="mw-reference-text"><cite id="CITEREFStoopsRush2014" class="citation journal cs1">Stoops WW, Rush CR (May 2014). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017926  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017926'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017926" class="external text external">"Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research"</a>. <i>Expert Review of Clinical Pharmacology</i>. <b>7</b> (3): 363–374. doi:<a href="javascript:if(confirm('https://doi.org/10.1586%2F17512433.2014.909283  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1586%2F17512433.2014.909283'" tppabs="https://doi.org/10.1586%2F17512433.2014.909283" class="external text external">10.1586/17512433.2014.909283</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017926  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017926'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017926" class="external text external">4017926</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24716825  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24716825'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24716825" class="external text external">24716825</a>. <q>Despite concerted efforts to identify a pharmacotherapy for managing stimulant use disorders, no widely effective medications have been approved.</q></cite></span></li><li id="cite_note-Miller+Grandy_2016-120"> <span id="mw-reference-text-cite_note-Miller+Grandy_2016-120" class="mw-reference-text"><cite id="CITEREFGrandyMillerLi2016" class="citation journal cs1">Grandy DK, Miller GM, Li JX (February 2016). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724540  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724540'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724540" class="external text external">"<span class="cs1-kern-left">"</span>TAARgeting Addiction"-The Alamo Bears Witness to Another Revolution: An Overview of the Plenary Symposium of the 2015 Behavior, Biology and Chemistry Conference"</a>. <i>Drug and Alcohol Dependence</i>. <b>159</b>: 9–16. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.drugalcdep.2015.11.014  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.drugalcdep.2015.11.014'" tppabs="https://doi.org/10.1016%2Fj.drugalcdep.2015.11.014" class="external text external">10.1016/j.drugalcdep.2015.11.014</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724540  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724540'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724540" class="external text external">4724540</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26644139  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26644139'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26644139" class="external text external">26644139</a>. <q>When considered together with the rapidly growing literature in the field a compelling case emerges in support of developing TAAR1-selective agonists as medications for preventing relapse to psychostimulant abuse.</q></cite></span></li><li id="cite_note-TAAR1_addiction_2015-121"> <span id="mw-reference-text-cite_note-TAAR1_addiction_2015-121" class="mw-reference-text"><cite id="CITEREFJingLi2015" class="citation journal cs1">Jing L, Li JX (August 2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532615  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532615'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532615" class="external text external">"Trace amine-associated receptor 1: A promising target for the treatment of psychostimulant addiction"</a>. <i>European Journal of Pharmacology</i>. <b>761</b>: 345–352. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ejphar.2015.06.019  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ejphar.2015.06.019'" tppabs="https://doi.org/10.1016%2Fj.ejphar.2015.06.019" class="external text external">10.1016/j.ejphar.2015.06.019</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532615  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532615'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532615" class="external text external">4532615</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26092759  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26092759'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26092759" class="external text external">26092759</a>. <q>Existing data provided robust preclinical evidence supporting the development of TAAR1 agonists as potential treatment for psychostimulant abuse and addiction.</q></cite></span></li><li id="cite_note-NHM-NMDA-122"> <span id="mw-reference-text-cite_note-NHM-NMDA-122" class="mw-reference-text"><cite class="citation book cs1">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 5: Excitatory and Inhibitory Amino Acids".  In Sydor A, Brown RY (eds.). <i>Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York, USA: McGraw-Hill Medical. pp.<span>&nbsp;</span>124–125. ISBN<span>&nbsp;</span><bdi>9780071481274</bdi>.</cite></span></li><li id="cite_note-Psychosocial_interventions_network_meta-analysis-125"> <span id="mw-reference-text-cite_note-Psychosocial_interventions_network_meta-analysis-125" class="mw-reference-text"><cite id="CITEREFDe_CrescenzoCiabattiniD'AlòDe_Giorgi2018" class="citation journal cs1">De Crescenzo F, Ciabattini M, D'Alò GL, De Giorgi R, Del Giovane C, Cassar C, Janiri L, Clark N, Ostacher MJ, Cipriani A (December 2018). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306153  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306153'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306153" class="external text external">"Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: A systematic review and network meta-analysis"</a>. <i>PLOS Medicine</i>. <b>15</b> (12): e1002715. doi:<a href="javascript:if(confirm('https://doi.org/10.1371%2Fjournal.pmed.1002715  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1371%2Fjournal.pmed.1002715'" tppabs="https://doi.org/10.1371%2Fjournal.pmed.1002715" class="external text external">10.1371/journal.pmed.1002715</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306153  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306153'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306153" class="external text external">6306153</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/30586362  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/30586362'" tppabs="https://pubmed.ncbi.nlm.nih.gov/30586362" class="external text external">30586362</a>.</cite></span></li><li id="cite_note-Addiction_review_2016-126"> <span id="mw-reference-text-cite_note-Addiction_review_2016-126" class="mw-reference-text"><cite id="CITEREFCarrollSmethells2016" class="citation journal cs1">Carroll ME, Smethells JR (February 2016). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745113  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745113'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745113" class="external text external">"Sex Differences in Behavioral Dyscontrol: Role in Drug Addiction and Novel Treatments"</a>. <i>Frontiers in Psychiatry</i>. <b>6</b>: 175. doi:<a href="javascript:if(confirm('https://doi.org/10.3389%2Ffpsyt.2015.00175  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3389%2Ffpsyt.2015.00175'" tppabs="https://doi.org/10.3389%2Ffpsyt.2015.00175" class="external text external">10.3389/fpsyt.2015.00175</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745113  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745113'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745113" class="external text external">4745113</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26903885  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26903885'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26903885" class="external text external">26903885</a>. <q>Physical Exercise<br>There is accelerating evidence that physical exercise is a useful treatment for preventing and reducing drug addiction<span>&nbsp;</span>... In some individuals, exercise has its own rewarding effects, and a behavioral economic interaction may occur, such that physical and social rewards of exercise can substitute for the rewarding effects of drug abuse.<span>&nbsp;</span>... The value of this form of treatment for drug addiction in laboratory animals and humans is that exercise, if it can substitute for the rewarding effects of drugs, could be self-maintained over an extended period of time. Work to date in [laboratory animals and humans] regarding exercise as a treatment for drug addiction supports this hypothesis.<span>&nbsp;</span>... Animal and human research on physical exercise as a treatment for stimulant addiction indicates that this is one of the most promising treatments on the horizon.</q></cite></span></li><li id="cite_note-Cochrane_2013_treatments-127"> <span id="mw-reference-text-cite_note-Cochrane_2013_treatments-127" class="mw-reference-text"><cite id="CITEREFPerez-ManaCastellsTorrensCapella2013" class="citation journal cs1">Perez-Mana C, Castells X, Torrens M, Capella D, Farre M (September 2013). "Efficacy of psychostimulant drugs for amphetamine abuse or dependence". <i>Cochrane Database of Systematic Reviews</i>. <b>9</b> (9): CD009695. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD009695.pub2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD009695.pub2'" tppabs="https://doi.org/10.1002%2F14651858.CD009695.pub2" class="external text external">10.1002/14651858.CD009695.pub2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23996457  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23996457'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23996457" class="external text external">23996457</a>.</cite></span></li><li id="cite_note-128"> <span id="mw-reference-text-cite_note-128" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20070217053619/http://www.merck.com/mmhe/sec07/ch108/ch108g.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20070217053619/http://www.merck.com/mmhe/sec07/ch108/ch108g.html'" tppabs="https://web.archive.org/web/20070217053619/http://www.merck.com/mmhe/sec07/ch108/ch108g.html" class="external text external">"Amphetamines: Drug Use and Abuse"</a>. <i>Merck Manual Home Edition</i>. Merck. February 2003. Archived from <a href="javascript:if(confirm('http://www.merckmanuals.com/home/special_subjects/drug_use_and_abuse/amphetamines.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.merckmanuals.com/home/special_subjects/drug_use_and_abuse/amphetamines.html'" tppabs="http://www.merckmanuals.com/home/special_subjects/drug_use_and_abuse/amphetamines.html" class="external text external">the original</a> on 17 February 2007<span class="reference-accessdate">. Retrieved <span class="nowrap">28 February</span> 2007</span>.</cite></span></li><li id="cite_note-Cochrane_Withdrawal-129"> <span id="mw-reference-text-cite_note-Cochrane_Withdrawal-129" class="mw-reference-text"><cite id="CITEREFShoptawKaoHeinzerlingLing2009" class="citation journal cs1">Shoptaw SJ, Kao U, Heinzerling K, Ling W (April 2009).  Shoptaw SJ (ed.). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138250  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138250'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138250" class="external text external">"Treatment for amphetamine withdrawal"</a>. <i>Cochrane Database of Systematic Reviews</i> (2): CD003021. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD003021.pub2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD003021.pub2'" tppabs="https://doi.org/10.1002%2F14651858.CD003021.pub2" class="external text external">10.1002/14651858.CD003021.pub2</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138250  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138250'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138250" class="external text external">7138250</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19370579  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19370579'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19370579" class="external text external">19370579</a>. <q>The prevalence of this withdrawal syndrome is extremely common (Cantwell 1998; Gossop 1982) with 87.6% of 647 individuals with amphetamine dependence reporting six or more signs of amphetamine withdrawal listed in the DSM when the drug is not available (Schuckit 1999)<span>&nbsp;</span>... The severity of withdrawal symptoms is greater in amphetamine dependent individuals who are older and who have more extensive amphetamine use disorders (McGregor 2005). Withdrawal symptoms typically present within 24<span>&nbsp;</span>hours of the last use of amphetamine, with a withdrawal syndrome involving two general phases that can last 3 weeks or more. The first phase of this syndrome is the initial "crash" that resolves within about a week (Gossop 1982;McGregor 2005)<span>&nbsp;</span>...</q></cite></span></li><li id="cite_note-Amphetamine_toxidrome-130"> <span id="mw-reference-text-cite_note-Amphetamine_toxidrome-130" class="mw-reference-text"><cite id="CITEREFSpillerHaysAleguas2013" class="citation journal cs1">Spiller HA, Hays HL, Aleguas A (June 2013). "Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management". <i>CNS Drugs</i>. <b>27</b> (7): 531–543. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs40263-013-0084-8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs40263-013-0084-8'" tppabs="https://doi.org/10.1007%2Fs40263-013-0084-8" class="external text external">10.1007/s40263-013-0084-8</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23757186  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23757186'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23757186" class="external text external">23757186</a>. <q>Amphetamine, dextroamphetamine, and methylphenidate act as substrates for the cellular monoamine transporter, especially the dopamine transporter (DAT) and less so the norepinephrine (NET) and serotonin transporter. The mechanism of toxicity is primarily related to excessive extracellular dopamine, norepinephrine, and serotonin.</q></cite></span></li><li id="cite_note-GDB2013-132"> <span id="mw-reference-text-cite_note-GDB2013-132" class="mw-reference-text"><cite id="CITEREFCollaborators2015" class="citation journal cs1">Collaborators (2015). <a href="javascript:if(confirm('http://www.thelancet.com/cms/attachment/2023546115/2043770889/mmc1.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.thelancet.com/cms/attachment/2023546115/2043770889/mmc1.pdf'" tppabs="http://www.thelancet.com/cms/attachment/2023546115/2043770889/mmc1.pdf" class="external text external">"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013"</a> <span class="cs1-format">(PDF)</span>. <i>The Lancet</i>. <b>385</b> (9963): 117–171. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0140-6736%2814%2961682-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0140-6736%2814%2961682-2'" tppabs="https://doi.org/10.1016%2FS0140-6736%2814%2961682-2" class="external text external">10.1016/S0140-6736(14)61682-2</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340604  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340604'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340604" class="external text external">4340604</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25530442  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25530442'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25530442" class="external text external">25530442</a><span class="reference-accessdate">. Retrieved <span class="nowrap">3 March</span> 2015</span>. <q>Amphetamine use disorders<span>&nbsp;</span>... 3,788<span>&nbsp;</span>(3,425–4,145)</q></cite></span></li><li id="cite_note-Acute_amph_toxicity-133"> <span id="mw-reference-text-cite_note-Acute_amph_toxicity-133" class="mw-reference-text"><cite id="CITEREFGreeneKerrBraitberg2008" class="citation journal cs1">Greene SL, Kerr F, Braitberg G (October 2008). "Review article: amphetamines and related drugs of abuse". <i>Emergency Medicine Australasia</i>. <b>20</b> (5): 391–402. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1742-6723.2008.01114.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1742-6723.2008.01114.x'" tppabs="https://doi.org/10.1111%2Fj.1742-6723.2008.01114.x" class="external text external">10.1111/j.1742-6723.2008.01114.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18973636  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18973636'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18973636" class="external text external">18973636</a>.</cite></span></li><li id="cite_note-Albertson_2011-134"> <span id="mw-reference-text-cite_note-Albertson_2011-134" class="mw-reference-text"><cite id="CITEREFAlbertson_TE2011" class="citation book cs1">Albertson TE (2011). "Amphetamines".  In Olson KR, Anderson IB, Benowitz NL, Blanc PD, Kearney TE, Kim-Katz SY, Wu AH (eds.). <i>Poisoning &amp; Drug Overdose</i> (6th ed.). New York: McGraw-Hill Medical. pp.<span>&nbsp;</span>77–79. ISBN<span>&nbsp;</span><bdi>9780071668330</bdi>.</cite></span></li><li id="cite_note-Humans&amp;Animals-136"> <span id="mw-reference-text-cite_note-Humans&amp;Animals-136" class="mw-reference-text"><cite id="CITEREFAdvokat_C2007" class="citation journal cs1">Advokat C (July 2007). "Update on amphetamine neurotoxicity and its relevance to the treatment of ADHD". <i>Journal of Attention Disorders</i>. <b>11</b> (1): 8–16. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F1087054706295605  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F1087054706295605'" tppabs="https://doi.org/10.1177%2F1087054706295605" class="external text external">10.1177/1087054706295605</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17606768  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17606768'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17606768" class="external text external">17606768</a>.</cite></span></li><li id="cite_note-Amph-induced_hyperthermia_and_neurotoxicity_review-137"> <span id="mw-reference-text-cite_note-Amph-induced_hyperthermia_and_neurotoxicity_review-137" class="mw-reference-text"><cite id="CITEREFBowyerHanig2014" class="citation journal cs1">Bowyer JF, Hanig JP (November 2014). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008711  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008711'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008711" class="external text external">"Amphetamine- and methamphetamine-induced hyperthermia: Implications of the effects produced in brain vasculature and peripheral organs to forebrain neurotoxicity"</a>. <i>Temperature</i>. <b>1</b> (3): 172–182. doi:<a href="javascript:if(confirm('https://doi.org/10.4161%2F23328940.2014.982049  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4161%2F23328940.2014.982049'" tppabs="https://doi.org/10.4161%2F23328940.2014.982049" class="external text external">10.4161/23328940.2014.982049</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008711  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008711'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008711" class="external text external">5008711</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27626044  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27626044'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27626044" class="external text external">27626044</a>. <q>Hyperthermia alone does not produce amphetamine-like neurotoxicity but AMPH and METH exposures that do not produce hyperthermia (≥40<span>&nbsp;</span>°C) are minimally neurotoxic. Hyperthermia likely enhances AMPH and METH neurotoxicity directly through disruption of protein function, ion channels and enhanced ROS production.<span>&nbsp;</span>... The hyperthermia and the hypertension produced by high doses amphetamines are a primary cause of transient breakdowns in the blood-brain barrier (BBB) resulting in concomitant regional neurodegeneration and neuroinflammation in laboratory animals.<span>&nbsp;</span>... In animal models that evaluate the neurotoxicity of AMPH and METH, it is quite clear that hyperthermia is one of the essential components necessary for the production of histological signs of dopamine terminal damage and neurodegeneration in cortex, striatum, thalamus and hippocampus.</q></cite></span></li><li id="cite_note-138"> <span id="mw-reference-text-cite_note-138" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20171002194327/https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/cgi-bin/sis/search2/f?.%2Ftemp%2F~mdjW95%3A1%3AFULL  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20171002194327/https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/cgi-bin/sis/search2/f?.%2Ftemp%2F~mdjW95%3A1%3AFULL'" tppabs="https://web.archive.org/web/20171002194327/https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/cgi-bin/sis/search2/f?.%2Ftemp%2F~mdjW95%3A1%3AFULL" class="external text external">"Amphetamine"</a>. <i>United States National Library of Medicine<span>&nbsp;</span>– Toxicology Data Network</i>. Hazardous Substances Data Bank. Archived from <a href="javascript:if(confirm('http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+@rel+300-62-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+@rel+300-62-9'" tppabs="http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+@rel+300-62-9" class="external text external">the original</a> on 2 October 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">2 October</span> 2017</span>. <q>Direct toxic damage to vessels seems unlikely because of the dilution that occurs before the drug reaches the cerebral circulation.</q></cite></span></li><li id="cite_note-Malenka_2009_02-139"> <span id="mw-reference-text-cite_note-Malenka_2009_02-139" class="mw-reference-text"><cite class="citation book cs1">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 15: Reinforcement and addictive disorders".  In Sydor A, Brown RY (eds.). <i>Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York, USA: McGraw-Hill Medical. p.<span>&nbsp;</span>370. ISBN<span>&nbsp;</span><bdi>9780071481274</bdi>. <q>Unlike cocaine and amphetamine, methamphetamine is directly toxic to midbrain dopamine neurons.</q></cite></span></li><li id="cite_note-Autoxidation1-140"> <span id="mw-reference-text-cite_note-Autoxidation1-140" class="mw-reference-text"><cite id="CITEREFSulzerZecca2000" class="citation journal cs1">Sulzer D, Zecca L (February 2000). "Intraneuronal dopamine-quinone synthesis: a review". <i>Neurotoxicity Research</i>. <b>1</b> (3): 181–195. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2FBF03033289  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2FBF03033289'" tppabs="https://doi.org/10.1007%2FBF03033289" class="external text external">10.1007/BF03033289</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12835101  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12835101'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12835101" class="external text external">12835101</a>.</cite></span></li><li id="cite_note-Autoxidation2-141"> <span id="mw-reference-text-cite_note-Autoxidation2-141" class="mw-reference-text"><cite id="CITEREFMiyazakiAsanuma2008" class="citation journal cs1">Miyazaki I, Asanuma M (June 2008). <a href="javascript:if(confirm('http://ousar.lib.okayama-u.ac.jp/files/public/3/30980/20160528022138672578/fulltext.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://ousar.lib.okayama-u.ac.jp/files/public/3/30980/20160528022138672578/fulltext.pdf'" tppabs="http://ousar.lib.okayama-u.ac.jp/files/public/3/30980/20160528022138672578/fulltext.pdf" class="external text external">"Dopaminergic neuron-specific oxidative stress caused by dopamine itself"</a> <span class="cs1-format">(PDF)</span>. <i>Acta Medica Okayama</i>. <b>62</b> (3): 141–150. doi:<a href="javascript:if(confirm('https://doi.org/10.18926%2FAMO%2F30942  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.18926%2FAMO%2F30942'" tppabs="https://doi.org/10.18926%2FAMO%2F30942" class="external text external">10.18926/AMO/30942</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18596830  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18596830'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18596830" class="external text external">18596830</a>.</cite></span></li><li id="cite_note-Hofmann-143"> <span id="mw-reference-text-cite_note-Hofmann-143" class="mw-reference-text"><cite id="CITEREFHofmann_FG1983" class="citation book cs1">Hofmann FG (1983). <a href="javascript:if(confirm('https://archive.org/details/handbookondrugal0002hofm/page/329  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archive.org/details/handbookondrugal0002hofm/page/329'" tppabs="https://archive.org/details/handbookondrugal0002hofm/page/329" class="external text external"><i>A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects</i></a> (2nd ed.). New York, USA: Oxford University Press. p.<span>&nbsp;</span><a href="javascript:if(confirm('https://archive.org/details/handbookondrugal0002hofm/page/329  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://archive.org/details/handbookondrugal0002hofm/page/329'" tppabs="https://archive.org/details/handbookondrugal0002hofm/page/329" class="external text external">329</a>. ISBN<span>&nbsp;</span><bdi>9780195030570</bdi>.</cite></span></li><li id="cite_note-FDA_Interactions-144"> <span id="mw-reference-text-cite_note-FDA_Interactions-144" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf'" tppabs="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf" class="external text external">"Adderall XR Prescribing Information"</a> <span class="cs1-format">(PDF)</span>. <i>United States Food and Drug Administration</i>. Shire US Inc. December 2013. pp.<span>&nbsp;</span>8–10<span class="reference-accessdate">. Retrieved <span class="nowrap">30 December</span> 2013</span>.</cite></span></li><li id="cite_note-Miller-145"> <span id="mw-reference-text-cite_note-Miller-145" class="mw-reference-text"><cite id="CITEREFMiller2011" class="citation journal cs1">Miller GM (January 2011). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005101  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005101'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005101" class="external text external">"The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity"</a>. <i>J. Neurochem</i>. <b>116</b> (2): 164–176. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1471-4159.2010.07109.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1471-4159.2010.07109.x'" tppabs="https://doi.org/10.1111%2Fj.1471-4159.2010.07109.x" class="external text external">10.1111/j.1471-4159.2010.07109.x</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005101  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005101'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005101" class="external text external">3005101</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21073468  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21073468'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21073468" class="external text external">21073468</a>.</cite></span></li><li id="cite_note-E_Weihe-146"> <span id="mw-reference-text-cite_note-E_Weihe-146" class="mw-reference-text"><cite id="CITEREFEidenWeihe2011" class="citation journal cs1">Eiden LE, Weihe E (January 2011). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183197  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183197'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183197" class="external text external">"VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse"</a>. <i>Ann. N. Y. Acad. Sci</i>. <b>1216</b>: 86–98. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/2011NYASA1216...86E  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/2011NYASA1216...86E'" tppabs="https://ui.adsabs.harvard.edu/abs/2011NYASA1216...86E" class="external text external">2011NYASA1216...86E</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1749-6632.2010.05906.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1749-6632.2010.05906.x'" tppabs="https://doi.org/10.1111%2Fj.1749-6632.2010.05906.x" class="external text external">10.1111/j.1749-6632.2010.05906.x</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183197  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183197'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183197" class="external text external">4183197</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21272013  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21272013'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21272013" class="external text external">21272013</a>. <q>VMAT2 is the CNS vesicular transporter for not only the biogenic amines DA, NE, EPI, 5-HT, and HIS, but likely also for the trace amines TYR, PEA, and thyronamine (THYR)<span>&nbsp;</span>... [Trace aminergic] neurons in mammalian CNS would be identifiable as neurons expressing VMAT2 for storage, and the biosynthetic enzyme aromatic amino acid decarboxylase (AADC).</q></cite></span></li><li id="cite_note-Amphetamine_VMAT2_pH_gradient-147"> <span id="mw-reference-text-cite_note-Amphetamine_VMAT2_pH_gradient-147" class="mw-reference-text"><cite id="CITEREFSulzerCraggRice2016" class="citation journal cs1">Sulzer D, Cragg SJ, Rice ME (August 2016). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850498  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850498'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850498" class="external text external">"Striatal dopamine neurotransmission: regulation of release and uptake"</a>. <i>Basal Ganglia</i>. <b>6</b> (3): 123–148. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.baga.2016.02.001  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.baga.2016.02.001'" tppabs="https://doi.org/10.1016%2Fj.baga.2016.02.001" class="external text external">10.1016/j.baga.2016.02.001</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850498  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850498'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850498" class="external text external">4850498</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27141430  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27141430'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27141430" class="external text external">27141430</a>. <q>Despite the challenges in determining synaptic vesicle pH, the proton gradient across the vesicle membrane is of fundamental importance for its function. Exposure of isolated catecholamine vesicles to protonophores collapses the pH gradient and rapidly redistributes transmitter from inside to outside the vesicle.<span>&nbsp;</span>... Amphetamine and its derivatives like methamphetamine are weak base compounds that are the only widely used class of drugs known to elicit transmitter release by a non-exocytic mechanism. As substrates for both DAT and VMAT, amphetamines can be taken up to the cytosol and then sequestered in vesicles, where they act to collapse the vesicular pH gradient.</q></cite></span></li><li id="cite_note-GIRK-148"> <span id="mw-reference-text-cite_note-GIRK-148" class="mw-reference-text"><cite id="CITEREFLedonneBerrettaDavoliRizzo2011" class="citation journal cs1">Ledonne A, Berretta N, Davoli A, Rizzo GR, Bernardi G, Mercuri NB (July 2011). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131148  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131148'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131148" class="external text external">"Electrophysiological effects of trace amines on mesencephalic dopaminergic neurons"</a>. <i>Front. Syst. Neurosci</i>. <b>5</b>: 56. doi:<a href="javascript:if(confirm('https://doi.org/10.3389%2Ffnsys.2011.00056  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.3389%2Ffnsys.2011.00056'" tppabs="https://doi.org/10.3389%2Ffnsys.2011.00056" class="external text external">10.3389/fnsys.2011.00056</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131148  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131148'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131148" class="external text external">3131148</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21772817  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21772817'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21772817" class="external text external">21772817</a>. <q>Three important new aspects of TAs action have recently emerged: (a) inhibition of firing due to increased release of dopamine; (b) reduction of D2 and GABAB receptor-mediated inhibitory responses (excitatory effects due to disinhibition); and (c) a direct TA1 receptor-mediated activation of GIRK channels which produce cell membrane hyperpolarization.</q></cite></span></li><li id="cite_note-Genatlas_TAAR1-149"> <span id="mw-reference-text-cite_note-Genatlas_TAAR1-149" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://genatlas.medecine.univ-paris5.fr/fiche.php?symbol=TAAR1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://genatlas.medecine.univ-paris5.fr/fiche.php?symbol=TAAR1'" tppabs="http://genatlas.medecine.univ-paris5.fr/fiche.php?symbol=TAAR1" class="external text external">"TAAR1"</a>. <i>GenAtlas</i>. University of Paris. 28 January 2012<span class="reference-accessdate">. Retrieved <span class="nowrap">29 May</span> 2014</span>. <q><span>&nbsp;</span><span>•</span><span> </span> tonically activates inwardly rectifying K(+) channels, which reduces the basal firing frequency of dopamine (DA) neurons of the ventral tegmental area (VTA)</q></cite></span></li><li id="cite_note-EAAT3-150"> <span id="mw-reference-text-cite_note-EAAT3-150" class="mw-reference-text"><cite id="CITEREFUnderhillWheelerLiWatts2014" class="citation journal cs1">Underhill SM, Wheeler DS, Li M, Watts SD, Ingram SL, Amara SG (July 2014). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159050  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159050'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159050" class="external text external">"Amphetamine modulates excitatory neurotransmission through endocytosis of the glutamate transporter EAAT3 in dopamine neurons"</a>. <i>Neuron</i>. <b>83</b> (2): 404–416. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.neuron.2014.05.043  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.neuron.2014.05.043'" tppabs="https://doi.org/10.1016%2Fj.neuron.2014.05.043" class="external text external">10.1016/j.neuron.2014.05.043</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159050  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159050'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159050" class="external text external">4159050</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25033183  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25033183'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25033183" class="external text external">25033183</a>. <q>AMPH also increases intracellular calcium (Gnegy et al., 2004) that is associated with calmodulin/CamKII activation (Wei et al., 2007) and modulation and trafficking of the DAT (Fog et al., 2006; Sakrikar et al., 2012).<span>&nbsp;</span>... For example, AMPH increases extracellular glutamate in various brain regions including the striatum, VTA and NAc (Del Arco et al., 1999; Kim et al., 1981; Mora and Porras, 1993; Xue et al., 1996), but it has not been established whether this change can be explained by increased synaptic release or by reduced clearance of glutamate.<span>&nbsp;</span>... DHK-sensitive, EAAT2 uptake was not altered by AMPH (Figure 1A). The remaining glutamate transport in these midbrain cultures is likely mediated by EAAT3 and this component was significantly decreased by AMPH</q></cite></span></li><li id="cite_note-DAT_regulation_review-151"> <span id="mw-reference-text-cite_note-DAT_regulation_review-151" class="mw-reference-text"><cite id="CITEREFVaughanFoster2013" class="citation journal cs1">Vaughan RA, Foster JD (September 2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831354  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831354'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831354" class="external text external">"Mechanisms of dopamine transporter regulation in normal and disease states"</a>. <i>Trends Pharmacol. Sci</i>. <b>34</b> (9): 489–496. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.tips.2013.07.005  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.tips.2013.07.005'" tppabs="https://doi.org/10.1016%2Fj.tips.2013.07.005" class="external text external">10.1016/j.tips.2013.07.005</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831354  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831354'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831354" class="external text external">3831354</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23968642  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23968642'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23968642" class="external text external">23968642</a>. <q>AMPH and METH also stimulate DA efflux, which is thought to be a crucial element in their addictive properties [80], although the mechanisms do not appear to be identical for each drug [81]. These processes are PKCβ– and CaMK–dependent [72, 82], and PKCβ knock-out mice display decreased AMPH-induced efflux that correlates with reduced AMPH-induced locomotion [72].</q></cite></span></li><li id="cite_note-Vyvanse-152"> <span id="mw-reference-text-cite_note-Vyvanse-152" class="mw-reference-text"><cite class="citation encyclopaedia cs1">"Identification". <a href="javascript:if(confirm('http://www.drugbank.ca/drugs/DB01255  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.drugbank.ca/drugs/DB01255#identification'" tppabs="http://www.drugbank.ca/drugs/DB01255#identification" class="external text external"><i>Lisdexamfetamine</i></a>. <i>DrugBank</i>. University of Alberta. 16 September 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">13 June</span> 2014</span>.</cite></span></li><li id="cite_note-Jasinski_2009-153"> <span id="mw-reference-text-cite_note-Jasinski_2009-153" class="mw-reference-text"><cite id="CITEREFJasinskiKrishnan2009" class="citation journal cs1">Jasinski DR, Krishnan S (June 2009). "Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse". <i>J. Psychopharmacol. (Oxford)</i>. <b>23</b> (4): 419–427. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F0269881109103113  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F0269881109103113'" tppabs="https://doi.org/10.1177%2F0269881109103113" class="external text external">10.1177/0269881109103113</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19329547  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19329547'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19329547" class="external text external">19329547</a>.</cite></span></li><li id="cite_note-FDA_adderall-154"> <span id="mw-reference-text-cite_note-FDA_adderall-154" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s024lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s024lbl.pdf'" tppabs="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s024lbl.pdf" class="external text external">"Adderall XR Prescribing Information"</a> <span class="cs1-format">(PDF)</span>. <i>United States Food and Drug Administration</i>. pp.<span>&nbsp;</span>1–18<span class="reference-accessdate">. Retrieved <span class="nowrap">7 October</span> 2013</span>.</cite></span></li><li id="cite_note-Drugbank-dexamph-155"> <span id="mw-reference-text-cite_note-Drugbank-dexamph-155" class="mw-reference-text"><cite class="citation encyclopaedia cs1"><a href="javascript:if(confirm('http://www.drugbank.ca/drugs/DB01576  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.drugbank.ca/drugs/DB01576#pharmacology'" tppabs="http://www.drugbank.ca/drugs/DB01576#pharmacology" class="external text external">"Pharmacology"</a>. <i>Dextroamphetamine</i>. <i>DrugBank</i>. University of Alberta. 8 February 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">5 November</span> 2013</span>.</cite></span></li><li id="cite_note-FDA_Pharmacokinetics-156"> <span id="mw-reference-text-cite_note-FDA_Pharmacokinetics-156" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf'" tppabs="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf" class="external text external">"Adderall XR Prescribing Information"</a> <span class="cs1-format">(PDF)</span>. <i>United States Food and Drug Administration</i>. Shire US Inc. December 2013. pp.<span>&nbsp;</span>12–13<span class="reference-accessdate">. Retrieved <span class="nowrap">30 December</span> 2013</span>.</cite></span></li><li id="cite_note-Drugbank-amph-157"> <span id="mw-reference-text-cite_note-Drugbank-amph-157" class="mw-reference-text"><cite class="citation encyclopaedia cs1"><a href="javascript:if(confirm('http://www.drugbank.ca/drugs/DB00182  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.drugbank.ca/drugs/DB00182#pharmacology'" tppabs="http://www.drugbank.ca/drugs/DB00182#pharmacology" class="external text external">"Pharmacology"</a>. <i>Amphetamine</i>. <i>DrugBank</i>. University of Alberta. 8 February 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">5 November</span> 2013</span>.</cite></span></li><li id="cite_note-HSDB_Toxnet_October_2017_Full_archived_record-158"> <span id="mw-reference-text-cite_note-HSDB_Toxnet_October_2017_Full_archived_record-158" class="mw-reference-text"><cite class="citation encyclopaedia cs1">"Metabolism/Pharmacokinetics". <a href="javascript:if(confirm('https://web.archive.org/web/20171002194327/https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/cgi-bin/sis/search2/f?.%2Ftemp%2F~mdjW95%3A1%3AFULL  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20171002194327/https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/cgi-bin/sis/search2/f?.%2Ftemp%2F~mdjW95%3A1%3AFULL'" tppabs="https://web.archive.org/web/20171002194327/https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/cgi-bin/sis/search2/f?.%2Ftemp%2F~mdjW95%3A1%3AFULL" class="external text external"><i>Amphetamine</i></a>. <i>United States National Library of Medicine<span>&nbsp;</span>– Toxicology Data Network</i>. Hazardous Substances Data Bank. Archived from <a href="javascript:if(confirm('http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+@rel+300-62-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+@rel+300-62-9'" tppabs="http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+@rel+300-62-9" class="external text external">the original</a> on 2 October 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">2 October</span> 2017</span>. <q>Duration of effect varies depending on agent and urine pH. Excretion is enhanced in more acidic urine. Half-life is 7 to 34<span>&nbsp;</span>hours and is, in part, dependent on urine pH (half-life is longer with alkaline urine).<span>&nbsp;</span>... Amphetamines are distributed into most body tissues with high concentrations occurring in the brain and CSF. Amphetamine appears in the urine within about 3<span>&nbsp;</span>hours following oral administration.<span>&nbsp;</span>... Three days after a dose of (+ or -)-amphetamine, human subjects had excreted 91% of the (14)C in the urine</q></cite></span></li><li id="cite_note-Metabolites-160"> <span id="mw-reference-text-cite_note-Metabolites-160" class="mw-reference-text"><cite id="CITEREFSantagatiFerraraMarrazzoRonsisvalle2002" class="citation journal cs1">Santagati NA, Ferrara G, Marrazzo A, Ronsisvalle G (September 2002). "Simultaneous determination of amphetamine and one of its metabolites by HPLC with electrochemical detection". <i>Journal of Pharmaceutical and Biomedical Analysis</i>. <b>30</b> (2): 247–255. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0731-7085%2802%2900330-8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0731-7085%2802%2900330-8'" tppabs="https://doi.org/10.1016%2FS0731-7085%2802%2900330-8" class="external text external">10.1016/S0731-7085(02)00330-8</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12191709  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12191709'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12191709" class="external text external">12191709</a>.</cite></span></li><li id="cite_note-161"> <span id="mw-reference-text-cite_note-161" class="mw-reference-text"><cite class="citation encyclopaedia cs1"><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3651  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3651'" tppabs="https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3651" class="external text external">"Compound Summary"</a>. <i>p-Hydroxyamphetamine</i>. <i>PubChem Compound Database</i>. United States National Library of Medicine<span>&nbsp;</span>– National Center for Biotechnology Information<span class="reference-accessdate">. Retrieved <span class="nowrap">15 October</span> 2013</span>.</cite></span></li><li id="cite_note-162"> <span id="mw-reference-text-cite_note-162" class="mw-reference-text"><cite class="citation encyclopaedia cs1"><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11099  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11099'" tppabs="https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11099" class="external text external">"Compound Summary"</a>. <i>p-Hydroxynorephedrine</i>. <i>PubChem Compound Database</i>. United States National Library of Medicine<span>&nbsp;</span>– National Center for Biotechnology Information<span class="reference-accessdate">. Retrieved <span class="nowrap">15 October</span> 2013</span>.</cite></span></li><li id="cite_note-163"> <span id="mw-reference-text-cite_note-163" class="mw-reference-text"><cite class="citation encyclopaedia cs1"><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=26934  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=26934'" tppabs="https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=26934" class="external text external">"Compound Summary"</a>. <i>Phenylpropanolamine</i>. <i>PubChem Compound Database</i>. United States National Library of Medicine<span>&nbsp;</span>– National Center for Biotechnology Information<span class="reference-accessdate">. Retrieved <span class="nowrap">15 October</span> 2013</span>.</cite></span></li><li id="cite_note-Pubchem_Kinetics-164"> <span id="mw-reference-text-cite_note-Pubchem_Kinetics-164" class="mw-reference-text"><cite class="citation encyclopaedia cs1"><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3007  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3007#section=Pharmacology-and-Biochemistry'" tppabs="https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3007#section=Pharmacology-and-Biochemistry" class="external text external">"Pharmacology and Biochemistry"</a>. <i>Amphetamine</i>. <i>Pubchem Compound Database</i>. United States National Library of Medicine<span>&nbsp;</span>– National Center for Biotechnology Information<span class="reference-accessdate">. Retrieved <span class="nowrap">12 October</span> 2013</span>.</cite></span></li><li id="cite_note-Substituted_amphetamines,_FMO,_and_DBH-165"> <span id="mw-reference-text-cite_note-Substituted_amphetamines,_FMO,_and_DBH-165" class="mw-reference-text"><cite id="CITEREFGlennon_RA2013" class="citation book cs1">Glennon RA (2013). <a href="javascript:if(confirm('https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA646  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA646'" tppabs="https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA646" class="external text external">"Phenylisopropylamine stimulants: amphetamine-related agents"</a>.  In Lemke TL, Williams DA, Roche VF, Zito W (eds.). <i>Foye's principles of medicinal chemistry</i> (7th ed.). Philadelphia, USA: Wolters Kluwer Health/Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>646–648. ISBN<span>&nbsp;</span><bdi>9781609133450</bdi>. <q>The simplest unsubstituted phenylisopropylamine, 1-phenyl-2-aminopropane, or amphetamine, serves as a common structural template for hallucinogens and psychostimulants. Amphetamine produces central stimulant, anorectic, and sympathomimetic actions, and it is the prototype member of this class (39).<span>&nbsp;</span>... The phase 1 metabolism of amphetamine analogs is catalyzed by two systems: cytochrome P450 and flavin monooxygenase.<span>&nbsp;</span>... Amphetamine can also undergo aromatic hydroxylation to <i>p</i>-hydroxyamphetamine.<span>&nbsp;</span>... Subsequent oxidation at the benzylic position by DA β-hydroxylase affords <i>p</i>-hydroxynorephedrine. Alternatively, direct oxidation of amphetamine by DA β-hydroxylase can afford norephedrine.</q></cite></span></li><li id="cite_note-DBH_amph_primary-166"> <span id="mw-reference-text-cite_note-DBH_amph_primary-166" class="mw-reference-text"><cite id="CITEREFTaylor_KB1974" class="citation journal cs1">Taylor KB (January 1974). <a href="javascript:if(confirm('http://www.jbc.org/content/249/2/454.full.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.jbc.org/content/249/2/454.full.pdf'" tppabs="http://www.jbc.org/content/249/2/454.full.pdf" class="external text external">"Dopamine-beta-hydroxylase. Stereochemical course of the reaction"</a> <span class="cs1-format">(PDF)</span>. <i>Journal of Biological Chemistry</i>. <b>249</b> (2): 454–458. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/4809526  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/4809526'" tppabs="https://pubmed.ncbi.nlm.nih.gov/4809526" class="external text external">4809526</a><span class="reference-accessdate">. Retrieved <span class="nowrap">6 November</span> 2014</span>. <q>Dopamine-β-hydroxylase catalyzed the removal of the pro-R hydrogen atom and the production of 1-norephedrine, (2S,1R)-2-amino-1-hydroxyl-1-phenylpropane, from d-amphetamine.</q></cite></span></li><li id="cite_note-FMO-167"> <span id="mw-reference-text-cite_note-FMO-167" class="mw-reference-text"><cite id="CITEREFKruegerWilliams2005" class="citation journal cs1">Krueger SK, Williams DE (June 2005). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1828602  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1828602'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1828602" class="external text external">"Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism"</a>. <i>Pharmacology &amp; Therapeutics</i>. <b>106</b> (3): 357–387. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.pharmthera.2005.01.001  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.pharmthera.2005.01.001'" tppabs="https://doi.org/10.1016%2Fj.pharmthera.2005.01.001" class="external text external">10.1016/j.pharmthera.2005.01.001</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1828602  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1828602'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1828602" class="external text external">1828602</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15922018  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15922018'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15922018" class="external text external">15922018</a>.</cite><br><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1828602/table/T5/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1828602/table/T5/'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1828602/table/T5/" class="external text external">Table 5: N-containing drugs and xenobiotics oxygenated by FMO</a></span></li><li id="cite_note-FMO3-Primary-168"> <span id="mw-reference-text-cite_note-FMO3-Primary-168" class="mw-reference-text"><cite id="CITEREFCashmanXiongXuJanowsky1999" class="citation journal cs1">Cashman JR, Xiong YN, Xu L, Janowsky A (March 1999). "N-oxygenation of amphetamine and methamphetamine by the human flavin-containing monooxygenase (form 3): role in bioactivation and detoxication". <i>Journal of Pharmacology and Experimental Therapeutics</i>. <b>288</b> (3): 1251–1260. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10027866  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10027866'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10027866" class="external text external">10027866</a>.</cite></span></li><li id="cite_note-pmid13977820-169"> <span id="mw-reference-text-cite_note-pmid13977820-169" class="mw-reference-text"><cite id="CITEREFSjoerdsmavon_Studnitz1963" class="citation journal cs1">Sjoerdsma A, von Studnitz W (April 1963). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1703637  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1703637'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1703637" class="external text external">"Dopamine-beta-oxidase activity in man, using hydroxyamphetamine as substrate"</a>. <i>British Journal of Pharmacology and Chemotherapy</i>. <b>20</b>: 278–284. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1476-5381.1963.tb01467.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1476-5381.1963.tb01467.x'" tppabs="https://doi.org/10.1111%2Fj.1476-5381.1963.tb01467.x" class="external text external">10.1111/j.1476-5381.1963.tb01467.x</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1703637  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1703637'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1703637" class="external text external">1703637</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/13977820  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/13977820'" tppabs="https://pubmed.ncbi.nlm.nih.gov/13977820" class="external text external">13977820</a>. <q>Hydroxyamphetamine was administered orally to five human subjects<span>&nbsp;</span>... Since conversion of hydroxyamphetamine to hydroxynorephedrine occurs in vitro by the action of dopamine-β-oxidase, a simple method is suggested for measuring the activity of this enzyme and the effect of its inhibitors in man.<span>&nbsp;</span>... The lack of effect of administration of neomycin to one patient indicates that the hydroxylation occurs in body tissues.<span>&nbsp;</span>... a major portion of the β-hydroxylation of hydroxyamphetamine occurs in non-adrenal tissue. Unfortunately, at the present time one cannot be completely certain that the hydroxylation of hydroxyamphetamine in vivo is accomplished by the same enzyme which converts dopamine to noradrenaline.</q></cite></span></li><li id="cite_note-Glycine_conjugation_review-170"> <span id="mw-reference-text-cite_note-Glycine_conjugation_review-170" class="mw-reference-text"><cite id="CITEREFBadenhorstvan_der_SluisErasmusvan_Dijk2013" class="citation journal cs1">Badenhorst CP, van der Sluis R, Erasmus E, van Dijk AA (September 2013). "Glycine conjugation: importance in metabolism, the role of glycine N-acyltransferase, and factors that influence interindividual variation". <i>Expert Opinion on Drug Metabolism &amp; Toxicology</i>. <b>9</b> (9): 1139–1153. doi:<a href="javascript:if(confirm('https://doi.org/10.1517%2F17425255.2013.796929  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1517%2F17425255.2013.796929'" tppabs="https://doi.org/10.1517%2F17425255.2013.796929" class="external text external">10.1517/17425255.2013.796929</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23650932  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23650932'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23650932" class="external text external">23650932</a>. <q>Figure 1. Glycine conjugation of benzoic acid. The glycine conjugation pathway consists of two steps. First benzoate is ligated to CoASH to form the high-energy benzoyl-CoA thioester. This reaction is catalyzed by the HXM-A and HXM-B medium-chain acid:CoA ligases and requires energy in the form of ATP.<span>&nbsp;</span>... The benzoyl-CoA is then conjugated to glycine by GLYAT to form hippuric acid, releasing CoASH. In addition to the factors listed in the boxes, the levels of ATP, CoASH, and glycine may influence the overall rate of the glycine conjugation pathway.</q></cite></span></li><li id="cite_note-DBH_4-HA_primary-171"> <span id="mw-reference-text-cite_note-DBH_4-HA_primary-171" class="mw-reference-text"><cite id="CITEREFHorwitzAlexanderLovenbergKeiser1973" class="citation journal cs1">Horwitz D, Alexander RW, Lovenberg W, Keiser HR (May 1973). "Human serum dopamine-β-hydroxylase. Relationship to hypertension and sympathetic activity". <i>Circulation Research</i>. <b>32</b> (5): 594–599. doi:<a href="javascript:if(confirm('https://doi.org/10.1161%2F01.RES.32.5.594  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1161%2F01.RES.32.5.594'" tppabs="https://doi.org/10.1161%2F01.RES.32.5.594" class="external text external">10.1161/01.RES.32.5.594</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/4713201  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/4713201'" tppabs="https://pubmed.ncbi.nlm.nih.gov/4713201" class="external text external">4713201</a>. <q>The biologic significance of the different levels of serum DβH activity was studied in two ways. First, in vivo ability to β-hydroxylate the synthetic substrate hydroxyamphetamine was compared in two subjects with low serum DβH activity and two subjects with average activity.<span>&nbsp;</span>... In one study, hydroxyamphetamine (Paredrine), a synthetic substrate for DβH, was administered to subjects with either low or average levels of serum DβH activity. The percent of the drug hydroxylated to hydroxynorephedrine was comparable in all subjects (6.5-9.62) (Table 3).</q></cite></span></li><li id="cite_note-pmid4457764-172"> <span id="mw-reference-text-cite_note-pmid4457764-172" class="mw-reference-text"><cite id="CITEREFFreemanSulser1974" class="citation journal cs1">Freeman JJ, Sulser F (December 1974). "Formation of p-hydroxynorephedrine in brain following intraventricular administration of p-hydroxyamphetamine". <i>Neuropharmacology</i>. <b>13</b> (12): 1187–1190. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0028-3908%2874%2990069-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0028-3908%2874%2990069-0'" tppabs="https://doi.org/10.1016%2F0028-3908%2874%2990069-0" class="external text external">10.1016/0028-3908(74)90069-0</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/4457764  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/4457764'" tppabs="https://pubmed.ncbi.nlm.nih.gov/4457764" class="external text external">4457764</a>. <q>In species where aromatic hydroxylation of amphetamine is the major metabolic pathway, <i>p</i>-hydroxyamphetamine (POH) and <i>p</i>-hydroxynorephedrine (PHN) may contribute to the pharmacological profile of the parent drug.<span>&nbsp;</span>... The location of the <i>p</i>-hydroxylation and β-hydroxylation reactions is important in species where aromatic hydroxylation of amphetamine is the predominant pathway of metabolism. Following systemic administration of amphetamine to rats, POH has been found in urine and in plasma.<br>The observed lack of a significant accumulation of PHN in brain following the intraventricular administration of (+)-amphetamine and the formation of appreciable amounts of PHN from (+)-POH in brain tissue in vivo supports the view that the aromatic hydroxylation of amphetamine following its systemic administration occurs predominantly in the periphery, and that POH is then transported through the blood-brain barrier, taken up by noradrenergic neurones in brain where (+)-POH is converted in the storage vesicles by dopamine β-hydroxylase to PHN.</q></cite></span></li><li id="cite_note-pmid2600821-173"> <span id="mw-reference-text-cite_note-pmid2600821-173" class="mw-reference-text"><cite id="CITEREFMatsudaHansonGibb1989" class="citation journal cs1">Matsuda LA, Hanson GR, Gibb JW (December 1989). "Neurochemical effects of amphetamine metabolites on central dopaminergic and serotonergic systems". <i>Journal of Pharmacology and Experimental Therapeutics</i>. <b>251</b> (3): 901–908. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2600821  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2600821'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2600821" class="external text external">2600821</a>. <q>The metabolism of <i>p</i>-OHA to <i>p</i>-OHNor is well documented and dopamine-β hydroxylase present in noradrenergic neurons could easily convert <i>p</i>-OHA to <i>p</i>-OHNor after intraventricular administration.</q></cite></span></li><li id="cite_note-ChemSpider-175"> <span id="mw-reference-text-cite_note-ChemSpider-175" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.9772458.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.9772458.html'" tppabs="http://www.chemspider.com/Chemical-Structure.9772458.html" class="external text external">"Lidsexamfetamine"</a>. <i>ChemSpider</i>. Royal Society of Chemistry. 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">22 April</span> 2019</span>.</cite></span></li><li id="cite_note-176"> <span id="mw-reference-text-cite_note-176" class="mw-reference-text"><cite id="CITEREFStahlWermuth2011" class="citation book cs1">Stahl, P. Heinrich; Wermuth, Camille G., eds. (2011). <i>Pharmaceutical Salts: Properties, Selection, and Use</i> (2nd ed.). John Wiley &amp; Sons. ISBN<span>&nbsp;</span><bdi>978-3-90639-051-2</bdi>.</cite></span></li><li id="cite_note-177"> <span id="mw-reference-text-cite_note-177" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.lenntech.com/calculators/molecular/molecular-weight-calculator.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.lenntech.com/calculators/molecular/molecular-weight-calculator.htm'" tppabs="http://www.lenntech.com/calculators/molecular/molecular-weight-calculator.htm" class="external text external">"Molecular Weight Calculator"</a>. Lenntech<span class="reference-accessdate">. Retrieved <span class="nowrap">19 August</span> 2015</span>.</cite></span></li><li id="cite_note-damph1-181"> <span id="mw-reference-text-cite_note-damph1-181" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id=2147491568  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id=2147491568'" tppabs="http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id=2147491568" class="external text external">"Dextroamphetamine Sulfate USP"</a>. Mallinckrodt Pharmaceuticals. March 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">19 August</span> 2015</span>.</cite></span></li><li id="cite_note-damph2-182"> <span id="mw-reference-text-cite_note-damph2-182" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.tocris.com/dispprod.php?ItemId=5305  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.tocris.com/dispprod.php?ItemId=5305#.VXpspvlViko'" tppabs="http://www.tocris.com/dispprod.php?ItemId=5305#.VXpspvlViko" class="external text external">"D-amphetamine sulfate"</a>. Tocris. 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">19 August</span> 2015</span>.</cite></span></li><li id="cite_note-Amph_sulfate_mass-183"> <span id="mw-reference-text-cite_note-Amph_sulfate_mass-183" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id=2147491599  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id=2147491599'" tppabs="http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id=2147491599" class="external text external">"Amphetamine Sulfate USP"</a>. Mallinckrodt Pharmaceuticals. March 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">19 August</span> 2015</span>.</cite></span></li><li id="cite_note-184"> <span id="mw-reference-text-cite_note-184" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id=2147491576  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id=2147491576'" tppabs="http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id=2147491576" class="external text external">"Dextroamphetamine Saccharate"</a>. Mallinckrodt Pharmaceuticals. March 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">19 August</span> 2015</span>.</cite></span></li><li id="cite_note-amph2-185"> <span id="mw-reference-text-cite_note-amph2-185" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id=2147491591  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id=2147491591'" tppabs="http://www2.mallinckrodt.com/WorkArea/DownloadAsset.aspx?id=2147491591" class="external text external">"Amphetamine Aspartate"</a>. Mallinckrodt Pharmaceuticals. March 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">19 August</span> 2015</span>.</cite></span></li><li id="cite_note-CNS_Spectrums-187"> <span id="mw-reference-text-cite_note-CNS_Spectrums-187" class="mw-reference-text"><cite id="CITEREFMattingly2010" class="citation journal cs1">Mattingly, G (May 2010). <a href="javascript:if(confirm('https://digitalcommons.wustl.edu/open_access_pubs/3506  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://digitalcommons.wustl.edu/open_access_pubs/3506'" tppabs="https://digitalcommons.wustl.edu/open_access_pubs/3506" class="external text external">"Lisdexamfetamine dimesylate: a prodrug stimulant for the treatment of ADHD in children and adults"</a>. <i>CNS Spectrums</i>. <b>15</b> (5): 315–25. doi:<a href="javascript:if(confirm('https://doi.org/10.1017%2FS1092852900027541  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1017%2FS1092852900027541'" tppabs="https://doi.org/10.1017%2FS1092852900027541" class="external text external">10.1017/S1092852900027541</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20448522  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20448522'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20448522" class="external text external">20448522</a>.</cite></span></li><li id="cite_note-FDAAdultApproval-188"> <span id="mw-reference-text-cite_note-FDAAdultApproval-188" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/021977s001ltr.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/021977s001ltr.pdf'" tppabs="http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/021977s001ltr.pdf" class="external text external">"FDA Adult Approval of Vyvanse – FDA Label and Approval History"</a> <span class="cs1-format">(PDF)</span>.</cite></span></li><li id="cite_note-189"> <span id="mw-reference-text-cite_note-189" class="mw-reference-text"><a href="javascript:if(confirm('http://205.193.93.51/NocWeb/viewnoce.jsp?noc=cigef  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://205.193.93.51/NocWeb/viewnoce.jsp?noc=cigef'" tppabs="http://205.193.93.51/NocWeb/viewnoce.jsp?noc=cigef" class="external text external">Health Canada Notice of Compliance – Vyvanse</a>. 19 February 2009, retrieved on 9 March 2009.</span></li><li id="cite_note-190"> <span id="mw-reference-text-cite_note-190" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm432543.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm432543.htm'" tppabs="https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm432543.htm" class="external text external">"Press Announcements – FDA expands uses of Vyvanse to treat binge-eating disorder"</a>. <i>FDA</i>. 30 January 2015.</cite></span></li><li id="cite_note-191"> <span id="mw-reference-text-cite_note-191" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.deadiversion.usdoj.gov/quotas/quota_history.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.deadiversion.usdoj.gov/quotas/quota_history.pdf'" tppabs="http://www.deadiversion.usdoj.gov/quotas/quota_history.pdf" class="external text external">"DEA Office of Diversion Control"</a> <span class="cs1-format">(PDF)</span>. DEA<span class="reference-accessdate">. Retrieved <span class="nowrap">1 July</span> 2014</span>.</cite></span></li><li id="cite_note-192"> <span id="mw-reference-text-cite_note-192" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/international/lisdexamfetamine.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/international/lisdexamfetamine.html'" tppabs="https://www.drugs.com/international/lisdexamfetamine.html" class="external text external">"Lisdexamfetamine international brands"</a>. Drugs.com<span class="reference-accessdate">. Retrieved <span class="nowrap">10 July</span> 2017</span>.</cite></span></li><li id="cite_note-LDX_adjunct_therapy-193"> <span id="mw-reference-text-cite_note-LDX_adjunct_therapy-193" class="mw-reference-text"><cite id="CITEREFDaleBang-AndersenSánchez2015" class="citation journal cs1">Dale E, Bang-Andersen B, Sánchez C (May 2015). <a href="javascript:if(confirm('https://doi.org/10.1016/j.bcp.2015.03.011  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016/j.bcp.2015.03.011'" tppabs="https://doi.org/10.1016/j.bcp.2015.03.011" class="external text external">"Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs"</a>. <i>Biochem. Pharmacol</i>. <b>95</b> (2): 81–97. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.bcp.2015.03.011  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.bcp.2015.03.011'" tppabs="https://doi.org/10.1016%2Fj.bcp.2015.03.011" class="external text external">10.1016/j.bcp.2015.03.011</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25813654  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25813654'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25813654" class="external text external">25813654</a>.</cite></span></li><li id="cite_note-Psychostimulants_in_the_therapy_of_treatment-resistant_depression_Review_of_the_literature_and_findings_from_a_retrospective_study_in_65_depressed_patients-194"> <span id="mw-reference-text-cite_note-Psychostimulants_in_the_therapy_of_treatment-resistant_depression_Review_of_the_literature_and_findings_from_a_retrospective_study_in_65_depressed_patients-194" class="mw-reference-text"><cite id="CITEREFStotzWoggonAngst1999" class="citation journal cs1">Stotz, G.; Woggon, B.; Angst, J. (1999). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181580  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181580'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181580" class="external text external">"Psychostimulants in the therapy of treatment-resistant depression Review of the literature and findings from a retrospective study in 65 depressed patients"</a>. <i>Dialogues Clin. Neurosci</i>. <b>1</b> (3): 165–74. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181580  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181580'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181580" class="external text external">3181580</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22034135  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22034135'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22034135" class="external text external">22034135</a>.</cite></span></li><li id="cite_note-195"> <span id="mw-reference-text-cite_note-195" class="mw-reference-text"><cite id="CITEREFHirschler2014" class="citation news cs1">Hirschler, Ben (7 February 2014). <a href="javascript:if(confirm('http://uk.reuters.com/article/2014/02/07/shire-vyvanse-idUKL2N0LB28F20140207  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://uk.reuters.com/article/2014/02/07/shire-vyvanse-idUKL2N0LB28F20140207'" tppabs="http://uk.reuters.com/article/2014/02/07/shire-vyvanse-idUKL2N0LB28F20140207" class="external text external">"UPDATE 2-Shire scraps Vyvanse for depression after failed trials"</a>. Reuters<span class="reference-accessdate">. Retrieved <span class="nowrap">13 February</span> 2014</span>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/lisdexamfetamine  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/lisdexamfetamine'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/lisdexamfetamine" class="external text external">"Lisdexamfetamine"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Amphetamine" style="padding:3px"><table class="nowraplinks mw-collapsible expanded navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Amphetamine" style="font-size:114%;margin:0 4em"><a href="Amphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amphetamine" title="Amphetamine">Amphetamine</a></div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align: center">Main articles <br>and <br>pharmaceuticals</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:10.5em"><a href="Amphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amphetamine" title="Amphetamine">Amphetamine</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Adzenys<span>&nbsp;</span>ER</i></li>
<li><i><span class="nowrap">Adzenys XR-ODT</span></i></li>
<li><i>Dyanavel<span>&nbsp;</span>XR</i></li>
<li><i>Evekeo</i></li>
<li><i>Evekeo<span>&nbsp;</span>ODT</i></li>
<li>Mixed amphetamine salts
<ul><li><i>Adderall</i></li>
<li><i>Adderall<span>&nbsp;</span>XR</i></li>
<li><i>Mydayis</i></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:10.5em"><a href="Levoamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Levoamphetamine" title="Levoamphetamine">Levoamphetamine</a></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">N/A</div></td></tr><tr><th scope="row" class="navbox-group" style="width:10.5em"><a href="Dextroamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dextroamphetamine" title="Dextroamphetamine">Dextroamphetamine</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Dexedrine</i></li>
<li><i>ProCentra</i></li>
<li><i>Zenzedi</i></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:10.5em"><a href="Lisdexamfetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lisdexamfetamine" title="Lisdexamfetamine">Lisdexamfetamine</a></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Vyvanse</i></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align: center">Neuropharmacology</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:10.5em">Biomolecular targets</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>TAAR1 (full agonist)</li>
<li>CART (<abbr>mRNA</abbr> inducer)</li>
<li>5-HT1A receptor (low affinity ligand)</li>
<li>MAO (weak competitive inhibitor)</li>
<li><a href="Carbonic_anhydrase.htm" tppabs="https://ptable.com/wiki/compounds/A/Carbonic_anhydrase" title="Carbonic anhydrase">Carbonic anhydrases</a> hCA4, hCA5A, hCA5B, hCA7, hCA12, hCA13, and hCA14 (enzyme activator)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:10.5em">Inhibited transporters</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>DAT</li>
<li>NET</li>
<li>SERT</li>
<li>VMAT1</li>
<li>VMAT2</li>
<li>EAAT3</li>
<li>SLC22A3</li>
<li>SLC22A5</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align: center">Active metabolites</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>4-Hydroxyamphetamine</li>
<li>4-Hydroxynorephedrine</li>
<li><a href="Phenylpropanolamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenylpropanolamine" title="Phenylpropanolamine">Norephedrine</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align: center">Related articles</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>ADHD</li>
<li>ADHD management</li>
<li>Amphetamine psychosis</li>
<li><a href="Dopamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dopamine" title="Dopamine">Dopamine</a></li>
<li>Doping in sport</li>
<li>Executive functions</li>
<li>Formetorex</li>
<li>ΔFosB</li>
<li>History and culture of substituted amphetamines</li>
<li>History of Benzedrine</li>
<li><a href="Methamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Methamphetamine" title="Methamphetamine">Methamphetamine</a></li>
<li><a href="Methylphenidate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methylphenidate" title="Methylphenidate">Methylphenidate</a></li>
<li><a href="N-Methylphenethylamine.htm" tppabs="https://ptable.com/wiki/compounds/A/N-Methylphenethylamine" title="N-Methylphenethylamine"><i>N</i>-Methylphenethylamine</a></li>
<li>Motivational salience
<ul><li>Incentive salience</li></ul></li>
<li>Narcolepsy</li>
<li>Neurobiological effects of physical exercise §<span>&nbsp;</span>Attention deficit hyperactivity disorder</li>
<li>Nootropic</li>
<li>Norepinephrine</li>
<li>Obesity</li>
<li>Performance-enhancing substance</li>
<li><a href="Phenethylamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenethylamine" title="Phenethylamine">Phenethylamine</a></li>
<li><a href="Phentermine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phentermine" title="Phentermine">Phentermine</a></li>
<li><a href="Phenylacetone.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenylacetone" title="Phenylacetone">Phenylacetone</a></li>
<li>Recreational drug use</li>
<li><a href="Serotonin.htm" tppabs="https://ptable.com/wiki/compounds/A/Serotonin" title="Serotonin">Serotonin</a></li>
<li>Substituted amphetamine</li>
<li>Trace amine</li></ul>
</div></td></tr><tr><td class="navbox-abovebelow hlist" colspan="2"><div>
<ul><li><figure-inline><span><img src="../I/m/Folder_Hexagonal_Icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Folder_Hexagonal_Icon.svg.png" data-file-width="36" data-file-height="31" data-file-type="drawing" height="14" width="16"></span></figure-inline> Category</li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="ADHD_pharmacotherapies" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="ADHD_pharmacotherapies" style="font-size:114%;margin:0 4em"><abbr>ADHD</abbr> pharmacotherapies</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align: center"><abbr>CNS</abbr> stimulants</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Amphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amphetamine" title="Amphetamine">Amphetamine</a> (Mixed amphetamine salts, <a href="Levoamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Levoamphetamine" title="Levoamphetamine">Levoamphetamine</a>, <a href="Dextroamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dextroamphetamine" title="Dextroamphetamine">Dextroamphetamine</a>, <a href="Lisdexamfetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lisdexamfetamine" title="Lisdexamfetamine">Lisdexamfetamine</a>)</li>
<li><a href="Methamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Methamphetamine" title="Methamphetamine">Methamphetamine</a></li>
<li><a href="Methylphenidate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methylphenidate" title="Methylphenidate">Methylphenidate</a></li>
<li>Dexmethylphenidate</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align: center">Non-classical<br><abbr>CNS</abbr> stimulants</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Armodafinil</li>
<li><a href="Atomoxetine.htm" tppabs="https://ptable.com/wiki/compounds/A/Atomoxetine" title="Atomoxetine">Atomoxetine</a></li>
<li><a href="Modafinil.htm" tppabs="https://ptable.com/wiki/compounds/A/Modafinil" title="Modafinil">Modafinil</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align: center">α<sub>2</sub>-adrenoceptor<br>agonists</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Clonidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Clonidine" title="Clonidine">Clonidine</a></li>
<li><a href="Guanfacine.htm" tppabs="https://ptable.com/wiki/compounds/A/Guanfacine" title="Guanfacine">Guanfacine</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align: center">Antidepressants</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Amitriptyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Amitriptyline" title="Amitriptyline">Amitriptyline</a></li>
<li><a href="Bupropion.htm" tppabs="https://ptable.com/wiki/compounds/A/Bupropion" title="Bupropion">Bupropion</a></li>
<li><a href="Buspirone.htm" tppabs="https://ptable.com/wiki/compounds/A/Buspirone" title="Buspirone">Buspirone</a></li>
<li>Desipramine</li>
<li><a href="Duloxetine.htm" tppabs="https://ptable.com/wiki/compounds/A/Duloxetine" title="Duloxetine">Duloxetine</a></li>
<li><a href="Imipramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Imipramine" title="Imipramine">Imipramine</a></li>
<li><a href="Milnacipran.htm" tppabs="https://ptable.com/wiki/compounds/A/Milnacipran" title="Milnacipran">Milnacipran</a></li>
<li><a href="Moclobemide.htm" tppabs="https://ptable.com/wiki/compounds/A/Moclobemide" title="Moclobemide">Moclobemide</a></li>
<li><a href="Nortriptyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Nortriptyline" title="Nortriptyline">Nortriptyline</a></li>
<li><a href="Reboxetine.htm" tppabs="https://ptable.com/wiki/compounds/A/Reboxetine" title="Reboxetine">Reboxetine</a></li>
<li><a href="Venlafaxine.htm" tppabs="https://ptable.com/wiki/compounds/A/Venlafaxine" title="Venlafaxine">Venlafaxine</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align: center">Miscellaneous/others</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Amantadine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amantadine" title="Amantadine">Amantadine</a></li>
<li><a href="Carbamazepine.htm" tppabs="https://ptable.com/wiki/compounds/A/Carbamazepine" title="Carbamazepine">Carbamazepine</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align: center">Related articles</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Attention deficit hyperactivity disorder (ADHD)</li>
<li>Attention deficit hyperactivity disorder management</li>
<li>Monoamine releasing agent</li>
<li><a href="Dopamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dopamine" title="Dopamine">Dopamine</a> (DA)</li>
<li>Dopamine transporter (DAT)</li>
<li>Dopamine reuptake inhibitor (DRI)</li>
<li>Norepinephrine (NE)</li>
<li>Norepinephrine transporter (NET)</li>
<li>Norepinephrine reuptake inhibitor (NRI)</li>
<li><a href="Serotonin.htm" tppabs="https://ptable.com/wiki/compounds/A/Serotonin" title="Serotonin">Serotonin</a> (5-HT)</li>
<li>Serotonin transporter (SERT)</li>
<li>Selective serotonin reuptake inhibitor (SSRI)</li>
<li>Serotonin-norepinephrine reuptake inhibitor (SNRI)</li>
<li>Norepinephrine-dopamine reuptake inhibitor (NDRI)</li>
<li>Serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI)</li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Monoamine_releasing_agents" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Monoamine_releasing_agents" style="font-size:114%;margin:0 4em">Monoamine releasing agents</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>DRAs</abbr></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px;text-align: left;"><div style="padding:0em 0.25em">
<ul><li><i>Morpholines:</i> Fenbutrazate</li>
<li>Fenmetramide</li>
<li>Morazone</li>
<li>Morforex</li>
<li><a href="Phendimetrazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phendimetrazine" title="Phendimetrazine">Phendimetrazine</a></li>
<li><a href="Phenmetrazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenmetrazine" title="Phenmetrazine">Phenmetrazine</a></li>
<li>Pseudophenmetrazine</li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-even" style="width:100%;padding:0px;text-align: left;"><div style="padding:0em 0.25em">
<ul><li><i>Oxazolines:</i> <a href="4-Methylaminorex.htm" tppabs="https://ptable.com/wiki/compounds/A/4-Methylaminorex" title="4-Methylaminorex">4-MAR</a></li>
<li><a href="Aminorex.htm" tppabs="https://ptable.com/wiki/compounds/A/Aminorex" title="Aminorex">Aminorex</a></li>
<li>Clominorex</li>
<li>Cyclazodone</li>
<li>Fenozolone</li>
<li>Fluminorex</li>
<li><a href="Pemoline.htm" tppabs="https://ptable.com/wiki/compounds/A/Pemoline" title="Pemoline">Pemoline</a></li>
<li>Thozalinone</li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px;text-align: left;"><div style="padding:0em 0.25em">
<ul><li><i>Phenethylamines:</i> 2-OH-PEA</li>
<li>4-CAB</li>
<li>4-FA</li>
<li>4-FMA</li>
<li>4-MA</li>
<li>4-MMA</li>
<li>Alfetamine</li>
<li>Amfecloral</li>
<li>Amfepentorex</li>
<li><a href="Amfepramone.htm" tppabs="https://ptable.com/wiki/compounds/A/Amfepramone" title="Amfepramone">Amfepramone</a></li>
<li><a href="Amphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amphetamine" title="Amphetamine">Amphetamine</a> (<a href="Dextroamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dextroamphetamine" title="Dextroamphetamine">Dextroamphetamine</a></li>
<li><a href="Levoamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Levoamphetamine" title="Levoamphetamine">Levoamphetamine</a>)</li>
<li>Amphetaminil</li>
<li><a href="Β-Methylphenethylamine.htm" tppabs="https://ptable.com/wiki/compounds/A/%CE%92-Methylphenethylamine" title="Β-Methylphenethylamine">β-Me-PEA</a></li>
<li>BDB</li>
<li>BOH</li>
<li><a href="Benzphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzphetamine" title="Benzphetamine">Benzphetamine</a></li>
<li>Buphedrone</li>
<li>Butylone</li>
<li><a href="Cathine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cathine" title="Cathine">Cathine</a></li>
<li><a href="Cathinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Cathinone" title="Cathinone">Cathinone</a></li>
<li>Clobenzorex</li>
<li><a href="Clortermine.htm" tppabs="https://ptable.com/wiki/compounds/A/Clortermine" title="Clortermine">Clortermine</a></li>
<li>D-Deprenyl</li>
<li><a href="Dimethoxyamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dimethoxyamphetamine" title="Dimethoxyamphetamine">DMA</a></li>
<li>DMMA</li>
<li>Dimethylamphetamine</li>
<li><a href="Ephedrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Ephedrine" title="Ephedrine">Ephedrine</a></li>
<li>Ethcathinone</li>
<li>EBDB</li>
<li>Ethylone</li>
<li>Etilamfetamine</li>
<li>Famprofazone</li>
<li><a href="Fenethylline.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenethylline" title="Fenethylline">Fenethylline</a></li>
<li><a href="Fenproporex.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenproporex" title="Fenproporex">Fenproporex</a></li>
<li>Flephedrone</li>
<li>Fludorex</li>
<li>Furfenorex</li>
<li>Hordenine</li>
<li>4-Hydroxyamphetamine</li>
<li>Iofetamine (123I)</li>
<li>Lophophine</li>
<li>Mefenorex</li>
<li>Mephedrone</li>
<li>Metamfepramone</li>
<li><a href="Methamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Methamphetamine" title="Methamphetamine">Methamphetamine</a>
<ul><li>Dextromethamphetamine</li>
<li>Levomethamphetamine</li></ul></li>
<li>Methcathinone</li>
<li>Methedrone</li>
<li>MMDA</li>
<li>MMDMA</li>
<li>MBDB</li>
<li><a href="3,4-Methylenedioxyamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/3%2C4-Methylenedioxyamphetamine" title="3,4-Methylenedioxyamphetamine">MDA (tenamfetamine)</a></li>
<li>MDEA</li>
<li><a href="MDMA.htm" tppabs="https://ptable.com/wiki/compounds/A/MDMA" title="MDMA">MDMA (midomafetamine)</a></li>
<li>MDMPEA</li>
<li>MDOH</li>
<li>MDPEA</li>
<li>Methylone</li>
<li>Morforex</li>
<li>Ortetamine</li>
<li><i>p</i>BA</li>
<li><i>p</i>CA</li>
<li><i>p</i>IA</li>
<li><a href="Pholedrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pholedrine" title="Pholedrine">Pholedrine</a></li>
<li><a href="Phenethylamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenethylamine" title="Phenethylamine">Phenethylamine</a></li>
<li><a href="Pholedrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pholedrine" title="Pholedrine">Pholedrine</a></li>
<li>Phenpromethamine</li>
<li><a href="Prenylamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Prenylamine" title="Prenylamine">Prenylamine</a></li>
<li>Propylamphetamine</li>
<li><a href="Pseudoephedrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pseudoephedrine" title="Pseudoephedrine">Pseudoephedrine</a></li>
<li>Tiflorex</li>
<li><a href="Tyramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Tyramine" title="Tyramine">Tyramine</a></li>
<li>Xylopropamine</li>
<li>Zylofuramine</li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-even" style="width:100%;padding:0px;text-align: left;"><div style="padding:0em 0.25em">
<ul><li><i>Piperazines:</i> 2C-B-BZP</li>
<li><a href="Benzylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzylpiperazine" title="Benzylpiperazine">BZP</a></li>
<li>MBZP</li>
<li>MDBZP</li>
<li>MeOPP</li>
<li>oMPP</li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px;text-align: left;"><div style="padding:0em 0.25em">
<ul><li><i>Others:</i> 2-ADN</li>
<li>2-AI</li>
<li><a href="2-Aminotetralin.htm" tppabs="https://ptable.com/wiki/compounds/A/2-Aminotetralin" title="2-Aminotetralin">2-AT</a></li>
<li><a href="4-Benzylpiperidine.htm" tppabs="https://ptable.com/wiki/compounds/A/4-Benzylpiperidine" title="4-Benzylpiperidine">4-BP</a></li>
<li>5-APDI</li>
<li>5-IAI</li>
<li><a href="Amineptine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amineptine" title="Amineptine">Amineptine</a></li>
<li>Clofenciclan</li>
<li>Cyclopentamine</li>
<li>Cypenamine</li>
<li>Cyprodenate</li>
<li>Feprosidnine</li>
<li>Gilutensin</li>
<li><a href="Heptaminol.htm" tppabs="https://ptable.com/wiki/compounds/A/Heptaminol" title="Heptaminol">Heptaminol</a></li>
<li>Hexacyclonate</li>
<li>Indanorex</li>
<li>Isometheptene</li>
<li>Methylhexanamine</li>
<li>Naphthylaminopropane</li>
<li><a href="Octodrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Octodrine" title="Octodrine">Octodrine</a></li>
<li>Phthalimidopropiophenone</li>
<li>Phenylbiguanide</li>
<li>Propylhexedrine
<ul><li>Levopropylhexedrine</li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>NRAs</abbr></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><td colspan="2" class="navbox-list navbox-even" style="width:100%;padding:0px;text-align: left;"><div style="padding:0em 0.25em">
<ul><li><i>Morpholines:</i> Fenbutrazate</li>
<li>Fenmetramide</li>
<li>Morazone</li>
<li>Morforex</li>
<li><a href="Phendimetrazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phendimetrazine" title="Phendimetrazine">Phendimetrazine</a></li>
<li><a href="Phenmetrazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenmetrazine" title="Phenmetrazine">Phenmetrazine</a></li>
<li>Pseudophenmetrazine</li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px;text-align: left;"><div style="padding:0em 0.25em">
<ul><li><i>Oxazolines:</i> <a href="4-Methylaminorex.htm" tppabs="https://ptable.com/wiki/compounds/A/4-Methylaminorex" title="4-Methylaminorex">4-MAR</a></li>
<li><a href="Aminorex.htm" tppabs="https://ptable.com/wiki/compounds/A/Aminorex" title="Aminorex">Aminorex</a></li>
<li>Clominorex</li>
<li>Cyclazodone</li>
<li>Fenozolone</li>
<li>Fluminorex</li>
<li><a href="Pemoline.htm" tppabs="https://ptable.com/wiki/compounds/A/Pemoline" title="Pemoline">Pemoline</a></li>
<li>Thozalinone</li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-even" style="width:100%;padding:0px;text-align: left;"><div style="padding:0em 0.25em">
<ul><li><i>Phenethylamines:</i> 2-OH-PEA</li>
<li>4-CAB</li>
<li>4-FA</li>
<li>4-FMA</li>
<li>4-MA</li>
<li>4-MMA</li>
<li>Alfetamine</li>
<li>Amfecloral</li>
<li>Amfepentorex</li>
<li><a href="Amfepramone.htm" tppabs="https://ptable.com/wiki/compounds/A/Amfepramone" title="Amfepramone">Amfepramone</a></li>
<li><a href="Amphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amphetamine" title="Amphetamine">Amphetamine</a>
<ul><li><a href="Dextroamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dextroamphetamine" title="Dextroamphetamine">Dextroamphetamine</a></li>
<li><a href="Levoamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Levoamphetamine" title="Levoamphetamine">Levoamphetamine</a></li></ul></li>
<li>Amphetaminil</li>
<li><a href="Β-Methylphenethylamine.htm" tppabs="https://ptable.com/wiki/compounds/A/%CE%92-Methylphenethylamine" title="Β-Methylphenethylamine">β-Me-PEA</a></li>
<li>BDB</li>
<li><a href="Benzphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzphetamine" title="Benzphetamine">Benzphetamine</a></li>
<li>BOH</li>
<li>Buphedrone</li>
<li>Butylone</li>
<li><a href="Cathine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cathine" title="Cathine">Cathine</a></li>
<li><a href="Cathinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Cathinone" title="Cathinone">Cathinone</a></li>
<li>Clobenzorex</li>
<li><a href="Clortermine.htm" tppabs="https://ptable.com/wiki/compounds/A/Clortermine" title="Clortermine">Clortermine</a></li>
<li>Dimethylamphetamine</li>
<li><a href="Dimethoxyamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dimethoxyamphetamine" title="Dimethoxyamphetamine">DMA</a></li>
<li>DMMA</li>
<li>EBDB</li>
<li><a href="Ephedrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Ephedrine" title="Ephedrine">Ephedrine</a></li>
<li>Ethcathinone</li>
<li>Ethylone</li>
<li>Etilamfetamine</li>
<li>Famprofazone</li>
<li><a href="Fenethylline.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenethylline" title="Fenethylline">Fenethylline</a></li>
<li><a href="Fenproporex.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenproporex" title="Fenproporex">Fenproporex</a></li>
<li>Flephedrone</li>
<li>Fludorex</li>
<li>Furfenorex</li>
<li>Hordenine</li>
<li>4-Hydroxyamphetamine</li>
<li>5-APDI (IAP)</li>
<li>Iofetamine (123I)</li>
<li><a href="Lisdexamfetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lisdexamfetamine" title="Lisdexamfetamine">Lisdexamfetamine</a></li>
<li>Lophophine</li>
<li>MBDB</li>
<li><a href="3,4-Methylenedioxyamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/3%2C4-Methylenedioxyamphetamine" title="3,4-Methylenedioxyamphetamine">MDA (tenamfetamine)</a></li>
<li>MDEA</li>
<li><a href="MDMA.htm" tppabs="https://ptable.com/wiki/compounds/A/MDMA" title="MDMA">MDMA (midomafetamine)</a></li>
<li>Metamfepramone</li>
<li>MDMPEA</li>
<li>MDOH</li>
<li>MDPEA</li>
<li>Mefenorex</li>
<li>Mephedrone</li>
<li><a href="Mephentermine.htm" tppabs="https://ptable.com/wiki/compounds/A/Mephentermine" title="Mephentermine">Mephentermine</a></li>
<li><a href="Methamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Methamphetamine" title="Methamphetamine">Methamphetamine</a>
<ul><li>Dextromethamphetamine</li>
<li>Levomethamphetamine</li></ul></li>
<li>Methcathinone</li>
<li>Methedrone</li>
<li>Methylone</li>
<li>Morforex</li>
<li>Naphthylaminopropane</li>
<li>Ortetamine</li>
<li><i>p</i>BA</li>
<li><i>p</i>CA</li>
<li>Pentorex</li>
<li><a href="Phenethylamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenethylamine" title="Phenethylamine">Phenethylamine</a></li>
<li><a href="Pholedrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pholedrine" title="Pholedrine">Pholedrine</a></li>
<li>Phenpromethamine</li>
<li><a href="Phentermine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phentermine" title="Phentermine">Phentermine</a></li>
<li><a href="Phenylpropanolamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenylpropanolamine" title="Phenylpropanolamine">Phenylpropanolamine</a></li>
<li><i>p</i>IA</li>
<li><a href="Prenylamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Prenylamine" title="Prenylamine">Prenylamine</a></li>
<li>Propylamphetamine</li>
<li><a href="Pseudoephedrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pseudoephedrine" title="Pseudoephedrine">Pseudoephedrine</a></li>
<li><a href="Selegiline.htm" tppabs="https://ptable.com/wiki/compounds/A/Selegiline" title="Selegiline">Selegiline</a> (also <span style="font-size:85%;">D</span>-Deprenyl)</li>
<li>Tiflorex</li>
<li><a href="Tyramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Tyramine" title="Tyramine">Tyramine</a></li>
<li>Xylopropamine</li>
<li>Zylofuramine</li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px;text-align: left;"><div style="padding:0em 0.25em">
<ul><li><i>Piperazines:</i> 2C-B-BZP</li>
<li><a href="Benzylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzylpiperazine" title="Benzylpiperazine">BZP</a></li>
<li>MBZP</li>
<li><a href="Meta-Chlorophenylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Meta-Chlorophenylpiperazine" title="Meta-Chlorophenylpiperazine">mCPP</a></li>
<li>MDBZP</li>
<li>MeOPP</li>
<li>oMPP</li>
<li>pFPP</li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-even" style="width:100%;padding:0px;text-align: left;"><div style="padding:0em 0.25em">
<ul><li><i>Others:</i> 2-ADN</li>
<li>2-AI</li>
<li><a href="2-Aminotetralin.htm" tppabs="https://ptable.com/wiki/compounds/A/2-Aminotetralin" title="2-Aminotetralin">2-AT</a></li>
<li>2-BP</li>
<li><a href="4-Benzylpiperidine.htm" tppabs="https://ptable.com/wiki/compounds/A/4-Benzylpiperidine" title="4-Benzylpiperidine">4-BP</a></li>
<li>5-IAI</li>
<li>Clofenciclan</li>
<li>Cyclopentamine</li>
<li>Cypenamine</li>
<li>Cyprodenate</li>
<li>Feprosidnine</li>
<li>Gilutensin</li>
<li><a href="Heptaminol.htm" tppabs="https://ptable.com/wiki/compounds/A/Heptaminol" title="Heptaminol">Heptaminol</a></li>
<li>Hexacyclonate</li>
<li>Indanorex</li>
<li>Isometheptene</li>
<li>Methylhexanamine</li>
<li><a href="Octodrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Octodrine" title="Octodrine">Octodrine</a></li>
<li>Phthalimidopropiophenone</li>
<li>Propylhexedrine (Levopropylhexedrine)</li>
<li><a href="Tuaminoheptane.htm" tppabs="https://ptable.com/wiki/compounds/A/Tuaminoheptane" title="Tuaminoheptane">Tuaminoheptane</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>SRAs</abbr></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Aminoindanes:</i> 5-IAI</li>
<li>AMMI</li>
<li>ETAI</li>
<li>MDAI</li>
<li>MDMAI</li>
<li>MMAI</li>
<li>TAI</li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-even" style="width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Aminotetralins:</i> 6-CAT</li>
<li>8-OH-DPAT</li>
<li>MDAT</li>
<li>MDMAT</li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Oxazolines:</i> <a href="4-Methylaminorex.htm" tppabs="https://ptable.com/wiki/compounds/A/4-Methylaminorex" title="4-Methylaminorex">4-Methylaminorex</a></li>
<li><a href="Aminorex.htm" tppabs="https://ptable.com/wiki/compounds/A/Aminorex" title="Aminorex">Aminorex</a></li>
<li>Clominorex</li>
<li>Fluminorex</li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-even" style="width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Phenethylamines:</i> 2-Methyl-MDA</li>
<li>4-CAB</li>
<li>4-FA</li>
<li>4-FMA</li>
<li>4-HA</li>
<li>4-MTA</li>
<li>5-APDB</li>
<li>5-Methyl-MDA</li>
<li>6-APDB</li>
<li>6-Methyl-MDA</li>
<li>AEMMA</li>
<li>Amiflamine</li>
<li>BDB</li>
<li>BOH</li>
<li>Brephedrone</li>
<li>Butylone</li>
<li><a href="Chlorphentermine.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorphentermine" title="Chlorphentermine">Chlorphentermine</a></li>
<li>Cloforex</li>
<li><a href="Amfepramone.htm" tppabs="https://ptable.com/wiki/compounds/A/Amfepramone" title="Amfepramone">Amfepramone</a></li>
<li>Metamfepramone</li>
<li>DCA</li>
<li><a href="Dexfenfluramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexfenfluramine" title="Dexfenfluramine">Dexfenfluramine</a></li>
<li>DFMDA</li>
<li><a href="Dimethoxyamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dimethoxyamphetamine" title="Dimethoxyamphetamine">DMA</a></li>
<li>DMMA</li>
<li>EBDB</li>
<li>EDMA</li>
<li>Ethylone</li>
<li>Etolorex</li>
<li><a href="Fenfluramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenfluramine" title="Fenfluramine">Fenfluramine</a></li>
<li>Flephedrone</li>
<li>Flucetorex</li>
<li>IAP</li>
<li>Iofetamine</li>
<li>Levofenfluramine</li>
<li>Lophophine</li>
<li>MBDB</li>
<li><a href="3,4-Methylenedioxyamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/3%2C4-Methylenedioxyamphetamine" title="3,4-Methylenedioxyamphetamine">MDA (tenamfetamine)</a></li>
<li>MDEA</li>
<li>MDHMA</li>
<li><a href="MDMA.htm" tppabs="https://ptable.com/wiki/compounds/A/MDMA" title="MDMA">MDMA (midomafetamine)</a></li>
<li>MDMPEA</li>
<li>MDOH</li>
<li>MDPEA</li>
<li>Mephedrone</li>
<li>Methedrone</li>
<li>Methylone</li>
<li>MMA</li>
<li>MMDA</li>
<li>MMDMA</li>
<li>MMMA</li>
<li>NAP</li>
<li>Norfenfluramine</li>
<li>4-TFMA</li>
<li>pBA</li>
<li>pCA</li>
<li>pIA</li>
<li><a href="Para-Methoxyamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Para-Methoxyamphetamine" title="Para-Methoxyamphetamine">PMA</a></li>
<li>PMEA</li>
<li>PMMA</li>
<li>TAP</li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Piperazines:</i> 2C-B-BZP</li>
<li><span class="new">3-MeOPP</span></li>
<li><a href="Benzylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzylpiperazine" title="Benzylpiperazine">BZP</a></li>
<li><span class="new">DCPP</span></li>
<li>MBZP</li>
<li><a href="Meta-Chlorophenylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Meta-Chlorophenylpiperazine" title="Meta-Chlorophenylpiperazine">mCPP</a></li>
<li>MDBZP</li>
<li>MeOPP</li>
<li>Mepiprazole</li>
<li>oMPP</li>
<li><a href="Para-Chlorophenylpiperazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Para-Chlorophenylpiperazine" title="Para-Chlorophenylpiperazine">pCPP</a></li>
<li>pFPP</li>
<li>pTFMPP</li>
<li>TFMPP</li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-even" style="width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Tryptamines:</i> 4-Methyl-αET</li>
<li>4-Methyl-αMT</li>
<li>5-CT</li>
<li>5-MeO-αET</li>
<li>5-MeO-αMT</li>
<li><a href="5-Methoxytryptamine.htm" tppabs="https://ptable.com/wiki/compounds/A/5-Methoxytryptamine" title="5-Methoxytryptamine">5-MT</a></li>
<li><a href="Alpha-Ethyltryptamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Alpha-Ethyltryptamine" title="Alpha-Ethyltryptamine">αET</a></li>
<li><a href="Alpha-Methyltryptamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Alpha-Methyltryptamine" title="Alpha-Methyltryptamine">αMT</a></li>
<li><a href="Dimethyltryptamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dimethyltryptamine" title="Dimethyltryptamine" class="mw-redirect">DMT</a></li>
<li><a href="Tryptamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Tryptamine" title="Tryptamine">Tryptamine</a></li></ul>
</div></td></tr><tr><td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Others:</i> Indeloxazine</li>
<li>Viqualine</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Monoamine activity enhancers:</i> BPAP</li>
<li>PPAP</li></ul>

<ul><li><i>DAT modulators:</i> <i>Agonist-like:</i> SoRI-9804</li>
<li><span class="new">SoRI-20040</span>; <i>Antagonist-like:</i> SoRI-20041</li></ul>

<ul><li><i>Adrenergic release blockers:</i> <a href="Bethanidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Bethanidine" title="Bethanidine">Bethanidine</a></li>
<li><a href="Bretylium.htm" tppabs="https://ptable.com/wiki/compounds/A/Bretylium" title="Bretylium">Bretylium</a></li>
<li><a href="Guanadrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Guanadrel" title="Guanadrel">Guanadrel</a></li>
<li>Guanazodine</li>
<li><a href="Guanethidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Guanethidine" title="Guanethidine">Guanethidine</a></li>
<li>Guanoxan</li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div><small><i><b>See also:</b> Receptor/signaling modulators • Monoamine reuptake inhibitors • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins</i></small></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Phenethylamines" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Phenethylamines" style="font-size:114%;margin:0 4em">Phenethylamines</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Phenethylamines</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Psychedelics:</i> 25B-NBOMe</li>
<li>25C-NBOMe</li>
<li>25D-NBOMe</li>
<li>25I-NBOMe</li>
<li>25N-NBOMe</li></ul>

<ul><li><a href="2C-B.htm" tppabs="https://ptable.com/wiki/compounds/A/2C-B" title="2C-B">2C-B</a></li>
<li><span class="new">2C-B-AN</span></li>
<li><span class="new">2C-Bn</span></li>
<li><span class="new">2C-Bu</span></li>
<li>2C-C</li>
<li><span class="new">2C-CN</span></li>
<li><span class="new">2C-CP</span></li>
<li>2C-D</li>
<li>2C-E</li>
<li><span class="new">2C-EF</span></li>
<li>2C-F</li>
<li>2C-G</li>
<li>2C-G-1</li>
<li>2C-G-2</li>
<li>2C-G-3</li>
<li>2C-G-4</li>
<li>2C-G-5</li>
<li>2C-G-6</li>
<li>2C-G-N</li>
<li><a href="2C-H.htm" tppabs="https://ptable.com/wiki/compounds/A/2C-H" title="2C-H">2C-H</a></li>
<li>2C-I</li>
<li>2C-iP</li>
<li>2C-N</li>
<li><span class="new">2C-NH2</span></li>
<li>2C-O</li>
<li>2C-O-4</li>
<li>2C-P</li>
<li><span class="new">2C-Ph</span></li>
<li>2C-SE</li>
<li>2C-T</li>
<li>2C-T-2</li>
<li><span class="new">2C-T-3</span></li>
<li>2C-T-4</li>
<li><span class="new">2C-T-5</span></li>
<li><span class="new">2C-T-6</span></li>
<li>2C-T-7</li>
<li>2C-T-8</li>
<li>2C-T-9</li>
<li><span class="new">2C-T-10</span></li>
<li><span class="new">2C-T-11</span></li>
<li><span class="new">2C-T-12</span></li>
<li>2C-T-13</li>
<li><span class="new">2C-T-14</span></li>
<li>2C-T-15</li>
<li>2C-T-16</li>
<li>2C-T-17</li>
<li><span class="new">2C-T-18</span></li>
<li>2C-T-19</li>
<li><span class="new">2C-T-20</span></li>
<li>2C-T-21</li>
<li><span class="new">2C-T-22</span></li>
<li><span class="new">2C-T-22.5</span></li>
<li><span class="new">2C-T-23</span></li>
<li><span class="new">2C-T-24</span></li>
<li><span class="new">2C-T-25</span></li>
<li><span class="new">2C-T-27</span></li>
<li><span class="new">2C-T-28</span></li>
<li><span class="new">2C-T-30</span></li>
<li><span class="new">2C-T-31</span></li>
<li><span class="new">2C-T-32</span></li>
<li><span class="new">2C-T-33</span></li>
<li><span class="new">2C-TFE</span></li>
<li>2C-TFM</li>
<li>2C-YN</li>
<li><span class="new">2C-V</span></li></ul>

<ul><li>Allylescaline</li>
<li>DESOXY</li>
<li>Escaline</li>
<li>Isoproscaline</li>
<li>Jimscaline</li>
<li>Macromerine</li>
<li>MEPEA</li>
<li>Mescaline</li>
<li>Metaescaline</li>
<li>Methallylescaline</li>
<li>Proscaline</li>
<li>Psi-2C-T-4</li>
<li>TCB-2</li>
<li><a href="Venlafaxine.htm" tppabs="https://ptable.com/wiki/compounds/A/Venlafaxine" title="Venlafaxine">Venlafaxine</a><br><i>Stimulants:</i> Phenylethanolamine</li>
<li>Hordenine</li>
<li><a href="Phenethylamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenethylamine" title="Phenethylamine">Phenethylamine</a></li>
<li><a href="Amphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amphetamine" title="Amphetamine">α-Methylphenethylamine</a> (amphetamine)</li>
<li><a href="Β-Methylphenethylamine.htm" tppabs="https://ptable.com/wiki/compounds/A/%CE%92-Methylphenethylamine" title="Β-Methylphenethylamine">β-Methylphenethylamine</a></li>
<li><i>m</i>-Methylphenethylamine</li>
<li><a href="N-Methylphenethylamine.htm" tppabs="https://ptable.com/wiki/compounds/A/N-Methylphenethylamine" title="N-Methylphenethylamine"><i>N</i>-Methylphenethylamine</a></li>
<li><i>o</i>-Methylphenethylamine</li>
<li><i>p</i>-Methylphenethylamine</li>
<li><a href="Methylphenidate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methylphenidate" title="Methylphenidate">Methylphenidate</a></li></ul>

<ul><li><i>Entactogens:</i> Lophophine</li>
<li>MDPEA</li>
<li>MDMPEA<br><i>Others:</i> BOH</li>
<li><a href="3,4-Dimethoxyphenethylamine.htm" tppabs="https://ptable.com/wiki/compounds/A/3%2C4-Dimethoxyphenethylamine" title="3,4-Dimethoxyphenethylamine">DMPEA</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Amphetamines</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Psychedelics:</i> 3C-BZ</li>
<li>3C-E</li>
<li>3C-P</li>
<li>Aleph</li>
<li>Beatrice</li>
<li>Bromo-DragonFLY</li>
<li>D-Deprenyl</li>
<li><a href="Dimethoxyamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dimethoxyamphetamine" title="Dimethoxyamphetamine">DMA</a></li>
<li><span class="new">DMCPA</span></li>
<li>DMMDA</li>
<li>DOB</li>
<li>DOC</li>
<li>DOEF</li>
<li><a href="2,5-Dimethoxy-4-ethylamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/2%2C5-Dimethoxy-4-ethylamphetamine" title="2,5-Dimethoxy-4-ethylamphetamine">DOET</a></li>
<li>DOI</li>
<li><a href="2,5-Dimethoxy-4-methylamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/2%2C5-Dimethoxy-4-methylamphetamine" title="2,5-Dimethoxy-4-methylamphetamine">DOM</a></li>
<li>DON</li>
<li>DOPR</li>
<li>DOTFM</li>
<li>Ganesha</li>
<li>MMDA</li>
<li>MMDA-2</li>
<li>Psi-DOM</li>
<li><a href="Trimethoxyamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Trimethoxyamphetamine" title="Trimethoxyamphetamine">TMA</a></li>
<li>TeMA<br><i>Stimulants:</i> 2-FA</li>
<li>2-FMA</li>
<li>3-FA</li>
<li>3-FMA</li>
<li>Acridorex</li>
<li>Alfetamine</li>
<li>Amfecloral</li>
<li>Amfepentorex</li>
<li><a href="Amphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Amphetamine" title="Amphetamine">Amphetamine</a> (<a href="Dextroamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dextroamphetamine" title="Dextroamphetamine">Dextroamphetamine</a>, <a href="Levoamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Levoamphetamine" title="Levoamphetamine">Levoamphetamine</a>)</li>
<li>Amphetaminil</li>
<li>Benfluorex</li>
<li><a href="Benzphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Benzphetamine" title="Benzphetamine">Benzphetamine</a></li>
<li><a href="Cathine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cathine" title="Cathine">Cathine</a></li>
<li>Clobenzorex</li>
<li>Dimethylamphetamine</li>
<li><a href="Ephedrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Ephedrine" title="Ephedrine">Ephedrine</a></li>
<li>Etilamfetamine</li>
<li>Fencamfamin</li>
<li>Fencamine</li>
<li><a href="Fenethylline.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenethylline" title="Fenethylline">Fenethylline</a></li>
<li><a href="Fenfluramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenfluramine" title="Fenfluramine">Fenfluramine</a> (<a href="Dexfenfluramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexfenfluramine" title="Dexfenfluramine">Dexfenfluramine</a>, Levofenfluramine)</li>
<li><a href="Fenproporex.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenproporex" title="Fenproporex">Fenproporex</a></li>
<li>Flucetorex</li>
<li>Fludorex</li>
<li>Formetorex</li>
<li>Furfenorex</li>
<li>Gepefrine</li>
<li>4-Hydroxyamphetamine</li>
<li>Iofetamine</li>
<li>Isopropylamphetamine</li>
<li>Lefetamine</li>
<li><a href="Lisdexamfetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lisdexamfetamine" title="Lisdexamfetamine">Lisdexamfetamine</a></li>
<li>Mefenorex</li>
<li><a href="Metaraminol.htm" tppabs="https://ptable.com/wiki/compounds/A/Metaraminol" title="Metaraminol">Metaraminol</a></li>
<li><a href="Methamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Methamphetamine" title="Methamphetamine">Methamphetamine</a> (Dextromethamphetamine, Levomethamphetamine)</li>
<li>Methoxyphenamine</li>
<li>MMA</li>
<li>Morforex</li>
<li>Norfenfluramine</li>
<li><a href="L-Norpseudoephedrine.htm" tppabs="https://ptable.com/wiki/compounds/A/L-Norpseudoephedrine" title="L-Norpseudoephedrine"><span style="font-size:90%;">L </span>-Norpseudoephedrine</a></li>
<li>N,alpha-Diethylphenylethylamine</li>
<li>Oxifentorex</li>
<li>Oxilofrine</li>
<li>Ortetamine</li>
<li>PBA</li>
<li>PCA</li>
<li>Phenpromethamine</li>
<li>PFA</li>
<li>PFMA</li>
<li>PIA</li>
<li><a href="Para-Methoxyamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Para-Methoxyamphetamine" title="Para-Methoxyamphetamine">PMA</a></li>
<li>PMEA</li>
<li>PMMA</li>
<li><a href="Phenylpropanolamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenylpropanolamine" title="Phenylpropanolamine">Phenylpropanolamine</a></li>
<li><a href="Pholedrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pholedrine" title="Pholedrine">Pholedrine</a></li>
<li><a href="Prenylamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Prenylamine" title="Prenylamine">Prenylamine</a></li>
<li>Propylamphetamine</li>
<li><a href="Pseudoephedrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Pseudoephedrine" title="Pseudoephedrine">Pseudoephedrine</a></li>
<li><a href="Sibutramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Sibutramine" title="Sibutramine">Sibutramine</a></li>
<li>Tiflorex</li>
<li><a href="Tranylcypromine.htm" tppabs="https://ptable.com/wiki/compounds/A/Tranylcypromine" title="Tranylcypromine">Tranylcypromine</a></li>
<li>Xylopropamine</li>
<li>Zylofuramine<br><i>Entactogens:</i> 4-FA</li>
<li>4-FMA</li>
<li>4-MA</li>
<li>4-MMA</li>
<li>4-MTA</li>
<li>5-APB</li>
<li>5-APDB</li>
<li>5-EAPB</li>
<li>5-IT</li>
<li>5-MAPB</li>
<li>5-MAPDB</li>
<li>6-APB</li>
<li>6-APDB</li>
<li>6-Chloro-MDMA</li>
<li>6-EAPB</li>
<li>6-IT</li>
<li>6-MAPB</li>
<li>6-MAPDB</li>
<li>EDA</li>
<li>IAP</li>
<li>2,3-MDA</li>
<li><a href="3,4-Methylenedioxyamphetamine.htm" tppabs="https://ptable.com/wiki/compounds/A/3%2C4-Methylenedioxyamphetamine" title="3,4-Methylenedioxyamphetamine">3,4-MDA (tenamfetamine)</a></li>
<li>MDEA</li>
<li>MDHMA</li>
<li><a href="MDMA.htm" tppabs="https://ptable.com/wiki/compounds/A/MDMA" title="MDMA">MDMA (midomafetamine)</a></li>
<li>MDOH</li>
<li>Methamnetamine</li>
<li>MMDMA</li>
<li>Naphthylaminopropane</li>
<li>TAP<br><i>Others:</i> 3,4-DCA</li>
<li>Amiflamine</li>
<li>DiFMDA</li>
<li><a href="Selegiline.htm" tppabs="https://ptable.com/wiki/compounds/A/Selegiline" title="Selegiline">Selegiline</a> (also <span style="font-size:90%;">D </span>-Deprenyl)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Phentermine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phentermine" title="Phentermine">Phentermines</a></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Stimulants:</i> <a href="Chlorphentermine.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorphentermine" title="Chlorphentermine">Chlorphentermine</a></li>
<li>Cloforex</li>
<li><a href="Clortermine.htm" tppabs="https://ptable.com/wiki/compounds/A/Clortermine" title="Clortermine">Clortermine</a></li>
<li>Etolorex</li>
<li><a href="Mephentermine.htm" tppabs="https://ptable.com/wiki/compounds/A/Mephentermine" title="Mephentermine">Mephentermine</a></li>
<li>Pentorex</li>
<li><a href="Phentermine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phentermine" title="Phentermine">Phentermine</a><br><i>Entactogens:</i> MDPH</li>
<li>MDMPH<br><i>Others:</i> Cericlamine</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Cathinones</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Stimulants:</i> 3-FMC</li>
<li>4-MC</li>
<li>4-BMC</li>
<li>4-CMC</li>
<li>4-EMC</li>
<li>4-FMC</li>
<li>4-MEC</li>
<li>4-MeMABP</li>
<li>4-MPD</li>
<li><a href="Amfepramone.htm" tppabs="https://ptable.com/wiki/compounds/A/Amfepramone" title="Amfepramone">Amfepramone</a></li>
<li>Benzedrone</li>
<li>Brephedrone</li>
<li>Buphedrone</li>
<li><a href="Bupropion.htm" tppabs="https://ptable.com/wiki/compounds/A/Bupropion" title="Bupropion">Bupropion</a></li>
<li><a href="Cathinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Cathinone" title="Cathinone">Cathinone</a></li>
<li>Dimethylcathinone</li>
<li>Ethcathinone</li>
<li>Eutylone</li>
<li>Hydroxybupropion</li>
<li>Methcathinone</li>
<li>Methedrone</li>
<li>NEB</li>
<li>N-Ethylhexedrone</li>
<li>N-Ethylpentedrone</li>
<li>Pentedrone</li>
<li>Pentylone</li>
<li>Radafaxine<br><i>Entactogens:</i> 3,4-DMMC</li>
<li>3-MMC</li>
<li>Butylone</li>
<li>Ethylone</li>
<li>Methylone</li>
<li>Methylenedioxycathinone</li>
<li>Mephedrone</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Phenylisobutylamines</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Entactogens:</i> 4-CAB</li>
<li>4-MAB</li>
<li>Ariadne</li>
<li>BDB</li>
<li>Butylone</li>
<li>EBDB</li>
<li>Eutylone</li>
<li>MBDB<br><i>Stimulants:</i> Phenylisobutylamine</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Phenylalkylpyrrolidines</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Stimulants:</i> α-PBP</li>
<li>α-PHP</li>
<li>α-PPP</li>
<li>α-PVP</li>
<li>MDPBP</li>
<li>MDPPP</li>
<li>MDPV</li>
<li>4-MePBP</li>
<li>4-MePHP</li>
<li>4-MePPP</li>
<li>MOPPP</li>
<li>MOPVP</li>
<li>MPBP</li>
<li>MPHP</li>
<li>MPPP</li>
<li>Naphyrone</li>
<li>PEP</li>
<li>Prolintane</li>
<li>Pyrovalerone</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Catecholamines<br><span style="font-size:90%;">(and close relatives) </span></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>6-FNE</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Oxidopamine  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Oxidopamine'" tppabs="https://ptable.com/wiki/compounds/A/6-Hydroxydopamine" title="6-Hydroxydopamine" class="mw-redirect">6-OHDA</a></li>
<li><a href="Alpha-Methyldopamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Alpha-Methyldopamine" title="Alpha-Methyldopamine">a-Me-DA</a></li>
<li>a-Me-TRA</li>
<li>Adrenochrome</li>
<li>Ciladopa</li>
<li><span style="font-size:90%;">D </span>-DOPA (Dextrodopa)</li>
<li>Dimetofrine</li>
<li><a href="Dopamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dopamine" title="Dopamine">Dopamine</a></li>
<li>Epinephrine</li>
<li>Epinine</li>
<li>Etilefrine</li>
<li>Ethylnorepinephrine</li>
<li><a href="Fenclonine.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenclonine" title="Fenclonine">Fenclonine</a></li>
<li>Ibopamine</li>
<li><a href="Isoprenaline.htm" tppabs="https://ptable.com/wiki/compounds/A/Isoprenaline" title="Isoprenaline">Isoprenaline</a></li>
<li><a href="Isoetarine.htm" tppabs="https://ptable.com/wiki/compounds/A/Isoetarine" title="Isoetarine">Isoetarine</a></li>
<li><a href="L-DOPA.htm" tppabs="https://ptable.com/wiki/compounds/A/L-DOPA" title="L-DOPA"><span style="font-size:90%;">L </span>-DOPA</a> (Levodopa)</li>
<li><a href="L-DOPS.htm" tppabs="https://ptable.com/wiki/compounds/A/L-DOPS" title="L-DOPS" class="mw-redirect"><span style="font-size:90%;">L </span>-DOPS</a> (Droxidopa)</li>
<li><a href="Phenylalanine.htm" tppabs="https://ptable.com/wiki/compounds/A/L-Phenylalanine" title="L-Phenylalanine" class="mw-redirect"><span style="font-size:90%;">L </span>-Phenylalanine</a></li>
<li><span style="font-size:90%;">L </span>-Tyrosine</li>
<li><i>m</i>-Tyramine</li>
<li>Metanephrine</li>
<li><a href="Metaraminol.htm" tppabs="https://ptable.com/wiki/compounds/A/Metaraminol" title="Metaraminol">Metaraminol</a></li>
<li>Metaterol</li>
<li><a href="Metirosine.htm" tppabs="https://ptable.com/wiki/compounds/A/Metirosine" title="Metirosine">Metirosine</a></li>
<li><a href="Methyldopa.htm" tppabs="https://ptable.com/wiki/compounds/A/Methyldopa" title="Methyldopa">Methyldopa</a></li>
<li>N,N-Dimethyldopamine</li>
<li>Nordefrin (Levonordefrin)</li>
<li>Norepinephrine</li>
<li><a href="Norfenefrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Norfenefrine" title="Norfenefrine">Norfenefrine</a> (<i>m</i>-Octopamine)</li>
<li>Normetanephrine</li>
<li><a href="Orciprenaline.htm" tppabs="https://ptable.com/wiki/compounds/A/Orciprenaline" title="Orciprenaline">Orciprenaline</a></li>
<li><i>p</i>-Octopamine</li>
<li><a href="Tyramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Tyramine" title="Tyramine"><i>p</i>-Tyramine</a></li>
<li><a href="Phenylephrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenylephrine" title="Phenylephrine">Phenylephrine</a></li>
<li><a href="Synephrine.htm" tppabs="https://ptable.com/wiki/compounds/A/Synephrine" title="Synephrine">Synephrine</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Miscellaneous</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>AL-LAD</li>
<li>Amidephrine</li>
<li><a href="Arbutamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Arbutamine" title="Arbutamine">Arbutamine</a></li>
<li>Cafedrine</li>
<li>Denopamine</li>
<li>Desvenlafaxine</li>
<li>Diphenidine</li>
<li>Dizocilpine</li>
<li><a href="Dobutamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Dobutamine" title="Dobutamine">Dobutamine</a></li>
<li>Dopexamine</li>
<li>Ephenidine</li>
<li>Etafedrine</li>
<li>ETH-LAD</li>
<li>Famprofazone</li>
<li>Fluorolintane</li>
<li>Hexapradol</li>
<li>IP-LAD</li>
<li>Lysergic acid amide</li>
<li>Lysergic acid 2-butyl amide</li>
<li>Lysergic acid 2,4-dimethylazetidide</li>
<li><a href="Lysergic_acid_diethylamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Lysergic_acid_diethylamide" title="Lysergic acid diethylamide">Lysergic acid diethylamide</a></li>
<li><a href="Methoxamine.htm" tppabs="https://ptable.com/wiki/compounds/A/Methoxamine" title="Methoxamine">Methoxamine</a></li>
<li>Methoxphenidine</li>
<li>MT-45</li>
<li>PARGY-LAD</li>
<li>Phenibut</li>
<li>PRO-LAD</li>
<li>Pronethalol</li>
<li><a href="Salbutamol.htm" tppabs="https://ptable.com/wiki/compounds/A/Salbutamol" title="Salbutamol">Salbutamol</a> (Levosalbutamol)</li>
<li>Solriamfetol</li>
<li>Theodrenaline</li>
<li><a href="Thiamphenicol.htm" tppabs="https://ptable.com/wiki/compounds/A/Thiamphenicol" title="Thiamphenicol">Thiamphenicol</a></li>
<li>UWA-101</li></ul>
</div></td></tr></tbody></table></div>
























<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-08-02" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Lisdexamfetamine&oldid=970755307  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Lisdexamfetamine&oldid=970755307'" tppabs="https://en.wikipedia.org/wiki/?title=Lisdexamfetamine&oldid=970755307">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>